Current
| In vitro study of antioxidative/antiinflammatory effects of natural and synthetic compounds. In vivo assessment of medicinal effects of selected compounds in experiments of healing skin wounds. | |
| Duration: | 1. 1. 2023 - 31. 12. 2027 |
| Evidence number: | 2/0008/23 |
| Program: | VEGA |
| Project leader: | RNDr. Valachová Katarína , PhD. |
| SAS cosolvers: | RNDr. Juránek Ivo, PhD., DrSc., Ing. Šoltés Ladislav, DrSc., Ing. Švík Karol, CSc. |
| CARDIOEND - Cardiovascular protection mediated by ³1AMPK against metabolic syndrome-mediated endothelial dysfunction 3 identifying new risk factors | |
| Duration: | 1. 7. 2023 - 30. 6. 2027 |
| Evidence number: | APVV-22-0154 |
| Program: | APVV |
| Project leader: | Ing. Kvandová Miroslava, PhD. |
| SAS cosolvers: | RNDr. Bališ Peter, PhD., doc. RNDr. Barteková Monika, PhD., RNDr. Bernátová Iveta, DrSc., Mgr. Csicsátková Nikoleta, PhD., Mgr. Duľová Ulrika, Mgr. Ferenczyová Kristína, PhD., Mgr. Grman Marián, PhD., RNDr. Hlaváčová Nataša, PhD., prof. PharmDr. Ježová Daniela, DrSc., RNDr. Karailiev Peter, PhD., Mgr. Kluknavský Michal, PhD., Mgr. Magyarová Silvia, doc. RNDr. Pecháňová Oľga, DrSc., doc. MUDr. Radošinská Jana, PhD., Mgr. Strapec Jakub, Mgr. Suroviaková Katarína, doc. MUDr. Török Jozef, CSc., Mgr. Zemančíková Anna, PhD. |
| Annotation: | Disruption of vascular homeostasis caused by decreased nitric oxide bioavailability oxide due to oxidative stress and inflammation is the most serious complication of metabolic syndrome (MetS), leading to increased morbidity and mortality. There is an unmet need to identify key factors that prevent or protect vascular endothelium and thus improve primary and secondary prevention of cardiovascular diseases. It appears that AMP-dependent protein kinase (AMPK) may be such a factor. Its protective properties and positive effect on endothelial function and oxidative stress are already known. These unique properties suggest that AMPK may be involved in improving metabolic control during MetS, but still, the molecular changes due to α1AMPK-related dysregulation during MetS development are poorly understood. The project focuses on risk factors affecting endothelial function during MetS and the AMPK as a potential tool to modify those risk factors resulting in MetS prevention or treatment. The originality of the project is based on a comprehensive evaluation of functional, molecular, and biochemical changes in endothelial function, inflammation, and metabolic senescence during MetS with a detailed focus on vascular endothelium - proliferation, senescence, and apoptosis. The focus will be put on risk factors affecting endothelial function such as the interaction/adhesion of leukocytes with the vascular endothelium and the AMPK-dependent role of erythrocytes during MetS development. The project will be enriched by the study of phenotypic and molecular changes at the level of the CNS, with an emphasis on neuroinflammation and behavioral changes. Importantly, the project has a translation character, as human studies in patients with MetS will also be performed. The obtained results may represent a potential tool for improving the current population’s health and reducing the economic burden associated with the treatment of this cardiometabolic disease. |
| HYDMIM - Effects of mesenchymal stem cells and HMGB1 inhibitor on cardiovascular system after experimentally induced myocardial infarction in hypertension and diabetes mellitus | |
| Duration: | 1. 7. 2023 - 30. 6. 2027 |
| Evidence number: | APVV-22-0271 |
| Program: | APVV |
| Project leader: | RNDr. Cebová Martina, PhD. |
| SAS cosolvers: | MVDr. Barta Andrej, PhD., Ing. Bendžala Štefan, Mgr. Bujnová Katarína, Bc. Hikl Jakub, RNDr. Klimentová Jana, PhD., MUDr. Lakota Ján, CSc., RNDr. Vranková Stanislava, PhD. |
| Other cosolvers: | Vojtková Mária doc. Ing. PhD. |
| Annotation: | Myocardial infarction is a serious disease of the coronary arteries, when part of the heart muscle dies and cardiac remodeling occurs as a result of persistent ischemia. The lack of oxygen and nutrients during ischemia results in inflammation, oxidative damage, and tissue degeneration. For a comprehensive understanding of the onset and progression of myocardial protection mechanisms during ischemia, it is necessary to monitor protective signaling molecules that can block or reverse the pathological process. Despite significant progress in the treatment of diseases of the cardiovascular system, myocardial infarction still remains the main cause of death in the world, especially in elderly patients with associated diseases such as hypertension and diabetes mellitus. The aim of the proposed project will be to clarify the significance of the nitric oxide signaling pathway after myocardial infarction in conditions of selected comorbidities. We will define the initial molecular and morphological changes that are caused by either the application of stem cells or glycyrrhizin, an HMGB1 inhibitor, applied after myocardial infarction. We will also examine the effectiveness of stem cells and glycyrrhizin to suppress pro-inflammatory and pro-fibrotic pathways with focus on PI3K-Akt-eNOS signaling pathway and JNK / Bax and TLR4 / NF-κB signaling pathway. The new results may provide information for targeted therapy aimed at the application of stem cells after myocardial infarction. In addition, in patients who are not suitable candidates for the given treatment, the application of an HMGB1 inhibitor can be an alternative for the treatment of myocardial infarction. |
| - | |
| Duration: | 1. 1. 2023 - 31. 12. 2026 |
| Evidence number: | 2/0133/23 |
| Program: | VEGA |
| Project leader: | RNDr. Dubovický Michal, CSc. |
| Functional and structural evaluation of changes in early and late postnatal myocardium, vasculature and other vital organs in a rat model of intrauterine growth restriction (IUGR). | |
| Duration: | 1. 1. 2023 - 31. 12. 2026 |
| Evidence number: | VEGA SR VEGA 1/0697/23 |
| Program: | VEGA |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| SAS cosolvers: | Ing. Frimmel Karel, PhD. |
| Ligand induced modulation of calcium pump SERCA – study of mechanism and design of new compounds | |
| Duration: | 1. 1. 2022 - 31. 12. 2026 |
| Evidence number: | 2/0103/22 |
| Program: | VEGA |
| Project leader: | RNDr. Májeková Magdaléna, PhD. |
| SAS cosolvers: | Mgr. Heger Vladimír, PhD., RNDr. Kováčiková Lucia, PhD., Ing. Micháliková Silvia, PhD., Mgr. Rezbáriková Petronela, PhD., Mgr. Šramel Peter, PhD. |
| Annotation: | Calcium signaling plays a crucial role in many physiological processes such as muscle contraction, gene expression, apoptosis and insulin secretion. A primary role in the maintenance of intracellular Ca2+ concentration belongs to SERCA – sarco/endoplasmic reticulum Ca2+-ATPase. As an impaired function of Ca2+-ATPase is associated with various chronic diseases and disorder, the compounds able to restore it are important as potential drugs. Our aim is to elucidate the mechanism of known SERCA activators by means of experimental and theoretical methods and to use this knowledge in design of new compounds, able to maintain SERCA function. In the framework of our research related to diabetes, we plan to include two more targets in our design – inhibition of polyol pathway and oxidation stress. |
| Neurocognitive mechanisms of semantic representation and control | |
| Duration: | 1. 1. 2023 - 31. 12. 2026 |
| Evidence number: | 2/0052/23 |
| Program: | VEGA |
| Project leader: | Mgr. Marko Martin, PhD. |
| SAS cosolvers: | Mgr. Bajzová Barbora, Ing. Bendžala Štefan, RNDr. Cimrová Barbora, PhD., Mgr. Kubinec Adam, Mgr. Marko Martin, PhD., Mgr. Michalko Drahomír, PhD., Mgr. Mitka Milan, PhD., MUDr. Riečanský Igor, PhD., Mgr. Rovný Rastislav |
| Annotation: | Semantic cognition underpins the processing, organization, and fluid retrieval of knowledge (facts, concepts, and their relations) stored in memory. It regulates mental processes and adaptive behavior, whereas deterioration of this system is present among several neuropsychiatric disorders and diseases. The aim of this project is to identify cognitive and neurobiological mechanisms that support the ability to search and retrieve conceptual representations within semantic memory. For this purpose, we will carry out a set of original experiments that combine systematic manipulation of cognitive interference, the measurement of cognitive load (effort) using pupillometry, and non-invasive (transcranial) electrical brain stimulation. Via such interdisciplinary approach, we intent to characterize key neurocognitive determinants of automatic and control (executive) functions of the human semantic system, which may inspire effective interventions for their enhancement. |
| Neuroprotective and cardioprotective potential of phenol acids in the prevention of civilization diseases | |
| Duration: | 1. 1. 2023 - 31. 12. 2026 |
| Evidence number: | VEGA 2/0018/23 |
| Program: | VEGA |
| Project leader: | RNDr. Gáspárová Zdenka, PhD. |
| SAS cosolvers: | MVDr. Bezek Štefan, DrSc., RNDr. Dubovický Michal, CSc. , RNDr. Juránek Ivo, PhD., DrSc., RNDr. Knezl Vladimír, PhD., Ing. Lepáček Marek, Ing. Pádej Ivan, Ing. Švík Karol, CSc. |
| Annotation: | The risk of the civilization disease can be reduced by adjusting the lifestyle and a diet low in fat and increasing the intake of vegetables and fruits rich in flavonoids. These include phenolic acids (PA), small molecules with good bioavailability, and beneficial effects on the body. The project is focused on the cardioprotective and neuroprotective effects of PA on the heart and hippocampus of rats in vitro. After selecting the most effective PA from in vitro experiments, this will be tested in vivo in a model of a metabolic syndrome induced by a high fat-fructose diet. A project innovation lies in (i) the use of promising low molecular weight PA, and (ii) the application of magnetic resonance spectroscopy for non-invasive monitoring of the neurochemical profile changes in the rat brain. The determination of inflammation and oxidative stress markers offers to characterize the mechanism of action of the selected PA. The behavioral test (NOR) will provide data on learning and memory improvements. |
| The contribution of new nano-carrier drug delivery systems to the enhancement of the anti-inflammatory effect of D-limonene, phellandrene, isoborneol and chrysophanol studied in vivo (2/0091/23) | |
| Duration: | 1. 1. 2023 - 31. 12. 2026 |
| Evidence number: | 2/0091/23 |
| Program: | VEGA |
| Project leader: | PharmDr. Dráfi František, PhD., MPH |
| SAS cosolvers: | PharmDr. Bauerová Katarína, PhD., DrSc., Mgr. Chrastina Martin, PharmDr. Khademnematolahi Sasan , Ing. Mihalová Danica, PharmDr. Poništ Silvester, PhD., Ing. Švík Karol, CSc., PharmDr. Taghdisiesfejír Mohsen, Mgr. Tóthová Nikola |
| Other cosolvers: | Bilková Andrea, Špaglová Miroslava, Kiňová Sepová Hana, Mikušová Veronika, Žigrayová Dominika (doktorand), Ferková Jarmila (doktorand). |
| Annotation: | Based on the scientific literature we hypothesize that an optimal anti-inflammatory effect of a selected naturalsubstance after its oral administration in its new nano-carrier drug delivery systems (NCDDS) might beneficiallymodulate immune processes in inflammatory diseases as in rheumatoid arthritis (RA). Adjuvant arthritis (AA) is used as one of the in vivo RA models to evaluate the pharmacology of molecules tested. High bioavailability will be achieved by the technological adjustment of the molecules into NCDDS (nanoemulsions and liposomes). Along with other parameters evaluated and focused mainly on inflammation, we will analyze the ability to reduce bone erosion and/or synovitis by the RANKL/RANK/osteoprotegerin signalling pathway. The significant benefit will be statistically assessed by their dose-dependency evaluation and possible synergic/additive pharmacological determination of concomitantly applied standards as methotrexate and upadacitinib, administered both in (sub)therapeutic doses. |
| SUFIBAR - Targeted suppression of pro-inflammatory and pro-fibrotic signaling pathways to prevent heart failure and occurrence of malignant arrhythmias | |
| Duration: | 1. 7. 2022 - 30. 6. 2026 |
| Evidence number: | APVV-21-0410 |
| Program: | APVV |
| Project leader: | RNDr. Szeiffová Bačová Barbara, PhD. |
| SAS cosolvers: | Mgr. Andelová Katarína, PhD., Mgr. Andelová Natália, PhD., RNDr. Barančík Miroslav, DrSc., Mgr. Boťanská Barbora, PhD., RNDr. Egan Beňová Tamara, PhD., Mgr. Farkašová Veronika, PhD, Mgr. Ferenczyová Kristína, PhD., Ing. Ferko Miroslav, PhD., Mgr. Fogarassyová Mária, Mgr. Kaločayová Barbora, PhD., RNDr. Knezl Vladimír, PhD., RNDr. Kura Branislav, PhD., RNDr. Okruhlicová Ľudmila, CSc., D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS, RNDr. Sýkora Matúš, PhD., RNDr. Tribulová Narcisa, DrSc., RNDr. Vlkovičová Jana, PhD. |
| Annotation: | Heart failure is characterized by a progressive reduction in cardiac output and occurrence of malignant arrhythmias resulting in substantial morbidity and mortality worldwide. Cardiac fibrosis, the key factor contributing to these life-threatening events, is still unresolved problem in clinic. Detection and management of myocardial fibrosis suffer from a lack of precision, therefore, novel approaches are extremely needed. We hypothesize that the determination of myocardial fibrosis phenotypes in a disease-specific way may reveal more precisely molecular targets for efficient prevention and/or treatment. The idea of the project is to differentiate myocardial fibrosis phenotypes via assessment of circulating markers of oxidative stress, inflammation and pro-fibrotic components along with determining the activation of actual signaling pathways and extent of fibrosis. In the same time to explore efficacy of selected compounds, AT1 receptor blocker, ACE inhibitor, melatonin, triiodothyronine, metoprolol, omega-3 fatty acids and molecular hydrogen, to suppress pro-inflammatory and pro-fibrotic signaling pathways including purinergic signaling mediated by connexin-43 hemichannels and panexin-1 channels and to prevent or attenuate adverse structural and electrical remodeling. Novel findings may provide fundamental input to targeted therapy aimed to reduce myocardial fibrosis burden and challenge to realize well designed clinical trials. |
| CARDIOPROT - New aspects of cardioprotection by natural antioxidants: role of ageing and lifestyle-related comorbidities | |
| Duration: | 1. 7. 2022 - 30. 6. 2026 |
| Evidence number: | APVV-21-0194 |
| Program: | APVV |
| Project leader: | doc. RNDr. Barteková Monika, PhD. |
| SAS cosolvers: | RNDr. Bališ Peter, PhD., RNDr. Barančík Miroslav, DrSc., Mgr. Berényiová Andrea, PhD., Mgr. Boťanská Barbora, PhD., Mgr. Farkašová Veronika, PhD, Mgr. Ferenczyová Kristína, PhD., Mgr. Fogarassyová Mária, Mgr. Kaločayová Barbora, PhD., Mgr. Kindernay Lucia, PhD., RNDr. Kura Branislav, PhD., MUDr. RNDr. Púzserová Angelika, PhD., RNDr. Sýkora Matúš, PhD., RNDr. Szeiffová Bačová Barbara, PhD., Mgr. Šnúriková Denisa, RNDr. Vlkovičová Jana, PhD. |
| Other cosolvers: | Radoš |
| Annotation: | Despite the important progress in the treatment of cardiovascular disease (CVD), the new therapeutic strategies as well as mechanisms involved are still being extensively studied to reach the optimal efficiency of the therapy. Ischemia/reperfusion (I/R) injury represents a clinically relevant problem associated with CVD (including ischemic heart disease and myocardial infarction) as well as with cardiac surgery. Natural antioxidants including flavonoid quercetin and several catechins have been shown to exert protective effects against cardiac I/R injury. However, most of the experimental studies have been performed in young healthy animals what is not corresponding to the situation in real life where the patients prone to acute ischemic event (myocardial infarction) are usually aged people suffering from some comorbidities such as hypertension or metabolic disorders. Thus the aim of the current project is to reveal the real therapeutic potential of selected natural antioxidants, quercetin and epicatechin against cardiac I/R injury in aged subjects and subjects suffering from selected metabolic comorbidities (type 2 diabetes, hypertriglyceridemia) and hypertension. Another goal of the project is to uncover intra- as well as intercellular mechanisms involved in the action of selected antioxidantss in individuals with comorbidities exposed to cardiac I/R, including their interactions with mechanisms involved in development of selected comorbidities. Meeting the objectives of the project will significantly help to better management of patients suffering from CVD, particularly from acute myocardial infarction |
| Aldo-keto reductase inhibitors in the personalized therapy of several types of cancer | |
| Duration: | 1. 1. 2022 - 31. 12. 2025 |
| Evidence number: | 2/0087/22 |
| Program: | VEGA |
| Project leader: | Ing. Šoltésová Prnová Marta, PhD. |
| SAS cosolvers: | Mgr. Boďo Pavol, RNDr. Kováčiková Lucia, PhD., Ing. Lepáček Marek, Ing. Štefek Milan, CSc. |
| Annotation: | Increased expression of aldo-keto reductases (AKRs) in tumors of lung, breast, prostate, cervix, testes and colon were reported, and the role of AKRs in the etiology of colorectal carcinoma has been confirmed. Although the AKRs have been studied extensively in the context of diabetic complications, studies in the last decade reveal the role of AKRs in the chemoresistance. The project will focus on the exploration of novel specific targets of chemoresistance represented by the AKRs and will comprise a multidisciplinary approach based on recognition of relevant genetic factors, namely specific mutations that cause chemoresistance, and their relationships to the molecular pathways mediated by AKRs. Moreover combination of QSAR and medicinal chemistry approaches will be used to explore the chemical space of AKR inhibitors with the aim to find the chemical entities of the highest efficacy and selectivity. The project is expected to contribute to establishing personalized therapy of cancer. |
| - | |
| Duration: | 1. 1. 2022 - 31. 12. 2025 |
| Evidence number: | 2/0063/22 |
| Program: | VEGA |
| Project leader: | Mgr. Heger Vladimír, PhD. |
| SAS cosolvers: | RNDr. Horáková Ľubica, PhD., Mgr. Kissova Lea, RNDr. Lomenová Jana, PhD., Mgr. Rezbáriková Petronela, PhD. |
| New methods of treating heart failure. Prevention of oxidative stress by molecular hydrogen. | |
| Duration: | 1. 1. 2022 - 31. 12. 2025 |
| Evidence number: | 2/0092/22 |
| Program: | VEGA |
| Project leader: | RNDr. Kura Branislav, PhD. |
| SAS cosolvers: | Formanková Iveta, Mgr. Kaločayová Barbora, PhD., Kniesová Adela , Mgr. Pavelková Patrícia, D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS, Mgr. Šnúriková Denisa, RNDr. Vlkovičová Jana, PhD. |
| Annotation: | Heart failure (HF) globally affects approximately 26 million people worldwide. Despite many therapeutic advances in the symptomatic treatment of HF, the prevalence, mortality and costs associated with treatment in developed countries continue. One of the key mechanisms involved in the development of the pathophysiology of the failing heart is the uncontrolled overproduction of reactive oxygen species, which causes damage to lipids in membranes, mitochondria, proteins and DNA, leading to cell death. Blocking hydroxyl and nitrosyl radicals could therefore prevent the destruction of cellular components and the progression of HF.Recently, it was discovered that molecular hydrogen (H2) has a protective effect in the case of damage to various organs, mainly due to its antioxidant activity. We hypothesize that H2 application could be a new effective treatment for HF patients. The project is aimed at investigating the therapeutic use of H2 and its ability to act cardioprotectively in the isoproterenol-induced HF model in older rats. |
| Study of the role of innate cardioprotection in the rat myocardium evoked by non-pharmacological adaptive stimuli under normal and pathological conditions. | |
| Duration: | 1. 1. 2022 - 31. 12. 2025 |
| Evidence number: | 2/0104/22 |
| Program: | VEGA |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| SAS cosolvers: | Mgr. Andelová Natália, PhD., prof., PharmDr. Duriš Adameová Adriana, PhD., Mgr. Farkašová Veronika, PhD, Ing. Ferko Miroslav, PhD., RNDr. Kura Branislav, PhD., D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS |
| Annotation: | Despite advances in pharmacotherapy, interventional cardiology, and surgery, a growth of ischemic heart disease as one of the main reasons for heart failure will not reduce over the next decades. It is due to longer survival aftermyocardial infarction (IM) but gradual impairment of its function and incidence of comorbidities. Attenuation of IM consequences employing ischemic “preconditioning“ (PC) is not commonly used in clinical praxis due to technical requirements and short-term duration. On the other hand, there are other adaptive interventions such as PC in a distant organ, physical activity, and/or chronic or acute hypoxia. Their advantage over classical IPC is anoninvasive, relatively simple, and safe mode of introduction with a possibility of repeated application that may be a prerequisite of greater efficiency in humane medicine. It is assumed that application of noninvasive forms of PC induces similar effects as IPC – activation of cell signaling cascades of endogenous cardioprotection |
| Development of diabetic nephropathy and its treatment with nutraceutic in experimental conditions | |
| Duration: | 1. 1. 2022 - 31. 12. 2025 |
| Evidence number: | 2/0148/22 |
| Program: | VEGA |
| Project leader: | Mgr. Kaločayová Barbora, PhD. |
| Development of multifunctional aldose reductase inhibitors based on triazinoindoles: Optimization of their biological activity, selectivity, bioavailability and antioxidant properties. | |
| Duration: | 1. 1. 2022 - 31. 12. 2025 |
| Evidence number: | 2/0008/22 |
| Program: | VEGA |
| Project leader: | RNDr. Kováčiková Lucia, PhD. |
| SAS cosolvers: | Mgr. Boďo Pavol, RNDr. Májeková Magdaléna, PhD., Ing. Šoltésová Prnová Marta, PhD., Mgr. Šramel Peter, PhD., Ing. Štefek Milan, CSc. |
| Annotation: | Aldose reductase inhibitors (ARIs) have been developed as therapeutics for the treatment of diabetic complications, inflammation and some types of cancer associated with chronic inflammation. In our previous projects, we identified derivatives of indol-1-yl acetic acid, 2-(3-thioxo 2H-[1,2,4]triazino[5,6-b]indol-5(3H)-yl)acetic acid (cemtirestat, CMTI) and 2-(3-oxo-2H-[1,2,4]triazino[5,6-b]indol-5(3H)-yl)acetic acid (OTI) as lead structures. Their high inhibitory effect and selectivity, favorable physicochemical parameters and good water solubility render these derivatives as promising candidates for structure optimization. The project focuses on the design and chemical synthesis of new structural analogs by optimizing the 5-carboxymethyltriazinoindole skeleton, in order toincrease inhibitory activity, selectivity, bioavailability, antioxidant activity and improve ADME properties. Theefficacy of the new derivatives will then be evaluated in vitro and ex vivo by a structure-activity relationship (SAR)study. |
| Zofenopril and erucin, H2S releasing coumpounds, in therapy of cardiovascular disorder in experimental model of obesity and 2 type diabetes | |
| Duration: | 1. 1. 2022 - 31. 12. 2025 |
| Evidence number: | 2/0147/22 |
| Program: | VEGA |
| Project leader: | RNDr. Čačányiová Soňa, PhD. |
| SAS cosolvers: | MSc. Aydemir Basak Gunes, Mgr. Berényiová Andrea, PhD., RNDr. Drobná Magdaléna, PhD., Mgr. Golas Samuel, PhD., Ing. Kožík Jozef, Mgr. Zemančíková Anna, PhD. |
| Annotation: | Hydrogen sulfide (H2S) represents an important gaseous transmitter involved in the vascular tone regulation, however, its role in pathological stages such diabetes and obesity remains unexplained. In both, arterial hypertension and metabolic disorder without obesity, H2S produced by arterial wall could participate in impaired vascular function, on the other side, sulfide signal pathway can be a part of compensatory vasoactive mechanisms. We suppose that the escalated metabolic disorder and obesity could impair balanced action of sulfide pathway and enhance the injury of vascular system. H2S-releasing compounds could provide the treatment leading to the decrease of detrimental vasoactive and pro-oxidative effects. We will investigate the chronic effect of angiotensin-converting enzyme inhibitor zofenopril and natural isothiocyanate erucin, both acting as H2S donors, on cardiovascular system of obese Zucker diabetic rats to confirm or refuse a beneficial effect of therapy with H2S releasing drugs in obesity. |
| ACE2MAS - Cardiometabolic effects of Mas receptor stimulation by modulation of the renin-angiotensin system - the key role of angiotensin-converting enzyme 2 | |
| Duration: | 1. 7. 2021 - 30. 6. 2025 |
| Evidence number: | APVV-20-0421 |
| Program: | APVV |
| Project leader: | RNDr. Čačányiová Soňa, PhD. |
| SAS cosolvers: | Mgr. Golas Samuel, PhD. |
| Annotation: | The renin-angiotensin system (RAS) is a hormonal cascade whose chronic activation contributes to the development of cardiovascular pathologies caused mainly by remodeling of the heart and blood vessels. It is becoming apparent that the benefit of RAS inhibitors includes, in addition to Ang II inhibition, stimulation of the alternative arm of RAS mediated by the ACE2/Ang1-7/Mas receptor, which has vasodilatory, antiproliferative, antiinflammatory and metabolic effects. The aim of the present project will be to compare the effect of ACE inhibition, AT1 blockade, stimulation of ACE2 (diminazene) and Mas receptor (cyclic Ang1-7, alamandine) in a model of old, obese, diabetic hypertensive Zucker rats with a focus on the potential benefit of Ang1-7/Ang1-5 on glucose utilization, insulin signal transduction, reduction of the inflammatory response and function of the cardiovascular system. Given the potentially key role of RAS and especially ACE2 in the development of acute respiratory distress syndrome (ARDS) and the severe course of COVID-19, the aim of the present project will be to detect changes in membrane and serum ACE2 and expression of other key molecules for viral infection (ADAM17, TMPRSS2, furin and B0AT1 transporter) using various pharmacological interventions. The dependence of the putative alterations on the activity of the Mas receptor will be monitored by its specific antagonist A779. In vitro, following treatment of human alveolar cells and adipocyte cultures with RAS and diminazene inhibitors, the changes in the ability to bind SARS-CoV-2 virus will be assessed using a pseudoviral methodology. The obtained results might contribute to the elucidation of the role of ACE2 and Mas receptor in the pathogenesis of obesity and diabetes. The project might also contribute to the clarification of the choice of an effective RAS inhibitor in the elderly with a combination of hypertension, obesity and diabetes. |
| NEKDIAKAR - Necroptotic and pleiotropic effects of RIP3 kinase acting as a convergent point in cardiac cell loss: understanding the basic mechanisms in the ischemic heart with or without metabolic stress as a tool for designing therapeutic approaches. | |
| Duration: | 1. 7. 2021 - 30. 6. 2025 |
| Evidence number: | APVV-20-0242 |
| Program: | APVV |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| Annotation: | Necroptosis, which has been found in ischemic heart, seems to be a significant factor in the body\'s fate. Themechanisms responsible for execution of this cell death are not fully elucidated and the canonical RIP1-RIP3-MLKLpathway does not appear to be the only one responsible for such cell loss. We suggested a dual pronecroptoticand proinflammatory role of RIP3 in the pathogenesis of post-infarction heart failure. In addition, we have indications on other pleiotropic action of RIP3 being associated with oxidative stress, as well as affectingmitochondrial activity and dynamics. Thus, it appears that RIP3, but not RIP1, may be a key node in intracellularsignaling. The proposed processes in the heart damaged by ischemia and reperfusion need to be examined in detail and it is also necessary to determine whether RIP3 inhibition is able to limit these processes and thusalleviate cardiac dysfunction and remodeling. A considerable originality of the project is the study of necroptosis in a metabolically-stressed heart due to diabetes and its precursor - prediabetes and its contribution to heart damage. We will investigate the canonical and the newly-proposed RIP3-mediated signaling and evaluate their activation depending on the glucose levels and other biochemical characteristics of these disturbances in glucose metabolism. We hypothesize that antidiabetic therapy is able to mitigate heart damage due to the limitation of necroptosis what is further amplified by antinecroptotic agents. An important concept is the assessment of released markers of necroptosis signaling into the circulation which could be a prognostic and diagnostic approach. Proposed studies and a variety of methodological approaches, employed according to the guideline for the evaluation of necroptosis in the heart, will provide innovative insights into the pathogenesis of prediabetic and diabetic heart and its damage due to ischemia, and thereby indicate a significant pharmacotherapeutic target. |
| StrokeRehab - Novel approach to post-stroke rehabilitation. A basic and translational study, aiming to restore posture control and body symmetry in post-stroke patients by sensory stimulation. | |
| Duration: | 1. 8. 2021 - 30. 6. 2025 |
| Evidence number: | APVV-20-0420 |
| Program: | APVV |
| Project leader: | RNDr. Bzdúšková Diana, PhD. |
| SAS cosolvers: | Mgr. Hirjaková Zuzana, PhD., RNDr. Kimijanová Jana, PhD., Mgr. Marko Martin, PhD., MUDr. Riečanský Igor, PhD., Mgr. Rovný Rastislav, Prof. MUDr. Valkovič Peter, PhD. |
| Annotation: | The main goal of this project is to investigate the pathophysiological mechanisms of keeping balance while sitting and standing in post-stroke patients and to define the rationale for interventions based on visual and proprioceptive stimulations for enhancing balance, impaired trunk mobility and trunk asymmetry. To achieve this, we will use the original method for rehabilitation and monitoring of patients as well as specialized devices together with softwares which we developed during our previous project APVV-16-0233. Stroke is a major health problem, especially considering that post-stroke patients typically have residual impairments to their motor and sensory functions directly affecting their postural system. Keeping balance while sitting up in bed or on a chair is with high probability the first thing a therapist addresses to patients. Controlled trunk function is an important and essential component for standing balance, gait and other daily activities. The voluntary movements of the trunk clearly reveal the postural and movement asymmetry of the upper part of the body. The asymmetric position is most often characterized by one-sided tilt of the trunk or its reduced mobility to one side. We aim to advance knowledge on the abnormal posture due to impairment of dynamic balance as a consequence of stroke, and to exploit visual and proprioceptive stimulations in order to improve posture and trunk asymmetry in post-stroke patients. Finally we will evaluate efficiency of rehabilitation procedures using two different approaches: i) by recording of the centre of pressure using force plate and ii) by recording of trunk tilts using inertial sensors. |
| HHTgINFL - The role of inflammation in the development of cardiovascular complications associated with metabolic syndrome and prediabetes | |
| Duration: | 1. 7. 2022 - 30. 6. 2025 |
| Evidence number: | SK-CZ-RD-21-0102 |
| Program: | APVV |
| Project leader: | RNDr. Čačányiová Soňa, PhD. |
| SAS cosolvers: | MSc. Aydemir Basak Gunes, Mgr. Berényiová Andrea, PhD., RNDr. Cebová Martina, PhD., RNDr. Drobná Magdaléna, PhD., Mgr. Golas Samuel, PhD. |
| Annotation: | Inflammatory conditions are one of the most important pathophysiological factors in the development of cardiovascular diseases. Perivascular adipose tissue (PVAT), its pro-inflammatory activities and its impact on vasoactive functions may play an important role in the development of cardiovascular complications. Moreover, impaired PVAT function leads to the secretion of proinflammatory factors and endothelial dysfunction which could be associated with unbalance in sulfide signaling. The aim of the proposed project will analyze the vasoactive and inflammatory mechanisms in the vessel wall and PVAT with special attention to sulfide signaling in model of metabolic syndrome. Crosstalk among them occurs, but the exact mechanism is unknown. The pro-inflammatory mechanisms are particularly triggered in the early stage of diabetes and metabolic syndrome, therefore, a unique model of prediabetes and metabolic syndrome, hereditary hypertriglyceridemic rats, will be used. Currently, increased attention is focused on aspects of personalized medicine, which can contribute to more effective therapy through precise targeting of a specifically defined group of patients.The development of cardiovascular complications and diabetes may depend on age, reproductive status, and genetic background. Cardiovascular riskis significantly increased in postmenopausal women, while it is lower in women under 40 than in men of the same age. The project will monitor the effect of gender and reproductive status in female rats after surgical ovariectomy to reveal possible differences in the mechanism of cardiovascular disorders and to help to better specify therapeutic targets appropriate to non-obese prediabetic postmenopausal women. In the next part, the project will investigate the possible beneficial effects of the administration of the bioflavonoid troxerutin in lowering the risk of developing cardiovascular complications associated with postmenopausal metabolic syndrome. |
| Multi-Glu - Multi-target approach to diverse molecular mechanisms of diabetic complications and other glucose toxicity related diseases | |
| Duration: | 1. 8. 2021 - 30. 6. 2025 |
| Evidence number: | APVV-20-0534 |
| Program: | APVV |
| Project leader: | RNDr. Májeková Magdaléna, PhD. |
| SAS cosolvers: | Mgr. Benešová Barbora, Mgr. Boďo Pavol, Mgr. Heger Vladimír, PhD., Mgr. Kissova Lea, RNDr. Kováčiková Lucia, PhD., RNDr. Lomenová Jana, PhD., Ing. Micháliková Silvia, PhD., Mgr. Rezbáriková Petronela, PhD., Ing. Šoltésová Prnová Marta, PhD., Mgr. Šramel Peter, PhD., Ing. Štefek Milan, CSc. |
| Annotation: | Diabetes mellitus and other diseases related to the glucose toxicity have multifactorial character comprised ofmultiple mechanisms. Besides others, the mechanisms include increased polyol pathway activity, non-enzymaticglycations of proteins, hexosamine pathway, altered protein kinase C activity, oxidation stress and impairedcalcium signaling. Targeting individual mechanisms could lead to design of new compounds - potential drugs for atreatment of diabetic complications. Our aim is to elucidate the impact and roles of individual mechanisms. In thisendeavor, we will build upon our previous results, which brought a new insight in details of polyols pathwaymechanisms by means of the study of cemtirestat and other novel compounds designed by our group. |
| AMVADYMESE - Significance of endothelial α1AMPK for vascular dysfunction and metabolic senescence in a rat model of metabolic syndrome/diabetes mellitus type II | |
| Duration: | 1. 7. 2022 - 30. 6. 2025 |
| Evidence number: | 1368/03/02 |
| Program: | SASPRO |
| Project leader: | Ing. Kvandová Miroslava, PhD. |
| Annotation: | Endothelial dysfunction is an early common feature of many cardiovascular diseases, caused by decreased nitric oxide (NO) production and/or increased NO inactivation due to oxidative stress. This influences a patient\'s risk of future cardiovascular events1. The overall goal is to improve primary and secondary prevention for cardiovascular diseases. Therefore, analyzing key factors that prevent or positively influence endothelial dysfunction is essential. Working group of prof. Münzel/Daiber (current affiliation) has been focused on the role of AMP-dependent protein kinase (AMPK) for several years. This ubiquitously expressed enzyme is the central energy sensor of cells in the cardiovascular system2. The protective effect of AMPK has been already demonstrated, especially its protective properties on endothelial function, oxidative stress, cell aging, and inflammation3,4. In addition, AMPK regulates many metabolic pathways that are disturbed in the context of diabetes mellitus, such as the activation of glucose transport in skeletal muscle or the inhibition of gluconeogenesis in the liver. These properties suggest that AMPK may improve diabetic metabolic control. It has been shown for diabetes mellitus that vascular changes are prognostically decisive5. Despite enormous research, the molecular changes that lead to endothelial dysfunction and predisposition to cardiovascular diseases due to α1AMPK-related dysregulation are insufficiently known. Therefore, the following questions will be addressed:1. How do α1AMPK influence endothelial function, formation of reactive oxygen species, and vascular inflammation in the rat model of the metabolic syndrome/diabetes mellitus II type?2. Exploring the role of α1AMPK expression in endothelial cell death and the development of metabolic senescence in hyperglycemia and diabetes?3. Are metabolic syndrome/diabetes mellitus II type mediated disorders of the endothelial function associated with the gender-specific regulation of α1AMPK? |
| - | |
| Duration: | 1. 1. 2021 - 31. 12. 2024 |
| Evidence number: | 2/0113/21 |
| Program: | VEGA |
| Project leader: | RNDr. Lomenová Jana, PhD. |
| SAS cosolvers: | Mgr. Benešová Barbora, Mgr. Heger Vladimír, PhD., RNDr. Májeková Magdaléna, PhD., Ing. Micháliková Silvia, PhD., Mgr. Rezbáriková Petronela, PhD. |
| Hyperuricemia in various comorbidities of the metabolic syndrome - mechanisms of the effect of uric acid on endothelial function and erythrocyte deformability. | |
| Duration: | 1. 1. 2021 - 31. 12. 2024 |
| Evidence number: | 2/0153/21 |
| Program: | VEGA |
| Project leader: | RNDr. Bališ Peter, PhD. |
| SAS cosolvers: | RNDr. Bernátová Iveta, DrSc., doc. RNDr. Dovinová Ima, PhD., MUDr. RNDr. Púzserová Angelika, PhD., RNDr. Regecová Valéria |
| Other cosolvers: | Radošinská Jana Doc. MUDr. PhD. |
| Annotation: | Numerous studies have shown a significant complex relationship between increased concentration of uric acid(UA) in blood (hyperuricemia) and noncommunicable diseases, including arterial hypertension, metabolicsyndrome, diabetes mellitus and cardiovascular diseases. Nevertheless, the mechanisms by which hyperuricemialead to organ damage are not elucidated yet. Higher UA levels in blood are independent predictors of general andcardiovascular mortality. UA may have a direct negative effect on endothelial function. Therefore, we are focusingon relationship between hyperuricemia and endothelial function in macro- and microcircula. The quality ofmicrocirculation is to high extent also determined by erythrocyte properties.The main aim of the project is to bring new information about the mechanisms of hyperuricemia-inducedendothelial dysfunction in various comorbidities of the metabolic syndrome, including arterial hypertension,diabetes mellitus, dyslipidemia and obesity, with the focus on microcirculation. |
| Cardioprotective potential of TRP channels: the role in remodelation, inflammation and calcium dysregulation | |
| Duration: | 1. 1. 2021 - 31. 12. 2024 |
| Evidence number: | VEGA SR 1/0775/21 |
| Program: | VEGA |
| Project leader: | Mgr. Farkašová Veronika, PhD |
| Postural threat in virtual reality in adults with height intolerance | |
| Duration: | 1. 1. 2022 - 31. 12. 2024 |
| Evidence number: | 2/0080/22 |
| Program: | VEGA |
| Project leader: | RNDr. Bzdúšková Diana, PhD. |
| SAS cosolvers: | Mgr. Bajzová Barbora, Mgr. Hirjaková Zuzana, PhD., RNDr. Kimijanová Jana, PhD., Mgr. Marko Martin, PhD., MUDr. Riečanský Igor, PhD., Prof. MUDr. Valkovič Peter, PhD. |
| Annotation: | Virtual reality (VR) is suitable for evaluating postural and psychophysiological parameters in different situations and different populations. Fear of height and subsequent fall causes limitations in daily living and avoidance of any height, which represents a postural threat. A possible solution to relieve the stress and anxiety is a stance on an elevated platform in VR, which can repeatedly create a real-life experience that the subject gradually becomes accustomed to, but in safe and controlled conditions. Intervention can be enhanced before exposure to height by transcranial stimulation (tDCS) of the cerebellum, which plays a significant role in postural control. The aim of the project is to gain new knowledge about postural and psychophysiological reactivity during the postural threat in VR and to explore it immediately after tDCS. The obtained results may be beneficial for the rehabilitation of patients with balance disorders, people with height intolerance, and the elderly at risk of falls. |
| SQUID magnetometry of nano- and microparticles, nanocolloids and nanostructures in new applications in the field of biomedicine and materials research associated with the development of new measurement methods and procedures | |
| Duration: | 1. 1. 2021 - 31. 12. 2024 |
| Evidence number: | 2/0141/21 |
| Program: | VEGA |
| Project leader: | RNDr. Bernátová Iveta, DrSc. |
| SAS cosolvers: | RNDr. Cigáň Alexander, CSc., Ing. Dvurečenskij Andrej, PhD., Ing. Lobotka Peter, CSc., Ing. Majerová Melinda, PhD., Mgr. Škrátek Martin, PhD. |
| Role of nuclear factor NRF2-mediated signalling in iron metabolism regulation during stress | |
| Duration: | 1. 1. 2021 - 31. 12. 2024 |
| Evidence number: | 2/0157/21 |
| Program: | VEGA |
| Project leader: | RNDr. Bernátová Iveta, DrSc. |
| SAS cosolvers: | RNDr. Bališ Peter, PhD., doc. RNDr. Dovinová Ima, PhD., Mgr. Kluknavský Michal, PhD., RNDr. Líšková Silvia, PhD., Mgr. Škrátek Martin, PhD. |
| Annotation: | Stress is considered to be an etiological factor associated with the development of various chronic non-communicable diseases. Stress may also alter iron metabolism. Nuclear factor erythroid 2-related factor 2 (NRF2)-regulates several genes involved in iron metabolism. Despite the accelerating information on the roles of NRF2, less is known about the NRF2 signalling in iron metabolism in conditions of stress. Thus, the aim of this project is to investigate the role of NRF2 signalling in iron metabolism in conditions of acute and chronic stress in rats with genetic predisposition to hypertension. In addition, the effects of pharmacological activation of NRF2 signalling and the distinct roles of inducible and endothelial nitric oxide synthases in iron metabolism in stress conditions will be investigated. Thus, we obtain the original results about NO and NRF2-mediated regulation of iron metabolism and about involvement of altered iron metabolism in the development of cardiovascular and metabolic disorders. |
| - | |
| Duration: | 1. 1. 2021 - 31. 12. 2024 |
| Evidence number: | 1/0193/21 |
| Program: | VEGA |
| Project leader: | RNDr. Vrbjar Norbert, CSc. |
| DIAMICROBIOTA - Gut microbiota and diabetic peripheral neuropathy: effect of cemtirestat in rat models of diabetes | |
| Duration: | 1. 7. 2020 - 30. 6. 2024 |
| Evidence number: | APVV-20-0411 |
| Program: | APVV |
| Project leader: | Ing. Šoltésová Prnová Marta, PhD. |
| SAS cosolvers: | Mgr. Boďo Pavol, RNDr. Kováčiková Lucia, PhD., Ing. Švík Karol, CSc. |
| Annotation: | A microbial imbalance inside the gastrointestinal tract (dysbiosis) can be associated with metabolic disorders such as obesity, insulin resistance, diabetes and immunity dysfunction. However, these relationships are still controversial and need further investigation. The aim of this project is focused on better understanding of mutual interactions of gut microbiota and the diabetic state and to reveal their consequences on development of chronic diabetic complications with the main attention to peripheral neuropathy. Effects of cemtirestat, a novel aldose reductase inhibitor, on the above mentioned processes will be studied. The experimental data will produce valuable knowledge on the role of microbiota alterations in the etiology of diabetic peripheral neuropathy and indicate potential therapeutic approaches. |
| Safe-MDs - In vitro biocompatibility testing of medical devices (MDs) and new generation bio-materials for MDs | |
| Duration: | 1. 7. 2020 - 30. 6. 2024 |
| Evidence number: | APVV-19-0591 |
| Program: | APVV |
| Project leader: | Dr.rer.nat., Ing. Kanďárová Helena, ERT |
| SAS cosolvers: | Mgr. Bögi Eszter, PhD., MVDr. Koprdová Romana, PhD., Ing. Lepáček Marek, RNDr. Mach Mojmír, PhD., Ing. Pôbiš Peter, Ing. Račková Lucia, PhD., Straková Zuzana |
| Annotation: | Medical devices (MDs) have an irreplaceable role in the healthcare of the 21st century. The term ‘medical device’ covers a broad spectrum of products that are crucial in diagnosis and treatment, disease prevention and improving the quality of life of people suffering from disabilities or injuries. MD must not cause adverse effects and must demonstrate bio-compatibility with the tissues in the patient’s body.Most of the MDs\' bio-compatibility assessments are still conducted in animals. However, thanks to the advances in cell and 3D tissue engineering and due to the accelerated progress of validation of alternative methods, the MD regulations also utilize in vitro tests, as demonstrated recently by the adoption of the in vitro reconstructed human epidermis (RhE) test for intra-cutaneous testing into the ISO standard 10993-23.The presented research proposal focuses on the development of in vitro methods for biocompatibility assessment of medical devices (MDs) and innovative materials to be used as MDs polymers and that are intended for the use in the oral and vaginal cavities or on/in ocular epithelium. |
| Cognitive and brain mechanisms of semantic processing | |
| Duration: | 1. 7. 2020 - 30. 6. 2024 |
| Evidence number: | APVV-19-0570 |
| Program: | APVV |
| Project leader: | MUDr. Riečanský Igor, PhD. |
| SAS cosolvers: | Ing. Bendžala Štefan, Mgr. Besterciová Dominika, RNDr. Bzdúšková Diana, PhD., RNDr. Cimrová Barbora, PhD., Mgr. Marko Martin, PhD., Mgr. Michalko Drahomír, PhD., Mgr. Mitka Milan, PhD., Mgr. Rovný Rastislav, PhD. |
| Annotation: | Semantic cognition regulates adaptive behavior and its disruption is associated with a number of neuropsychological conditions. Despite recent progress in the field, fundamental cognitive and neurobiological mechanisms of semantic processing remain unknown. This interdisciplinary project introduces a series of experimental studies that are jointly aimed on the rigorous investigation of main neurocognitive mechanisms of semantic cognition and their interactions. For this purpose, we will draw upon original cognitive assessment tools and paradigms, using which we will identify the fundamental semantic processes and determine their relationship with the executive functions and connectivity of semantic memory. Furthermore, by means of electroencephalography (EEG), we will investigate the dynamic of brain activity associated with specific semantic operations and functions. Finally, based on the behavioral and EEG findings, we will use non-invasive transcranial electric brain stimulation (tES) to modulate the excitability and oscillatory activity of the brain regions that support semantic cognition. Such modern and complex experimental approach will shed light on the architecture of the human semantic system and the fundamental cognitive and neuronal mechanisms that govern semantic processing. |
| HNOSES - Study of biological effects of H2S/NO/selenium products and molecular mechanisms of their actions | |
| Duration: | 1. 7. 2020 - 30. 6. 2024 |
| Evidence number: | APVV-19-0154 |
| Program: | APVV |
| Project leader: | Mgr. Berényiová Andrea, PhD. |
| Annotation: | Reactive sulfur (RSS), nitrogen (RNS) and selenium species (RSEs) are groups of simple chemical molecules ofradical or non-radical nature, which interact with cellular components and thereby influence various biologicalprocesses. The study of biological effects of RSS, RNS and RSeS and their mutual interactions is important for theunderstanding of their biological roles, moreover for the potential application of these species in medicine. Ourstudies of the reactive species interaction in the last 3 years showed that:- products of hydrogen sulfide (H2S) and polysulfides (H2Sn, n≥2) interaction with nitric oxide (NO) or seleniumcompounds (R-Se) significantly affect oxygen radicals concentrations, hydroperoxide cleavage, DNA damage, ratblood pressure and tension/relaxation of isolated aorta.- H2S and H2S2 interact with tetracycline antibiotics, mainly doxycycline (DOXY) and thereby produce/inhibitsuperoxide and hydroxyl radicals and induce/inhibit DNA damageThese findings imply the possibility that reactive oxygen species (ROS) and other H2S/NO/R-Se interactionproducts affect (patho)physiological functions in living organisms. In the project´s aims we will build on the previousfindings and investigate following new hypotheses:1) Do mixtures (H2Sn/R-Se, H2Sn/R-Se/NO alebo H2Sn/DOXY) produce ROS or other biologically activecompounds?2) Are these products responsible for production/inhibition of radicals, cleavage of hydroperoxides andinduction/inhibition of DNA damage?3) Do interaction products affect ferroptosis or intracellular calcium concentration in cells?4) Do these products affect rat blood pressure, arterial pulse waveform and tension of isolated arteries?The aim of this project is to investigate the chemical biology, activity and effects of the interaction products oncellular, organ and whole-organism level. These findings may contribute to the development of novel therapeuticinterventions based on the modulation of cellular redox biology. |
| MIRCVD - The role of miRNAs in the onset and progression of cardiovascular diseases - new approach to the protection of the heart in situations of increased production of reactive oxygen species | |
| Duration: | 1. 7. 2020 - 30. 6. 2024 |
| Evidence number: | APVV-19-0317 |
| Program: | APVV |
| Project leader: | RNDr. Kura Branislav, PhD. |
| SAS cosolvers: | Mgr. Andelová Katarína, PhD., Mgr. Andelová Natália, PhD., RNDr. Barančík Miroslav, DrSc., Ing. Ferko Miroslav, PhD., Mgr. Fogarassyová Mária, Ing. Frimmel Karel, PhD., Mgr. Kaločayová Barbora, PhD., Mgr. Kindernay Lucia, PhD., MUDr. Ravingerová Táňa, DrSc., FIACS, D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS, RNDr. Sýkora Matúš, PhD., RNDr. Szeiffová Bačová Barbara, PhD., Mgr. Šnúriková Denisa, RNDr. Tribulová Narcisa, DrSc., RNDr. Vrbjar Norbert, CSc. |
| Annotation: | Despite progress in prevention, diagnosis and treatment, cardiovascular disease (CVD) is one of the highest morbidity and mortality rates in the world. World Health Organization statistics suggest that in 2030 approximately 23.6 million people will die of CVD, particularly from heart failure and myocardial infarction. One of the most common causes of many CVDs is excessive production of reactive oxygen species (ROS). These arise naturally in all organisms that gain energy by oxidizing substrates, but are also the result of various exogenous effects, such as radiation or air pollution. ROSs affect all types of cells in the body. By their activity, they cleave electrons from the molecules, making the surrounding molecules unstable and subsequently damaging other surrounding molecules. This damage process leads to cell apoptosis, tissue damage and pathological processes and diseases. At present, many experimental works emphasize the use of microRNAs (miRNAs) in diagnostics and potentially also in CVD therapy. miRNA is a group of short non-coding RNAs that, upon binding to a protein mRNA chain, inhibit its synthesis, greatly affecting many processes in the body. ROS production and the effect of miRNA expression are linked to the development of many CVDs, so it is important to understand the relationship between these factors. Research into new suitable substances and methods that can positively affect the effects of excessive ROS formation on the cardiovascular system can significantly improve the quality of life of cardiological patients. The aim of the project is to look for suitable substances that will prevent toxic effects of excessively formed ROS and positively affect the mechanisms that cause damage. At the same time, elucidation of the role of miRNA involvement in signaling pathways associated with the action of ROS on the development and progression of various CVDs is also be presented. |
| NEISAD - The role of non-ischemic adaptive stimuli in protection of ischemic myocardium: study of triggering mechanisms and cardioprotective cell signaling | |
| Duration: | 1. 7. 2019 - 30. 6. 2024 |
| Evidence number: | APVV-19-0540 |
| Program: | APVV |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| Annotation: | Cardiovascular diseases, especially ischemic heart disease (IHD) as a leading cause of heart failure and mortalityworldwide, will not reduce over the coming decades despite the progress in pharmacotherapy, interventionalcardiology and surgery. It is due to aging population and longer survival after acute myocardial infarction (MI),gradual decline of its function and incidence of comorbidities (diabetes, hypertension, dyslipidemia). Experimentalstudies revealed attenuation of MI by adaptive phenomenon of ischemic “conditioning“. However, it is not usuallyapplicable in clinical medicine. In line with translation-oriented research, the project is aimed to: 1. verify theefficiency of cardioprotection induced by non-ischemic stimuli, such as motoric activity, hypoxia and non-invasiveremote “conditioning“; 2. identify triggering mechanisms and pathways of signal transduction (“survival” cascadesRISK and SAFE) to the target structures involved in heart injury reduction (mitochondrial permeability transitionVV 2019 Základný výskumAPVV-19-0540Akronym: NEISAD 06.07.2020 10:48 Strana/Page: 2pore, MPTP, nuclear PPAR receptors); 3. investigate the impact of comorbidities, age and gender on the adaptiveprocesses considering functional, structural and subcellular cardiac alterations. Special emphasis will be placed onthe role of small non-coding RNA (miRNA) regulating cell “survival” pathways and processes of apoptosis andnecroptosis associated with cell oxidative state and Ca2+ homeostasis. We will focus on disclosure of the benefitsof combination therapy: pleiotropic effects of PPAR agonists, MPTP inhibitors, coupled with noninvasive adaptiveinterventions not only under normal but also under pathological conditions (hypertension, hyperlipidemia,hyperglycemia). On animal in vivo and ex vivo models, combination of physiological, biochemical, selectedbiophysical and molecular biology methods will enable to elucidate processes of heart failing/regeneration and gainresults that may lead to development of novel/modified strategies of IHD management. |
| OffRISK - Novel antidepressant therapy - long term consequencies on offspring | |
| Duration: | 1. 7. 2020 - 28. 6. 2024 |
| Evidence number: | APVV-19-0435 |
| Program: | APVV |
| Project leader: | RNDr. Dubovický Michal, CSc. |
| Annotation: | Maternal depression experienced during pregnancy endangers both mother and her offspring. It may alter brain activity of offspring on multiple systemic level. Behavioral changes observed in offspring are caused not only by depression-altered maternal behavior, but also by biochemical changes in offspring brain occurring duringpregnancy and manifested in altered neuronal excitability in relevant brain regions. These alterations may differbetween male and female offspring and may recess during adolescence. Antidepressant treatment duringpregnancy may relieve maternal depression, but it may also prevent negative effects of maternal depression onoffspring. We will focus on consequences of maternal depression on mental and physical status of offspring and on possible prevention of negative consequences by suitable treatment of the mother during pregnancy. We will characterize health status of offspring on multiple systemic levels starting with whole animal level characterized by animal behavior, through altered neuronal excitability on level of neuronal networks, following with excitability of individual neurons, biochemical alterations of neuronal metabolism, up to subcellular regulation of calcium homeostasis. We will investigate health effect and underlying cellular mechanism of antidepressant mirtazapine, which is commonly used in clinics, yet mechanism of its action is still not fully understood. We will use an established model of maternal depression activated by three weeks long pregestational stress. During weaning period we will assess maternal behavior of mirtazapine-treated and mock-treated mothers. Main focus of the project will be on effects of maternal stress on second generation, i.e., on offspring of treated and untreated of depressed mothers. Further, we will differentiate effects on male and female pups. |
| Experimental therapy of neonatal hypoxic-ischemic encephalopathy (nHIE): potentiation of hypothermic neuroprotection by melatonin in newborn rats | |
| Duration: | 1. 1. 2020 - 31. 12. 2023 |
| Evidence number: | 2/0166/20 |
| Program: | VEGA |
| Project leader: | RNDr. Juránek Ivo, PhD., DrSc. |
| Annotation: | Neonatal hypoxic-ischemic encephalopathy (nHIE) is among most serious causes of mortality and morbidity in newborns. Efficacy of current nHIE treatment is rather low. Routinely used therapeutic hypothermia (HT) is only partially effective. To augment hypothermic neuroprotection, drugs like erythropoietin, anticonvulsants, antioxidants and inert gases are tested. In this project, using newborn rats, we will study possible augmentation of hypothermia effect by combining HT with melatonin (MEL)-derived antioxidants. We will assess brain damage and efficacy of each intervention by various techniques, including noninvasive in vivo MRI and MRS, histology and neurobehavioral testing. Novelty of the project lies in testing our idea that MEL-derivative possessing antioxidative properties 100 fold higher than MEL will be more effective in potentiating the hypothermic effect than MEL itself. Anticipated results may help understand better nHIE mechanisms and to propose new strategies to treat birth asphyxia effectively. |
| - | |
| Duration: | 1. 1. 2020 - 31. 12. 2023 |
| Evidence number: | 2/0136/20 |
| Program: | VEGA |
| Project leader: | PharmDr. Bauerová Katarína, PhD., DrSc. |
| SAS cosolvers: | RNDr. Dubovický Michal, CSc. , Mgr. Chrastina Martin, PharmDr. Khademnematolahi Sasan , Ing. Mihalová Danica, PharmDr. Poništ Silvester, PhD., Mgr. Pružinská Katarína, Ing. Švík Karol, CSc., PharmDr. Taghdisiesfejír Mohsen, MSc. Viñas Noguera Mireia |
| Bio-compatibility assessment of medical devices and novel medical device materials using in vitro methods based on 3D reconstructed human tissue models. | |
| Duration: | 1. 1. 2020 - 31. 12. 2023 |
| Evidence number: | 2/0153/20 |
| Program: | VEGA |
| Project leader: | Dr.rer.nat., Ing. Kanďárová Helena, ERT |
| SAS cosolvers: | RNDr. Mach Mojmír, PhD., Ing. Milec Lucia, Ing. Pôbiš Peter, Ing. Račková Lucia, PhD., Straková Zuzana |
| Annotation: | The project focuses on the development of highly sensitive and reproducible methods for in vitro safety and bio-compatibility assessment of medical devices (MDs) and assessment of bio-compatibility of innovative materials that may come into the direct contact with human tissues, namely oral and vaginal cavity and ocular epithelium.Representative reconstituted human tissue models (i.e., in vitro 3D models of cornea and models of oral and vaginal epithelium) will be exposed to a set of precisely characterized reference samples representing materials and chemicals used in the manufacturing process of MDs, including toxic impurities and irritating monomers, which may result of manufacturing and/or sterilization cycle.Early detection of toxic materials and impurities in MDs that may pose health risk to patients and consumers will help to increase the safety of medical devices. At the same time, in vitro methods will help to reduce or eliminate the need for follow-up tests on animals in selected classes of MDs. |
| Mesenteric perivascular fat and its specific role in regulation of intestinal circulation in rats with different feeding regimens | |
| Duration: | 1. 1. 2021 - 31. 12. 2023 |
| Evidence number: | 2/0156/21 |
| Program: | VEGA |
| Project leader: | Mgr. Zemančíková Anna, PhD. |
| SAS cosolvers: | Mgr. Berényiová Andrea, PhD., RNDr. Čačányiová Soňa, PhD., RNDr. Poljak Valašková Zuzana, PhD., doc. MUDr. Török Jozef, CSc. |
| Annotation: | This project will solve questions to what extent and in which way might the different diet and feeding regimens(intermittent, ad libitum, high fat diet) influence the regulation of smooth muscle activity of rat mesenteric arteriesby perivascular fat, and which signal mechanisms participate on these processes. Besides healthy individuals,obese rats will be used in which the vascular sympathetic tone is enhanced and its activity is specificallyregulated by mesenteric adipose tissue. On isolated conduit and small mesenteric arteries, the effect ofmesenteric fat on their reactivity, biochemical processes, and function of perivascular nerves will be measured.The results of this study should be aimed to respond the question how much these processes might be involvedin ingestion/utilization of food in subjects under different dietary regimens, and subsequently in regulation of bodyweight and visceral adiposity in individuals negatively influenced by obesity. |
| Are connexin channels involved in extracellular matrix remodeling of overloaded heart? | |
| Duration: | 1. 1. 2020 - 31. 12. 2023 |
| Evidence number: | 2/0002/19 |
| Program: | VEGA |
| Project leader: | RNDr. Tribulová Narcisa, DrSc. |
| SAS cosolvers: | RNDr. Egan Beňová Tamara, PhD., RNDr. Knezl Vladimír, PhD., RNDr. Sýkora Matúš, PhD., RNDr. Szeiffová Bačová Barbara, PhD. |
| Annotation: | Cardiac connexin (Cx) channels that are localized at the gap junctions in intercalated discs ensure electrical and molecular signals propagation among cardiomyocytes. Such direct intercellular signaling is essential for synchronized heart contraction. Cardiovascular diseases in humans as well as in animal models are accompanied by abnormal Cx43 expression and its enhanced localization to the lateral sides of the cardiomyocytes. Consequently, it deteriorates synchronized heart function and increase a risk for malignant arrhythmias. Based on general knowledge and our studies we hypothesize that laterally localized Cx43 channels might transmit signals from cardiomyocytes into extracellular space and by this way contribute to adverse extracellular matrix remodeling. Intention of the project is to reveal the possible implication of Cx43 channels in modulation of extracellular space in diseased heart. It may stimulate to search novel approaches in protection from cardiac dysfunction and arrhythmias. |
| Comparison of antidepressant effects of natural psychoplastogen and an mTOR activator in animal model of depression | |
| Duration: | 1. 1. 2021 - 31. 12. 2023 |
| Evidence number: | 2/0118/21 |
| Program: | VEGA |
| Project leader: | RNDr. Vranková Stanislava, PhD. |
| SAS cosolvers: | Ing. Bendžala Štefan, Mgr. Benko Jakub, RNDr. Bzdúšková Diana, PhD., RNDr. Cimrová Barbora, PhD., doc. MUDr. Janega Pavol, PhD, RNDr. Klimentová Jana, PhD., MUDr. Riečanský Igor, PhD., Mgr. Rovný Rastislav, PhD. |
| Annotation: | Increasing prevalence of depression presents an unavoidable problem for psychiatry. Existing antidepressantsexert their effect only after several weeks of continuous treatment. In addition, their serious side effects inone-third of patients call for urgent action. Recent advances have given rise to the concept of psychoplastogens.These compounds are capable of fast structural and functional rearrangement of neural networks by targetingmechanisms previously implicated in the development of depression. Furthermore, evidence shows that theyexert potent acute and long-term positive effects. Several of them are naturally occurring compounds, such as7,8-dihydroxyflavone (7,8-DHF). The aim of our study is to investigate the effects of 7,8-DHF and NV-5138, anmTOR (mammalian target of rapamycin) activator, and their combinations, on the development of depressive-likesymptoms in animal model. Results of this project will contribute to elucidating the pathogenesis of depressionand their treatment possibilities. |
| The use of mass spectrometry for comparative study of different rats strains glycoprofiles within metabolic disturbances intervention | |
| Duration: | 1. 1. 2021 - 31. 12. 2023 |
| Evidence number: | VEGA-02/0104/21 |
| Program: | VEGA |
| Project leader: | Ing. Brnoliaková Zuzana, PhD. |
| SAS cosolvers: | MVDr. Bezek Štefan, DrSc., MSc Kapoor Sonam, Ing. Pádej Ivan, Ing. Račková Lucia, PhD., Doc. RNDr. Ujházy Eduard, CSc. |
| Annotation: | Metabolic syndrome (MetS) defines a cluster of interrelated risk factors for diabetes mellitus. Glycobiology ishelping in search for biomarkers of severe diseases, the bioanalytical metods were patented. We hypothesize:the glycomic profiling of blood sera has the potential in MetS diagnostics. The goals are to acquire glycomicprofiles, by means of mass spectrometry, derived from blood sera of different rats strains; to characterize theircomposition; to correlate with pathophysiology; to evaluate the differences with respect to the glycosylationchanges (sialylation, fucosylation). In vivo: to realize the study with nutritional intervention; to evaluate the effectof allimentary habits preferences on the metabolic condition. In vitro: to investigate the impact of key mechanismsof MetS in association with cellular glycoprofile induced changes. As the output: might be the model glycomic toolfor basic research appointed to test therap. approaches with perspespective for clinical researchrecommendations. |
| Prenatal programming of adult diseases: treatment and prevention of outcomes of gestational hypoxia in rat offspring | |
| Duration: | 1. 1. 2020 - 31. 12. 2023 |
| Evidence number: | 2/0154/20 |
| Program: | VEGA |
| Project leader: | RNDr. Mach Mojmír, PhD. |
| SAS cosolvers: | Mgr. Bögi Eszter, PhD., RNDr. Dubovický Michal, CSc. , RNDr. Gáspárová Zdenka, PhD., MSc Kapoor Sonam, MVDr. Koprdová Romana, PhD., PharmDr. Piešová Michaela, Mgr. Šimončičová Eva, Doc. RNDr. Ujházy Eduard, CSc. |
| Annotation: | Hypoxia during pregnancy, labor or early life stage is a major determinant of neurological morbidity and mortality in the neonatal period. In the last decade the fetal origin of chronic adult diseases was proposed as the most important factor in genesis of diabetes and hypertension in adulthood. The scientists showed that malnutrition, and inadequate oxygen supply during embryofetal development may lead to the inadequate apoptosis/necrosis, and caused maldevelopment of the organs responsible for regulation blood pressure, glucose, or improper brain wiring. Although the understanding of perinatal asphyxia-related pathophysiology is gradually increasing, limited therapeutic options are available to prevent or even mitigate the devastating process that unfolds after injury. Mitochondria-targeted antioxidants (MTA) are one of the most important therapies for providing neuroprotection in cerebral ischemia. The aim of the project will be to explore the possibilities of using MTA in late gestational hypoxia model. |
| Crosslinking of some necrosis-like forms of cell death: signaling and a multi-targeting tool to mitigate heart damage due to ischemia? | |
| Duration: | 1. 1. 2020 - 31. 12. 2023 |
| Evidence number: | VEGA SR 1/0016/20 |
| Program: | VEGA |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| SAS cosolvers: | Mgr. Farkašová Veronika, PhD, Ing. Ferko Miroslav, PhD. |
| Annotation: | Necrosis-like cell death (CD), such as necroptosis and pyroptosis, and autophagy seem to play a more significant role in cardiac damage than apoptosis. Their signaling is complex and involves some common proteins whose activation depending on conditions leads to the certain form of CD. In the ischemic heart, we examine the relationship between these forms of CD and determine whether the necroptotically damaged area of the heart causes propagation of damage to surrounding tissue due to release of pyroptosis-linked molecules. Their analysis, including TNF, is aimed to assess CD induction. Sensitivity of individual heart cells to such molecules and paracrine pro-necroptotic signaling will be examined. We study whether autophagy induced by cardiac ischemia is associated with or converts to necroptosis. We also test whether the simultaneous inhibition of the particular forms of CD is more effective than individual inhibition in limiting cell death and ameliorating cardiac dysfunction and remodeling. |
| SVBENMKVS - Investigation of endotoxin effects on mechanosensoric complex in the heart of normotensive rats. | |
| Duration: | 1. 12. 2020 - 31. 12. 2023 |
| Evidence number: | 2/0073/20 |
| Program: | VEGA |
| Project leader: | RNDr. Okruhlicová Ľudmila, CSc. |
| SAS cosolvers: | Ing. Frimmel Karel, PhD., Mgr. Kindernay Lucia, PhD., D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS |
| Study of new mechanisms of cardioprotection against ischemia-reperfusion injury of the heart: role of extracellular vesicles, non-coding RNAs and impact of metabolic co-morbidities on these mechanisms | |
| Duration: | 1. 1. 2020 - 31. 12. 2023 |
| Evidence number: | 2/0104/20 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Barteková Monika, PhD. |
| SAS cosolvers: | RNDr. Barančík Miroslav, DrSc., Mgr. Ferenczyová Kristína, PhD., Mgr. Fogarassyová Mária, Mgr. Jelemenský Marek, Mgr. Kaločayová Barbora, PhD., RNDr. Vlkovičová Jana, PhD. |
| Annotation: | Ischemic heart disease and myocardial infarction represent major diseases associated with ischemia-reperfusion(I/R) injury of the heart. Despite several powerful cardioprotective interventions against I/R injury includingendogenous (e.g. ischemic conditioning) as well as exogenous ones including treatment with natural antioxidants,have been proposed, molecular mechanisms of cardioprotection are not fully clarified so far; moreover, there areserious translational gaps in transferring cardioprotective interventions into clinics due to comorbidities present inreal patients suffering from cardiac I/R injury. The aim of the present project is to uncover the role of extracellularvesicles as new players in cardioprotection, to identify particular non-coding RNAs involved in cardioprotection,and to explore the effect of metabolic co-morbidities on molecular mechanisms and efficiency of cardioprotection,altogether in the sake of effective transfer of experimental knowledge to human personalized medicine. |
| The role of macroautophagy and chaperone-mediated autophagy (CMA) in the responses and adaptation of animal cells to doxorubicin-induced effects | |
| Duration: | 1. 1. 2021 - 31. 12. 2023 |
| Evidence number: | 2/0179/21 |
| Program: | VEGA |
| Project leader: | RNDr. Barančík Miroslav, DrSc. |
| SAS cosolvers: | doc. RNDr. Barteková Monika, PhD., Mgr. Boťanská Barbora, PhD., Mgr. Fogarassyová Mária |
| Annotation: | The project is focused on characterization of the role of macroautophagy and chaperone-mediated autophagy (CMA) in molecular mechanisms involved in responses of animal cells to the effects of doxorubicin (DOX). The aim is also to study the involvement of intracellular (protein kinases) and redox (Nrf2) signaling in regulation of both types of autophagy after DOX effects. The effects of flavonoid quercetin and Nrf2 pathway activator sulphoraphane on modulation of autophagy and autophagy-related signaling after effects of DOX will also be studied. |
| The effect of aging and hypertension on experimental myocardial infarction | |
| Duration: | 1. 1. 2020 - 31. 12. 2023 |
| Evidence number: | 2/0132/20 |
| Program: | VEGA |
| Project leader: | RNDr. Cebová Martina, PhD. |
| SAS cosolvers: | MVDr. Barta Andrej, PhD., RNDr. Klimentová Jana, PhD., doc. RNDr. Pecháňová Oľga, DrSc., Şaman Ezgi, PhD |
| Annotation: | Myocardial infarction is a serious cardiovascular disease associated with cardiac remodeling as a consequenceof ischemia. Hypertension and aging aggravate the consequences of heart attack by the formation of oxidativeand inflammatory mediators in the heart. Mereover, reperfusion after ischemia creates additional oxidative stresswith a negative effect on myocardial tissue. To monitor the signaling molecules that can block or reverse thepathological process of infarction in hypertension is an important hypothesis for successful treatment ofmyocardial infarction. Therefore, our goal will be to exmine the effect of hypertension and aging on myocardialinfarction and to analyze the effect of nitric oxide production, free oxygen radicals, and pleiotropic transcriptionfactor Nrf2. In particular, the activation of Nrf2 and its target genes in elderly individuals may provide a novelmechanism of protection the myocardium from pathological cardiac remodeling. |
| - | |
| Duration: | 1. 1. 2020 - 31. 12. 2023 |
| Evidence number: | VEGA 1/0284/20 |
| Program: | VEGA |
| Project leader: | Ing. Račková Lucia, PhD. |
| SAS cosolvers: | Mgr. Csekes Erika, Ing. Škandík Martin |
| Annotation: | Research work in the field of natural sources of antimicrobial active substances from the last two decades confirms the strong potential of natural substances and extracts, both in the eradication of resistant bacteria and fungi, but also in the prevention of biofilm formation and its destruction. The aim of this project is to test the biological activities of selected plant extracts, their secondary metabolites and their semisynthetic derivatives as potential antimicrobial and antibiofilm, as well as antioxidant, antiphlogistic and immunomodulatory agents. At the same time to exclude their cytotoxic potential on human cells in vitro and to evaluate the fingerprint of plant extracts by modern analytical methods. The target site for the action of these substances should be microbes colonizing skin infections (especially poorly healing, burns, surgical / postoperative wounds) and infections of the oral mucosa (especially the root canals of devital teeth and periradicular tissues). Another aim is to create a combination of active substances / extracts (synergistically acting), which will be adjusted to a gel base, which will be enriched with high-purity micronized beta-glucan in order to eradicate microbes on the skin and mucosa and promote tissue regeneration. |
Finished
| Centre for biomedical research - BIOMEDIRES - II. stage | |
| Duration: | 12. 3. 2020 - 30. 6. 2023 |
| Evidence number: | ITMS2014+: NFP313010W428 |
| Program: | Štrukturálne fondy EÚ Výskum a vývoj |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| TOXINOVAGE - Innovative approaches in toxicology of ageing | |
| Duration: | 1. 7. 2019 - 30. 6. 2023 |
| Evidence number: | APVV-18-0336 |
| Program: | APVV |
| Project leader: | Ing. Račková Lucia, PhD. |
| SAS cosolvers: | Mgr. Baráth Peter, PhD., MVDr. Bezek Štefan, DrSc., Mgr. Bögi Eszter, PhD., Mgr. Brezovska Erika, Ing. Brnoliaková Zuzana, PhD., Mgr. Csatlósová Kristína, PhD., MSc Kapoor Sonam, MVDr. Koprdová Romana, PhD., RNDr. Mach Mojmír, PhD., Ing. Nemčovič Marek, PhD., Ing. Pakanová Zuzana, PhD., Ing. Pančík Filip, PhD., Mgr. Šedivá Mária, PhD., Ing. Škandík Martin |
| The study of structural changes of complex glycoconjugates in the proces of inherited metabolic and civilization diseases | |
| Duration: | 1. 3. 2021 - 30. 6. 2023 |
| Evidence number: | EU projekt ITMS2014+ 313021Y920 |
| Program: | Štrukturálne fondy EÚ Výskum a inovácie |
| Project leader: | Ing. Brnoliaková Zuzana, PhD. |
| Annotation: | The project is focused on the improvement of condition and integration capacities of an excellent independent and industrial research within the functional glycomics with preferencies in inherited metabolic and civilization diseases of humans. The research field is oriented towards the identification of clinically and prognostically relevant glyco-biomarkers and diagnostic approaches. |
| The role of matrix metalloproteinases in pathophysiology of cardiovascular system diseases and their relation to cellular redox signaling. | |
| Duration: | 1. 7. 2019 - 30. 6. 2023 |
| Evidence number: | APVV-18-0548 |
| Program: | APVV |
| Project leader: | RNDr. Barančík Miroslav, DrSc. |
| SAS cosolvers: | doc. RNDr. Barteková Monika, PhD., Mgr. Boťanská Barbora, PhD., Mgr. Ferenczyová Kristína, PhD., Mgr. Fogarassyová Mária, RNDr. Tribulová Narcisa, DrSc. |
| Annotation: | The aim of the project is to characterize the role of matrix metalloproteinases and Nrf2 signaling in responses of cardiac cells to pathological conditions associated with effects of anthracycline doxorubicin and in conditions of diabetes. The goal will also be to determine the effects of Nrf2 activator sulforaphane and flavonoid quercetin on activation of responses mediated by Nrf2 pathway, on modulation of cellular injury, and on changes in activity/function of matrix metalloproteinases. To clarify the mechanisms connected with Nrf2 signaling, the intracellular (protein kinase pathways) and intercellular (connexin-43) signaling as well as regulation of enzymes involved in protection of cells against stress pathological conditions will be determined. |
| BIOVID-19 - Development of biomodels to improve efficiency assessment of drugs and substances that have the potential to treat COVID-19 (BIOVID-19) | |
| Duration: | 9. 6. 2021 - 30. 6. 2023 |
| Evidence number: | 313011AVG3 |
| Program: | Štrukturálne fondy EÚ Regionálny operačný program |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| Other cosolvers: | Lekárska fakulta UK |
| Annotation: | The aim of the project is to develop an animal model to improve the evaluation of the effectiveness of drugs identified as having potential in the treatment of COVID-19. We will use the current knowledge about this disease, but mainly the findings obtained from samples of patients who died in direct connection with COVID-19 infection. We will currently test the most suitable treatment on the developed model. |
| Project website: | http://www.esif-cemsav.sk/ |
| Development of products by modification of natural compounds and study of their multi-modal effects onCOVID-19 disease | |
| Duration: | 1. 7. 2021 - 30. 6. 2023 |
| Evidence number: | 313011ATT2 |
| Program: | Európsky fond regionálneho rozvoja (EFRR) |
| Project leader: | RNDr. Májeková Magdaléna, PhD. |
| SAS cosolvers: | Dr.rer.nat., Ing. Kanďárová Helena, ERT, RNDr. Kováčiková Lucia, PhD., RNDr. Lomenová Jana, PhD., RNDr. Mach Mojmír, PhD., Mgr. Rezbáriková Petronela, PhD., Straková Zuzana, Ing. Šoltésová Prnová Marta, PhD., Mgr. Šramel Peter, PhD. |
| - | |
| Duration: | 1. 10. 2022 - 31. 3. 2023 |
| Evidence number: | |
| Program: | Iné projekty |
| Project leader: | Ing. Ferko Miroslav, PhD. |
| - | |
| Duration: | 1. 1. 2019 - 31. 12. 2022 |
| Evidence number: | 2/0124/19 |
| Program: | VEGA |
| Project leader: | RNDr. Dubovický Michal, CSc. |
| - | |
| Duration: | 1. 1. 2019 - 31. 12. 2022 |
| Evidence number: | VEGA-2/0112/19 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| Cognitive and neurophysiological determinants of semantic cognition | |
| Duration: | 1. 1. 2020 - 31. 12. 2022 |
| Evidence number: | 2/0059/20 |
| Program: | VEGA |
| Project leader: | Mgr. Marko Martin, PhD. |
| SAS cosolvers: | Ing. Bendžala Štefan, Mgr. Besterciová Dominika, MUDr. Jagla Fedor, CSc., Mgr. Michalko Drahomír, PhD., Mgr. Mitka Milan, PhD., Mgr. Mokošáková Miroslava, PhD., MUDr. Riečanský Igor, PhD., Mgr. Rovný Rastislav, PhD. |
| Annotation: | Semantic system creates and structures knowledge that guides adaptive cognition and behavior. The ability to access and use relevant semantic information is underpinned by a number of neurocognitive mechanisms, which are poorly understood. Our research aim is to investigate the cognitive systems and mechanisms that regulate the retrieval of information from semantic memory. For this purpose, we will use systematic manipulation of cognitive load and non-invasive transcranial electrical stimulation (tES) of the prefrontal brain cortex. Using these experimental approaches, we will inspect the role of executive control in semantic retrieval and provide a detailed description of the fundamental cognitive and neurophysiological determinants of semantic retrieval functions. |
| Project website: | https://www.researchgate.net/project/Cognitive-and-neurophysiological-determinants-of-semantic-cognition |
| Modulation of dysregulation of extracellular matrix and intercellular communication as a heart protection from its functional failure | |
| Duration: | 1. 1. 2019 - 31. 12. 2022 |
| Evidence number: | 2/0158/19 |
| Program: | VEGA |
| Project leader: | RNDr. Szeiffová Bačová Barbara, PhD. |
| SAS cosolvers: | RNDr. Barančík Miroslav, DrSc., RNDr. Egan Beňová Tamara, PhD., RNDr. Sýkora Matúš, PhD., RNDr. Tribulová Narcisa, DrSc. |
| Annotation: | Cardiovascular diseases are accompanied by extracellular matrix remodeling and fibrosis associated with impaired myocardial gap junction communication, what subsequently results in the development of heart failure and malignant arrhythmias. Cardiac fibrosis is one of the major problems in medicine with no effective treatment. We aimed in this project to characterize key factors involved in profibrotic signaling in rats with hypertension, altered thyroid status, post-infarction injury and to examine the possibilities of pharmacological and non-pharmacological modulation of these profibrotic factors. This approach should reveal key signaling pathways and proteins whose modulation could reverse or stop fibrosis process and then improve intercellular communication in the myocardium. Project results should contribute to new knowledge potentially usable in clinical practice as well. |
| - | |
| Duration: | 1. 11. 2019 - 31. 12. 2022 |
| Evidence number: | 2019/4-CEMSAV-1 |
| Program: | Iné projekty |
| Project leader: | D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS |
| - | |
| Duration: | 1. 1. 2020 - 31. 12. 2022 |
| Evidence number: | |
| Program: | Vnútroústavné |
| Project leader: | PharmDr. Poništ Silvester, PhD. |
| - | |
| Duration: | 1. 1. 2019 - 31. 12. 2022 |
| Evidence number: | VEGA-1/0035/19 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| TraiN-SafeMDs - Training Network for improving of safety of medical devices - focus on oral cavity | |
| Duration: | 1. 3. 2020 - 31. 12. 2022 |
| Evidence number: | DS-FR-19-0048 |
| Program: | APVV |
| Project leader: | Dr.rer.nat., Ing. Kanďárová Helena, ERT |
| SAS cosolvers: | PharmDr. Piešová Michaela |
| Annotation: | Medical devices (MDs) have irreplaceable role in modern healthcare. The term ‘medical device’ covers a broad spectrum of products that are crucial in diagnosis and treatment, disease prevention and improving the quality of life of people suffering from disabilities or injuries. MDs used in the oral cavity are usually those helping in the treatment of aphthae or canker sores irritations and lesions of the oral mucosa by forming a barrier that adheres to the oral mucosa and promotes healing. Dental materials and dental prosthetic devices are also an important group of MDs with apparent contact with oral mucosa. Most of the MDs bio-compatibility assessments is still conducted in animals. However, thanks to the advances in cell and 3D tissue engineering and due to the accelerated progress in validation of alternative methods, the MD regulations are also in vitro tests, as demonstrated recently by the adoption of the in vitro reconstructed epidermis test for intra-cutaneous testing into the ISO standard 10993-23 (Kandarova et al.,/DeJong et al., 2018). Biocompatibility testing of MDs is based on the toxicity assessment of extracts from MDs, that are in fact highly diluted solutions of potential irritants. Therefore any already validated in vitro tests and prediction models must be fine-tuned to achieve different levels of sensitivity for this specific type of materials.The proposed project builds on the practical experiences gained in the validation study for intra-cutaneous testing of MDs in which the research teams from Slovakia and Czech republic participated between 2012-2018. The current project will use 3D reconstructed tissues of oral/buccal epithelia and cell cultures with the origin in oral cavity with the aim to develop highly sensitive testing strategy for local tolerance testing in vitro. The project alsoaims into the training of PhD students and early career scientist in the use of in vitro methods for the safety assessment of MDs. |
| Project website: | medicaldevicessafety.com |
| Effects of natural and synthetic compounds on oxidative damage of biomacromolecules. Pro-oxidative and antioxidative mechanisms. | |
| Duration: | 1. 1. 2019 - 31. 12. 2022 |
| Evidence number: | |
| Program: | VEGA |
| Project leader: | RNDr. Valachová Katarína , PhD. |
| - | |
| Duration: | 1. 1. 2019 - 31. 12. 2022 |
| Evidence number: | 2/0162/19 |
| Program: | VEGA |
| Project leader: | Ing. Frimmel Karel, PhD. |
| Vazoactive effects of hydrogen sulphide signalling pathway and its interaction with nitric oxide in different animal models of metabolic syndrome | |
| Duration: | 1. 1. 2019 - 31. 12. 2022 |
| Evidence number: | 2/0111/19 |
| Program: | VEGA |
| Project leader: | Mgr. Berényiová Andrea, PhD. |
| SAS cosolvers: | RNDr. Čačányiová Soňa, PhD., RNDr. Drobná Magdaléna, PhD., Ing. Kožík Jozef, Mgr. Majzúnová Miroslava, PhD. |
| Annotation: | Nitric oxide (NO) and hydrogen sulphide (H2S) are signalling molecules involved into the regulation of the arterial tone. The synthesis of both has been shown in arterial wall, moreover their contribution in physiological (relaxation of arterial smooth muscle cells) and pathophysiological processes (hypertension, diabetes mellitus, atherosclerosis) have been already proved. Metabolic syndrome (MS) is a group of abnormalities including obesity, hypertension, hyperlipidemia which that together increase the risk of developing cardiovascular disease. Studies have characterised H2S signalisation and NO-H2S interaction especially in normotensive rats, information about their role in experimental hypertension are just limited and about their engagement into the etiopathogenesis of metabolic syndrome is totally missing. The main goal of this project is to describe the vasomotoric role of NO and H2S in different models of MS: induced by high-fructose diet, by high-fat diet in normotension and primary hypertension. |
| Effect of fructose diet in experimental models of metabolic syndrome and in healthy subjects: proposal of effective pharmacological treatment | |
| Duration: | 1. 1. 2019 - 31. 12. 2022 |
| Evidence number: | 2/0120/19 |
| Program: | VEGA |
| Project leader: | RNDr. Gáspárová Zdenka, PhD. |
| SAS cosolvers: | MVDr. Bezek Štefan, DrSc., Ing. Brnoliaková Zuzana, PhD., RNDr. Knezl Vladimír, PhD., Mgr. Micháliková Dominika, Ing. Pádej Ivan, RNDr. Sotníková Ružena, CSc., Ing. Švík Karol, CSc. |
| Annotation: | The project will contribute to the knowledge about etiopathogenesis of metabolic syndrome (MetS). It extend the current project, where we study the impact of high-fat and high-fat-high-fructose diet on hypertriacylglycerolemic(HTG) rats. Chronic diseases such as MetS are generally multifactorial. Thus in their origin and development play a role not only environment (diet, physical activity, stress) but also genetic predisposition. In the new project, we will examine effect of fructose diet (FD) on various animal models (spontaneously hypertensive, HTG, Zucker obese/nonobese and Wistar healthy rats) and find which main risk factor of MetS together with FD cause the most serious damage. We will test the effect of the prospective pyridoindole SMe1EC2 and omega-3 fatty acids on the established model. By combining of these drugs, we expect increased effect on a number of risk factors of cardiovascular and cerebrovascular diseases without causing adverse effects, thus a proposal for a new more effective treatment. |
| Terapia KVO - Effect of therapy on redox regulation, biochemical markers and cell signaling of age-dependent cardiovascular and neurodegenerative diseases. | |
| Duration: | 1. 1. 2020 - 31. 12. 2022 |
| Evidence number: | 2/0158/20 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Dovinová Ima, PhD. |
| SAS cosolvers: | Mgr. Grešová Linda, PhD., RNDr. Regecová Valéria, Mgr. Rezbáriková Petronela, PhD. |
| Other cosolvers: | Kašparová Svatava, RNDr., PhD. |
| Annotation: | In cardiovascular damage, oxidative stress is triggered by an increase in oxidative stress, affecting changes in the activities of SOD / NOS proteins, biochemical markers, metabolites, as well as redox regulation of SERCA Ca2 + -ATPases. Oxidative stress is a regulated antioxidant and detoxification response by activating the transcription factor Nrf2.The nuclear receptor and nutritional factor PPAR gamma is another regulator of signaling pathways that is positively linked to the regulation of Nrf2. PPAR gamma nuclear receptor agonists play an important role in the regulation of cardiovascular and hypertensive diseases. |
| - | |
| Duration: | 10. 11. 2021 - 31. 3. 2022 |
| Evidence number: | |
| Program: | Iné projekty |
| Project leader: | Ing. Ferko Miroslav, PhD. |
| Indole-1-acetic acid derivatives as aldose reductase inhibitors: structure – activity relationships | |
| Duration: | 1. 1. 2018 - 31. 12. 2021 |
| Evidence number: | 2/0005/18 |
| Program: | VEGA |
| Project leader: | Ing. Šoltésová Prnová Marta, PhD. |
| SAS cosolvers: | RNDr. Kováčiková Lucia, PhD., Ing. Pádej Ivan, Ing. Račková Lucia, PhD., Ing. Štefek Milan, CSc. |
| Electrophysiological correlates and determinants of visual working memory precision | |
| Duration: | 1. 1. 2019 - 31. 12. 2021 |
| Evidence number: | 2/0170/19 |
| Program: | VEGA |
| Project leader: | MUDr. Riečanský Igor, PhD. |
| SAS cosolvers: | Ing. Bendžala Štefan, doc. PaedDr. RNDr. Katina Stanislav, PhD., Mgr. Marko Martin, PhD., Mgr. Mitka Milan, PhD., Mgr. Rovný Rastislav, PhD. |
| Mitochondria as a key effector in processes of cardioprotective intervention | |
| Duration: | 1. 1. 2018 - 31. 12. 2021 |
| Evidence number: | VEGA 2/0121/18 |
| Program: | VEGA |
| Project leader: | Ing. Ferko Miroslav, PhD. |
| Nitroso-sulphide signal pathway - novel regulator vasoactive effects in different types of arterial hypertension | |
| Duration: | 1. 1. 2018 - 31. 12. 2021 |
| Evidence number: | 2/0103/18 |
| Program: | VEGA |
| Project leader: | RNDr. Čačányiová Soňa, PhD. |
| SAS cosolvers: | Mgr. Berényiová Andrea, PhD., doc. RNDr. Dovinová Ima, PhD., Ing. Kožík Jozef, Mgr. Zemančíková Anna, PhD. |
| Annotation: | Nitric oxide (NO) and hydrogen sulphide (H2S) belong to important gaseous molecules engaged to the regulation of arterial tone in normotensive conditions. NO and H2S interaction includes a formation of new products which are part of an original nitroso-sulphide signalling pathway. Our previous experiments in Wistar rats demonstrated that these new signal molecules triggered a specific vasoactive response, different from the effect evoked by NO and H2S. In condition of arterial hypertension, the vasoactive effects of the novel signalisation have not been described yet. The aim of this project is to characterise the role of NO and H2S as well as of the nitroso-sulphide signalling pathway in different animal models of hypertension: essential (SHR), NO-deficient and also metabolic syndrome (hypertriglyceridemia – HTG). A simultaneous investigation of human vessels isolated from patients with hypertension and dyslipidemia represents an appropriate way how to associate results of basic research with clin. practise. |
| Novel compounds in prevention and treatment of diseases caused by glucose toxicity | |
| Duration: | 1. 1. 2018 - 31. 12. 2021 |
| Evidence number: | VEGA 2/0127/18 |
| Program: | VEGA |
| Project leader: | RNDr. Májeková Magdaléna, PhD. |
| SAS cosolvers: | Mgr. Benešová Barbora, Mgr. Kissova Lea, RNDr. Lomenová Jana, PhD., Ing. Šoltésová Prnová Marta, PhD., Mgr. Šramel Peter, PhD., Ing. Štefek Milan, CSc. |
| Annotation: | In the long term lasting plasma glucose level may affect the course of physiological processes through numerousmetabolic pathways. A polyol pathway ranks among the important mechanisms of glucose toxicity and its mainenzyme – aldose reductase – is a frequent target in design of drugs reducing the progress of chronic diabeticcomplications. Another target could be introduced by calcium homeostasis in cells, as the cytosolic calcium levelis an important factor for many physiological processes, e.g. the insulin secretion. A modulation of calcium pumpSERCA becomes another mechanism for the manifestation of glucose toxicity. The aim of our project is to findnew compounds with polypharmacological effect, by means of combinatorial library of potential aldose reductaseinhibitors and actual knowledge on SERCA activity. |
| ACE2-TXZF - New perspectives in the treatment of cardiovascular complications associated with COVID-19 | |
| Duration: | 16. 9. 2020 - 31. 12. 2021 |
| Evidence number: | PP-COVID-20-0043 |
| Program: | APVV |
| Project leader: | RNDr. Čačányiová Soňa, PhD. |
| SAS cosolvers: | RNDr. Bališ Peter, PhD., MVDr. Barta Andrej, PhD., Mgr. Berényiová Andrea, PhD., RNDr. Bernátová Iveta, DrSc., RNDr. Cebová Martina, PhD., doc. RNDr. Dovinová Ima, PhD., RNDr. Drobná Magdaléna, PhD., Ing. Galšneiderová Mária, Mgr. Golas Samuel, PhD., Mgr. Kluknavský Michal, PhD., Ing. Kršková Katarína, PhD., Mgr. Mičurová Andrea, PhD., RNDr. Poljak Valašková Zuzana, PhD., Şaman Ezgi, PhD, Ing. Šoltés Ladislav, DrSc., doc. MUDr. Török Jozef, CSc., RNDr. Valachová Katarína , PhD., Mgr. Zemančíková Anna, PhD. |
| Annotation: | Coronavirus disease 2019 (COVID-19), linked to severe acute respiratory syndrome induced by coronavirus-2(SARS-CoV-2), was declared as a global pandemic. While respiratory failure is the major cause of mortality due toCOVID-19, the great number of patients exhibit cardiovascular disorders. Understanding the underlyingmechanisms of cardiovascular complications associated with COVID-19 is of the great importance to reach theeffective therapy and to reduce mortality due to COVID-19. In this project we will imitate the inhibition of ACE2-mediated signalling induced by SARS-Cov-2 using highly specific ACE2 inhibitor MLN-4760. In thispharmacological model of COVID-19 in spontaneously hypertensive rats (SHR) we intend to examine the extend ofMLN-4760-induced vascular damage as well as the mechanisms underlying the action of taxifoline and zofenapril,as perspective pharmacological tools for the treatment of cardiovascular complications associated with COVID-19.TX has been chosen as it was shown as promising drug-like substance inhibiting SARS-Cov-2 replication viainhibition of the main protease (Mpro). ZF is sulfhydryl-containing angiotensin converting enzyme (ACE) inhibitorspontaneously releasing hydrogen sulfide (H2S). Both substances provide several additional cardioprotectiveeffects associated with elevated NO bioavailability and H2S release, respectively. These effects can improvefunction of the cardiovascular system via elevation of NO and H2S-mediated vasodilatation, inhibition oftrombogenesis and induction of antioxidant and antiinflamatory action. |
| - | |
| Duration: | 1. 1. 2019 - 31. 12. 2021 |
| Evidence number: | 2/0115/19 |
| Program: | VEGA |
| Project leader: | PharmDr. Poništ Silvester, PhD. |
| SAS cosolvers: | PharmDr. Bauerová Katarína, PhD., DrSc., PharmDr. Dráfi František, PhD., MPH, Mgr. Chrastina Martin, PharmDr. Jančinová Viera, PhD., doc. Ing. Jurčovičová Jana, CSc., Mgr. Krnáčová Katarína, PhD., Ing. Mihalová Danica, PharmDr. Poništ Silvester, PhD., Ing. Švík Karol, CSc. |
| Other cosolvers: | Czigle Sz |
| Heart protection in situations of excessive formation of oxygen and nitrosyl radicals: Molecular hydrogen as a new potential therapeutic tool? | |
| Duration: | 1. 1. 2018 - 31. 12. 2021 |
| Evidence number: | 2/0063/18 |
| Program: | VEGA |
| Project leader: | RNDr. Kura Branislav, PhD. |
| SAS cosolvers: | RNDr. Egan Beňová Tamara, PhD., Formanková Iveta, Ing. Frimmel Karel, PhD., Mgr. Kaločayová Barbora, PhD., Kniesová Adela , RNDr. Kura Branislav, PhD., MUDr. Ravingerová Táňa, DrSc., FIACS, RNDr. Tribulová Narcisa, DrSc., RNDr. Vrbjar Norbert, CSc., MUDr. Zálešák Marek, PhD. |
| Project website: | https://evega.minedu.sk/e-vega/(S(yi1zctb4lxjmuf55ntk1jfbm))/default.aspx |
| Study of triggering factors and signal transduction mechanisms induced by noninvasive adaptive interventions in rats aimed to protect myocardium against schemia | |
| Duration: | 1. 1. 2018 - 31. 12. 2021 |
| Evidence number: | 2/0141/18 |
| Program: | VEGA |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| Annotation: | Cardiovascular diseases are one of the leading causes of mortality in modern society. They are predicted to rise over the coming decades, due to aging population, longer survival of patients after myocardial infarction, and incidence of civilization diseases. Research pointed out to the protective effects of adaptive phenomenon of ischemic preconditioning (IPC) and its novel clinically acceptable and safer forms. Currently, cellular mechanisms activated by stimuli like exercise, acute hypoxia and PC of the remote organ are not yet completely elucidated as compared with classiccal IPC. For that reason, several pathological animal models (myocardial ischemia, hypertension, d. mellitus, dyslipidemia) will be used. Acute and longer lasting adaptive interventions will be tested using relevant methodology (combination of physiological, morphological and biochemical techniques). The results obtained in this project may lead to development of novel or modified therapeutic strategies to manage myocardial ischemia |
| The effect of virtual reality on the sensory regulation of balance control, physiological and psychological functions in humans | |
| Duration: | 1. 1. 2019 - 31. 12. 2021 |
| Evidence number: | 2/0104/19 |
| Program: | VEGA |
| Project leader: | Mgr. Hirjaková Zuzana, PhD. |
| SAS cosolvers: | RNDr. Bzdúšková Diana, PhD., Ing. Hlavačka František, CSc., RNDr. Kimijanová Jana, PhD., Mgr. Marko Martin, PhD., MUDr. Šaling Marián, CSc. |
| Annotation: | Virtual reality (VR) is an environment that can be used to assess the postural and psycho-physiologicalparameters of different groups of people. The virtual environment provides an experience close to reality inlaboratory conditions or at home. The aim of the project is to gain new knowledge about the body orientation,sensory regulation of balance control and the level of psycho-physiological stimulation in the VR. The volunteerswill be introduced into the VR and at the same time their postural activity, reactions to vibratory stimulation oflower limb muscles, physiological and psychological level of arousal and stress will be recorded. We assume thatthe project results will provide the basis for designing promising methods for testing sensory balance control andpsycho-physiological reactivity to the virtual environment. The obtained results may be helpful in rehabilitation ofpatients with postural balance disorders as well as people with psychological or physiological difficulties. |
| RIDD - Research of magnetic forms of iron in development of cardiovascular diseases and behavioural disorders | |
| Duration: | 1. 7. 2017 - 30. 6. 2021 |
| Evidence number: | APVV-16-0263 |
| Program: | APVV |
| Project leader: | RNDr. Bernátová Iveta, DrSc. |
| SAS cosolvers: | RNDr. Bališ Peter, PhD., MVDr. Barta Andrej, PhD., doc. RNDr. Barteková Monika, PhD., RNDr. Cigáň Alexander, CSc., Mgr. Farkašová Veronika, PhD, Mgr. Jelemenský Marek, Mgr. Kluknavský Michal, PhD., Ing. Kvandová Miroslava, Mgr. Majzúnová Miroslava, PhD., Ing. Maňka Ján, CSc., Mgr. Muráriková Martina, PhD., MUDr. RNDr. Púzserová Angelika, PhD., MUDr. Ravingerová Táňa, DrSc., FIACS, RNDr. Regecová Valéria, Mgr. Svoreň Pavol, Mgr. Šestáková Natália |
| Annotation: | This project proposal is focused on the investigation of the role of iron in development of cardiovascular and behavioural disorders, prevalence of which is increasing during aging. The aim of this project is to investigate theimpact of aging on the metabolism of biogenic iron and its magnetic properties in association with metabolic and functional alterations in the cardiovascular system and brain in rats with various genetic predispositions tohypertension. We will determine the molecular biological changes on the level of gene expression, their encoded proteins and the activities of the enzymes involved in the endogenous antioxidant protection, the regulation of nitric oxide production and cell death due to ferroptosis in course of aging. We will also investigate the impact ofexogenously administered iron in the form of the biocompatible ultrasmall superparamagnetic iron oxide nanoparticles (USPIONs) on blood pressure regulation and function of the heart and blood vessels in conditions of normotension, chronically increased blood pressure and acute stress (i.e. acutely elevated blood pressure).Results achieved in this project will contribute to better understanding of the effects of the altered iron metabolism, magnetic forms of bodily iron, as well as iron in the form of USPIONs, on the cardiovascular andcentral nervous systems and to prevention of cardiovascular risk resulting from the use of USPIONs in targeted drug delivery or as the contrast materials for new imaging methods in medicine. |
| Crosstalk of metabolic factors and neurogenic signaling in experimental models of depression | |
| Duration: | 1. 1. 2018 - 31. 12. 2020 |
| Evidence number: | |
| Program: | VEGA |
| Project leader: | RNDr. Vranková Stanislava, PhD. |
| SAS cosolvers: | Ing. Bendžala Štefan, Mgr. Benko Jakub, RNDr. Cimrová Barbora, PhD., MUDr. Riečanský Igor, PhD., Mgr. Rovný Rastislav, PhD. |
| Mechanisms involved in uric acid-induced endothelial dysfunction depending on the age and genetic predisposition to hypertension | |
| Duration: | 1. 1. 2017 - 31. 12. 2020 |
| Evidence number: | 2/0190/17 |
| Program: | VEGA |
| Project leader: | MUDr. RNDr. Púzserová Angelika, PhD. |
| SAS cosolvers: | RNDr. Bališ Peter, PhD., RNDr. Bernátová Iveta, DrSc., Ing. Kvandová Miroslava, RNDr. Regecová Valéria, Mgr. Šestáková Natália |
| Annotation: | Studies have shown a significant relationship between increased concentration of uric acid in the blood (hyperuricaemia) and cardiovascular diseases, including hypertension. But there is little information on the mechanisms by which uric acid can lead to end-organ damage. Hyperuricaemia combined with hypertension is associated with endothelial dysfunction. However, the mechanisms by which hyperuricaemia causes endothelial dysfunction are not clarified. This project aims to clarify the relationship of hyperuricaemia and hypertension, especially in terms of endothelial function. The aim is to bring new results highlighting the impact of elevated concentrations of uric acid on the endothelium, and to reveal the mechanisms involved in endothelial dysfunction in conductive and resistant arteries isolated from peri-pubertal and adult normotensive, prehypertensive and hypertensive rats. The results will contribute to the knowledge about pathophysiology of hyperuricaemia-induced endothelial dysfunction. |
| Redox Homeostasis, Proteostasis and Inflammation as Potential Targets For Influencing Ageing and Age-Related Diseases: Modulation by the compounds of natural and synthetic origin | |
| Duration: | 1. 1. 2017 - 31. 12. 2020 |
| Evidence number: | VEGA 2/0041/17 |
| Program: | VEGA |
| Project leader: | Ing. Račková Lucia, PhD. |
| SAS cosolvers: | MVDr. Bezek Štefan, DrSc., RNDr. Blaškovič Dušan, PhD., Mgr. Brezovska Erika, RNDr. Mucha Ján, CSc., Ing. Škandík Martin, Ing. Šoltésová Prnová Marta, PhD. |
| Annotation: | Ageing is a natural and inevitable phenomenon which is also the main risk factor for the serious diseases. Free-radical theory of ageing states that organisms age because cells accumulate free radical damage over time. These changes are significantly amplified by the decline in proteolytic capacity. Microglia, as the main immune effector cells of the CNS, undergo these alterations as well. This results in their chronic activation and increased risk of neurodegeneration. The aim of the project is to investigate the potential of compounds of natural and synthetic origin to up-regulate Nrf-2/Keap-1 signalling pathway (in particular, the activation of genes responsible for maintenance of redox homeostasis and proteostasis), also in view of their simultaneous down-regulation of NFkB in microglia. Subject of the project will be also investigation of postranslantional modifications in the regulatory mechanisms of proteolysis in microglial cells. |
| Role of Nrf2 signaling pathway in responses of cardiac cells to pathological conditions | |
| Duration: | 1. 1. 2018 - 31. 12. 2020 |
| Evidence number: | 2/0160/18 |
| Program: | VEGA |
| Project leader: | RNDr. Barančík Miroslav, DrSc. |
| SAS cosolvers: | doc. RNDr. Barteková Monika, PhD., Mgr. Ferenczyová Kristína, PhD., Mgr. Fogarassyová Mária |
| Properties of the Na,K-ATPase, representing one of the crucial systems in maintaining the sodium homeostasis in the organism, after irradiation. | |
| Duration: | 1. 1. 2017 - 31. 12. 2020 |
| Evidence number: | 2/0166/17 |
| Program: | VEGA |
| Project leader: | RNDr. Vrbjar Norbert, CSc. |
| Annotation: | The present project is oriented to obtain new data concerning the maintenance of intracellular homeostasis of sodium, representing one of the unavoidable factors for appropriate regulation of cellular viability, after application of radiotherapy. Using in vivo model (rat) we will investigate the influence of gamma irradiation on the cerebral and renal Na,K-ATPase which is one of the crucial systems in maintaining appropriate intracellular concentration of sodium ions. The data will contribute to elucidation of molecular background of processes involved inmaintaining the cell’s viability in kidney and in brain from the aspect of possible protection of the organism against deleterious side-effects of radiotherapy. |
| - | |
| Duration: | 1. 1. 2020 - 31. 12. 2020 |
| Evidence number: | |
| Program: | Iné projekty |
| Project leader: | PharmDr. Piešová Michaela |
| Effect of ultrasmall superparamagnetic iron oxide nanoparticles on the cardiovascular system of rats with high blood pressure | |
| Duration: | 1. 1. 2017 - 31. 12. 2020 |
| Evidence number: | |
| Program: | VEGA |
| Project leader: | RNDr. Bernátová Iveta, DrSc. |
| SAS cosolvers: | RNDr. Bališ Peter, PhD., Mgr. Kluknavský Michal, PhD., Ing. Maňka Ján, CSc., MUDr. RNDr. Púzserová Angelika, PhD., RNDr. Regecová Valéria, Mgr. Šestáková Natália |
| Annotation: | This project will investigate the effect of ultrasmall superparamagnetic iron oxide nanoparticles (USPIONs) on function and structure of the arterial wall and the heart in rats with high blood pressure. We will investigate if acute stress and chronic high blood pressure can facilitate the USPIONs uptake in the arterial wall and heart, tomodify cardiovascular function, including blood pressure regulation and to induce metabolic disorders, oxidative damage and alterations of the Fe2+/Fe3+ ratio in the heart and vasculature. We will investigate if L-type ofvoltage-dependent calcium channels is involved in iron uptake after USPIONs treatment. Results achieved in this project will contribute to better understanding of USPIONs effects on the cardiovascular system in conditions ofacute stress and high blood pressure as well as on prevention of cardiovascular risk resulting from the use of USPIONs in targeted drug delivery. |
| Research on possibilities and development of SQUID magnetometry for selected applications in biomedicine and material research | |
| Duration: | 1. 1. 2017 - 31. 12. 2020 |
| Evidence number: | 2/0164/17 |
| Program: | VEGA |
| Project leader: | RNDr. Bernátová Iveta, DrSc. |
| Annotation: | Project has an interdisciplinary character.The aim is to show the possibilities of use of the SQUID magnetometry in study of the actual processes in medicine, biology and material research:-in analysis of the properties and magnetic characterization of the nanoparticles and nanoliquids, especiallyultra-small superparamagnetic nanoparticles based on iron oxides (USPIONs)-in investigation of the influence of the USPIONs on the function and structure of the blood vessels and heart, on development of the oxidative damage and in study of processes of the USPIONs transport through cell membranes, blood vessels and organs of rats with normal and high blood pressure-in development of the procedures and methods of quantification of the magnetic substances content in thehuman and animal cell cultures and organs- in study and development of the aluminate glasses with photoluminescence properties and other applications. |
| Relationship between body adiposity and functional properties of arteries in rat | |
| Duration: | 1. 1. 2018 - 31. 12. 2020 |
| Evidence number: | 2/0147/18 |
| Program: | VEGA |
| Project leader: | Mgr. Zemančíková Anna, PhD. |
| SAS cosolvers: | Mgr. Berényiová Andrea, PhD., RNDr. Čačányiová Soňa, PhD., doc. MUDr. Török Jozef, CSc. |
| Annotation: | High levels of body mass index are considered as an important risk factor contributing to cardiovascular impairment. However, recent studies have brought some noteworthy findings that moderately increased amount of body fat is beneficial with respect to prognosis of patients with heart and vessel diseases. The aim of this project is to analyse the relationship between the level of body adiposity/weight and cardiovascular function in terms of blood pressure regulation and functional properties of selected arteries in rat. An effort will be made to reveal how the vessels are modulated by the adjacent perivascular adipose tissue (PVAT) in healthy normotensive and in hypertensive rats after moderate and considerable increase in body adiposity induced by dietetic interventions in different ontogenetic stages. Several biometric and hemodynamic parameters will be measured, as well as some biochemical parameters in blood and tissues and in vitro reactivity of arteries in the presence of PVAT and after its removal. |
| DYSRPONEP - Dynamics of myocardial damage: a role of necroptotic cell death and survival of cardiomyocytes. | |
| Duration: | 1. 7. 2016 - 30. 6. 2020 |
| Evidence number: | APVV-15-0607 |
| Program: | APVV |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| SAS cosolvers: | Mgr. Farkašová Veronika, PhD, Ing. Ferko Miroslav, PhD., Mgr. Kancírová Ivana, PhD., Mgr. Kindernay Lucia, PhD., RNDr. Lonek Ľubomír, PhD. |
| Annotation: | Cardiomyocytes have a limited capability to proliferate, self-renew and repair. Therefore, the number of cardiac cells during postnatal development determines how the heart can deal with stress and workload demands. Both sudden acute or chronic progressive loss of heart cells are involved in the development of ventricular dysfunction and the progression of heart failure (HF). In cardiomyocyte loss, apoptosis seems to play a minor role comparedto necrosis. In line with this, we have found that markers of a newly described form of regulated necrosis – necroptosis are increased in human failing hearts whereas apoptotic ones are unchanged. Although it has been proposed that these markers form a cytotoxic complex, it is unclear how it induces necroptotic cell death. In this process, a protein RIP1 plays an important role. However, when it is polyubiquitinated it may trigger pro-survivalpathways instead. Stimuli, which preferentially trigger RIP1-mediated cell survival at the expense of cell death, are mostly unknown. In this project, we will study the cytotoxic action of necroptotic complexes with respect totranslocation into cell structures, disturbed ion homeostasis and oxidative stress. In addition, we will study whichRIP1-associated signaling is triggered during cell survival (eg. ischemic preconditioning - IPC) and which RIP1 pathways lead to the contrary, death of cardiac cells in acute myocardial infarction and during the development of HF of various origin. By using a necroptosis inhibitor, we will try to determine whether it affects IPC-induced cardioprotection with respect to cell viability and whether its time-dependent application can relieve remodeling and cardiac dysfunction due to myocardial infarction or induce regression of damage. Cardiomoycytes, isolated hearts and in vivo studies will be used to investigate signaling pathways and autocrine/paracrine and systemwide responses to a primary impulz that induces the damage/ adaptation of the heart. |
| G-LUCK - Pharmacological intervention in glucose-toxicity in type 2 diabetes | |
| Duration: | 1. 7. 2016 - 30. 6. 2020 |
| Evidence number: | APVV-15-0455 |
| Program: | APVV |
| Project leader: | RNDr. Májeková Magdaléna, PhD. |
| SAS cosolvers: | RNDr. Balleková Jana, MVDr. Bezek Štefan, DrSc., Mgr. Heger Vladimír, PhD., RNDr. Horáková Ľubica, PhD., Mgr. Kissova Lea, RNDr. Kováčiková Lucia, PhD., RNDr. Lomenová Jana, PhD., Ing. Micháliková Silvia, PhD., Mgr. Rezbáriková Petronela, PhD., Ing. Šoltésová Prnová Marta, PhD., Mgr. Šramel Peter, PhD., Ing. Štefek Milan, CSc. |
| Other cosolvers: | Májek Pavel Ing. PhD. |
| Annotation: | Glucose toxicity plays important role not only in a development of chronic diabetic complications but also in aninduction of insulin secretion disorder, decrease of beta cell mass and development of insulin resistance. Theaim of this project is to design and test novel compounds with indolyl acetic acid scaffold, multi-target-directedligands, which should slow down the onset of diabetes mellitus type 2 and reduce progression of diabeticcomplications. |
| MEDMEX - Study of endogenous compensatory mechanisms effective against energy deficiency in pathologycally loaded myocardium: Innovative approaches in experimental cardioprotection. | |
| Duration: | 1. 7. 2016 - 30. 6. 2020 |
| Evidence number: | APVV-15-0119 |
| Program: | APVV |
| Project leader: | Ing. Ferko Miroslav, PhD. |
| Annotation: | Research on field of compensatory mechanisms appears to be promising method for endogenous protection inpathologically loaded myocardium under condition of increased energy demands. The project aims to contributeto the knowledge in the field of experimental cardiology and point to new, alternative cardioprotective proceduresagainst ischemia-reperfusion injury. It is necessary to study the protective signaling pathways, propose potentialcardiomarkers and identify positive functional changes observed at the level of cardiac mitochondria and heart itsself for comprehensive understanding of the onset and progression of mechanisms of endogenous myocardialprotection leading to effective compensation against energy deficiency in ischemia/reperfusion injury. Severalapproaches utilize processes of endogenous protection to achieve cardioprotection, such as ischemic andpharmacological preconditioning, clinically applicable „remote“ ischemic preconditioning (RIP) as well asexperimental streptozotocine-induced diabetes mellitus in acute state. Coexistence of several comorbidities (hypercholesterolaemia, hypertension) suppress mechanisms of cell signaling involved in protective effect ofischemic preconditioning that promotes necrotic and apoptotic processes in the myocytes during ischemiareperfusionchallenge and also reduces energy production. With respect to bioenergetics and the role ofmitochondria involved in the execution phase of cardioprotection as a common mechanism in various types ofadaptive phenomena, the information is scarse up to date. It is expected that the project will help to characterizethe changes caused by functional remodeling of the mitochondrial membrane, and provide a new and currentlyabsenting information on regulation of mechanisms against increased enegetic demands resulting in myocardialsurvival. |
| - | |
| Duration: | 1. 7. 2016 - 30. 6. 2020 |
| Evidence number: | APVV-15-0308 |
| Program: | APVV |
| Project leader: | PharmDr. Bauerová Katarína, PhD., DrSc. |
| SAS cosolvers: | Mgr. Bögi Eszter, PhD., PharmDr. Dráfi František, PhD., MPH, RNDr. Dubovický Michal, CSc. , PharmDr. Jančinová Viera, PhD., RNDr. Knezl Vladimír, PhD., Ing. Mihalová Danica, prof. MUDr. Nosáľ Radomír, DrSc., PharmDr. Poništ Silvester, PhD., Ing. Račková Lucia, PhD., Straková Zuzana, Ing. Šoltés Ladislav, DrSc., Ing. Švík Karol, CSc., Urgošová Jana, RNDr. Valachová Katarína , PhD., Ing. Zorad Štefan, CSc. |
| Other cosolvers: | spoluriešitelia z UK v Bratislave |
| NO-NEW-REG - New regulatory effects of nitric oxide and their role in the development of essential hypertension | |
| Duration: | 1. 7. 2016 - 30. 6. 2020 |
| Evidence number: | APVV-15-0565 |
| Program: | APVV |
| Project leader: | RNDr. Čačányiová Soňa, PhD. |
| SAS cosolvers: | Mgr. Balážová Lucia, PhD., Mgr. Berényiová Andrea, PhD., RNDr. Dobrócsyová Viktória, PhD., doc. RNDr. Dovinová Ima, PhD., RNDr. Drobná Magdaléna, PhD., Mgr. Grešová Linda, Ing. Kovácsová Mária, PhD., Ing. Kvandová Miroslava, Doc.MUDr. Lietava Ján, CSc., Mgr. Majzúnová Miroslava, PhD., Mgr. Mišák Anton, PhD., MUDr. RNDr. Púzserová Angelika, PhD., Mgr. Zemančíková Anna, PhD., Ing. Zorad Štefan, CSc. |
| Annotation: | High blood pressure is a main risk factor in sustained increased morbidity and mortality of humans suffering cardiovascular diseases. Understanding of causes leading to hypertension enable to reveal new preventive andtherapeutic decisions. A new regulatory system involved in vessel tree regulation seems to be neuronal NOsynthase (nNOS) and its interactions with other regulatory systems. On the level of the kidney nNOS signal pathway interferes with renin-angiotensin system (RAS) and sulfide signalization (H2S), and the interactionsamong them are the unexplored area of regulatory mechanisms. nNOS in macula densa stimulate renin syntesis and via it influences RAS and sympathetic nerve system, on the other hand, H2S inhibits renin synthesis. Moreover, the regulatory pathways of nNOS and also endothelial eNOS could interact with endogenous NOSinhibitor, asymmetric dimetylarginine ADMA, on local as well as systemic level. The aim of the project is to study the effect of interactions of NO/nNOS/eNOS signalization with mentioned regulatory pathways (RAS, H2S,ADMA) on cardiovascular system and to find out their role in the specificity of nNOS and/or eNOS action in the conditions of essential hypertension. The availability of the results will be reached via using complex approach(functional, molecular, morphological). Moreover, on the level of acute experiments, we will confront selectedbiochemical markers of perivascular adipose tissue (plasma/serum) as well as vasoactive responses of arteriesisolated from normotensive and hypertensive rats with biochemical markers and reactivity of vessels isolated after nephrectomy from normotensive patients and patients with essential hypertension. |
| SCAVRAD - Protection of the heart in situations of increased production of oxygen free radicals: Radiation and reperfusion injury. | |
| Duration: | 1. 7. 2016 - 30. 6. 2020 |
| Evidence number: | APVV-15-0376 |
| Program: | APVV |
| Project leader: | D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS |
| Other cosolvers: | EVPU N.Dubnica |
| Annotation: | According to statistics, cardiovascular and cancer are the main cause of more than 93% of the global morbidityand mortality.One of the most used methods to treat patients with cancer is radiotherapy, which uses ionizing radiation.Ionizing radiation damages the cancer cells, leading to their apoptosis and to potential patient recovery.However, during irradiation of cancer cells may also occur unintended exposure of surrounding healthy tissue,which in turn can cause serious health complications including radiation-induced heart disease. Ionising radiationacts directly on the DNA of cells, or indirectly through the formation of free radicals, which then damage theindividual organelles of cells or DNA. Production of oxygen free radicals, which in addition have a signalingfunction, at higher concentrations have toxic effects on all parts of the heart and blood vessels, is a commondenominator of both ionizing radiation and inflammation, as well as ischemic and reperfusion injury. Therefore,research in this field, and finding novel suitable materials which can positively influence the effects of over |
| Prenatal and postnatal effects of δ and µ opioid receptor ligands on the hippocampal development and function | |
| Duration: | 1. 7. 2016 - 30. 6. 2020 |
| Evidence number: | APVV-15-0388 |
| Program: | APVV |
| Project leader: | RNDr. Dubovický Michal, CSc. |
| SAS cosolvers: | Mgr. Bögi Eszter, PhD. |
| Annotation: | Ligands of opioid receptors δ (DOR) and µ opioid receptors (MOR) are commonly used in treatment of severe acute and chronic pain. DORs are involved also in mood disorders like depression and anxiety, which are related to the hippocampal function. Treatment with DOR ligands does not result in adverse effects including addiction, which are common with MOR ligands. However, much less is known about DOR – activated signaling pathways than about MOR – activated pathways. We will analyze the effect of acute (seconds to minutes) and chronic (hours to days) in in vitro and in vivo (prenatal and postnatal) administration of DOR ligands on the morphological and electrophysiological properties of rat hippocampal neurons and compare them with effects of MOR ligands and with effects of ligands specific for MOR-DOR heteromers. Further, involvement of calcium transporting proteins in signal transduction pathways activated by DORs and MORs ligands will be addressed by molecular biology methods. Possible remodeling of the dendritic spines will be investigated using transmission electron microscopy. Effect of DOR ligands on hippocampal plasticity in control and stressed rats will be examined using behavioral tests and molecular neuroscience techniques. Excitability will be investigated in primary culture of hippocampal neurons by patch clamp and in situ by in vivo electrophysiology. Both models enable to follow effects of acute and chronic drug application as well as possible receptor desensitization and offer complementary advantages. Primary neuronal culture is the possibility to visually identify neurons, characterize in details both action potentials and underlying ionic currents and to correlate electrophysiology and molecular biology on the same batch of neurons. In vivo electrophysiology offers the possibility to measure neuronal activity within its normal environment including all interactions with other brain parts. |
| Investigation of anatomical-functional differences between the effects of aripiprazole and quetiapine, atypical antipsychotics with similar therapeutic indications, but different impact on brain dopaminergic receptors, in experimental animals | |
| Duration: | 1. 7. 2016 - 30. 6. 2020 |
| Evidence number: | APVV-15-0037 |
| Program: | APVV |
| Project leader: | RNDr. Mach Mojmír, PhD. |
| SAS cosolvers: | MVDr. Koprdová Romana, PhD., Mgr. Sedláčková Natália, PhD. |
| Annotation: | Antipsychotics (APs) represent a group of drugs used in the treatment of spectrum of psychotic and depressive disorders. However, frequency of ATs treatment is rather increasing than decreasing and growing number of atypical AP drugs have also been emerged over the last few years. In addition, APs treatment is connected with a number of unwanted side effects, such as extrapyramidal syndrome, akathisia, body mass increase, agranulocytosis, tardive dyskinesia, somnolencia, etc. Anatomical-functional investigations are incessantly bringing information about the effects of APs on the activity of neurons and their spatial distribution in the brain, which allows more precisely to define and predict the consequences of the APs treatment. The aim of the present study is to reveal the effect of acute and repeated treatment of two, relatively new atypical APs, aripiprazole (ARI) and quetiapine (QUE), on the activity of neurons in the forebrain and extra forebrain areas of the brain, to identify the phenotype (chemical) character of the targeted neurons, to investigate their impact on the behavior and to compare their impact on the activity of signaling pathways, expression of signaling molecules, and secretion of selected neuropeptides in anatomically precisely defined brain structures. The data of the present project will be new and will serve for the deeper understanding of the biology of serious mental disorders. They also may bring new impulses to the drug developing processing to prepare drugs with more directed and beneficial therapeutic features. |
| H2S-NO - Study of biological effects of H2S/NO products and molecular mechanism of their actions | |
| Duration: | 1. 7. 2016 - 30. 6. 2020 |
| Evidence number: | APVV-15-0371 |
| Program: | APVV |
| Project leader: | RNDr. Čačányiová Soňa, PhD. |
| SAS cosolvers: | RNDr. Kristek František, DrSc. |
| Annotation: | Now it is well acknowledged that endogenously produced H2S affects and is involved in regulation of many physiological and pathological functions of living organisms. It is suggested that biological effects of H2S mightnot result from actions of H2S alone, but from its oxidation products, which come from e.g. interaction of H2S with NO. Last four years, our “international” group indentified the following products of H2S and NO interaction:nitrosopersulfide (SSNO−), polysulfides (HSn−) and dinitrososulfite [N-nitrosohydroxylamine-N-sulfonate (SULFI/NO) (Proc Natl Acad Sci U S A. 112, 2015, E4651-E4660). Biological effects and molecular mechanisms of these products are not completely understood Therefore the aim of our project is to explore biological effectsof the products of H2S/NO interactions and to study their molecular mechanism of their actions. Particularly, as a continuation of our research, we will study their effects on rat blood pressure and aortic rings relaxation. Toelucidate molecular mechanisms of their biological effects, we will study their influence on expression ofenzymes that endogenously produce H2S (CBS, CSE and 3-MST), on intracellular membrane channels,concentration of intracellular calcium, lipid peroxidation and their antioxidant properties. Goal of the project isalso to find out, if studied compounds could provide us with information leading to a drug design based on their molecular structure, what could be an object for next application studies and lead to implementation in medical praxis. |
| MuTaLig - Multi-target paradigm for innovative ligand identification in the drug discovery process | |
| Duration: | 18. 4. 2016 - 17. 4. 2020 |
| Evidence number: | |
| Program: | Vedecko-technické projekty |
| Project leader: | RNDr. Májeková Magdaléna, PhD. |
| SAS cosolvers: | Mgr. Heger Vladimír, PhD., RNDr. Horáková Ľubica, PhD., RNDr. Kováčiková Lucia, PhD., Ing. Micháliková Silvia, PhD., Ing. Šoltésová Prnová Marta, PhD., Ing. Štefek Milan, CSc. |
| Other cosolvers: | Pavel Májek Ing. CSc. |
| Annotation: | The aim of this COST Action is to join highly-qualified research teams working in disciplines around the field of medicinal chemistry, into a novel network devoted to the multi-target issue in drug discovery. The choice of this theme is related to its marked multidisciplinary character, which can ensure a strong interaction among all COST Action participants. Currently, an important and emerging issue in modern drug discovery is to design novel or identify existing bioactive compounds, endowed with the capability to interact selectively with two or more macromolecular targets, exerting their effects against certain therapeutic goals in a synergic fashion. This leading concept stimulated this COST Action focusing on novel ligands able to recognize selected multiple targets, to promote closer scientific links among European research groups involved in medicinal chemistry field at both academic and industrial level. The research competencies of the network will span around medicinal chemistry, from synthetic chemistry, natural products and biophysics to theoretical chemistry, molecular modelling and biological screening. |
| Hypoxia in the prevention of heart failure in rats and its influence in various stages of heart failure: Characteristics of functional, structural and molecular changes. | |
| Duration: | 1. 1. 2017 - 31. 12. 2019 |
| Evidence number: | 2/0151/17 |
| Program: | VEGA |
| Project leader: | Mgr. Farkašová Veronika, PhD |
| SAS cosolvers: | Mgr. Kindernay Lucia, PhD., RNDr. Lonek Ľubomír, PhD., MUDr. Ravingerová Táňa, DrSc., FIACS, MUDr. Zálešák Marek, PhD. |
| RADISCAV - New methods to improve diagnostics, prevention, and treatment of cardiovascular diseases with focus on oxidative stress. Protection from radiation-induced heart damage. Reperfusion injury - heart transplantation | |
| Duration: | 1. 12. 2018 - 31. 12. 2019 |
| Evidence number: | 2018/7838:1-26C0 |
| Program: | Iné projekty |
| Project leader: | D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS |
| SAS cosolvers: | RNDr. Barančík Miroslav, DrSc., Ing. Frimmel Karel, PhD., RNDr. Kura Branislav, PhD., RNDr. Okruhlicová Ľudmila, CSc., MUDr. Ravingerová Táňa, DrSc., FIACS, RNDr. Sýkora Matúš, PhD., RNDr. Szeiffová Bačová Barbara, PhD., RNDr. Tribulová Narcisa, DrSc. |
| Project website: | https://stimuly.vedatechnika.sk/ |
| - | |
| Duration: | 1. 1. 2019 - 31. 12. 2019 |
| Evidence number: | VEGA 2/0115/19 |
| Program: | VEGA |
| Project leader: | PharmDr. Poništ Silvester, PhD. |
| Protection of mechanisms modulating endothelial permeability in the heart. | |
| Duration: | 1. 1. 2016 - 31. 12. 2019 |
| Evidence number: | 2/0022/16 |
| Program: | VEGA |
| Project leader: | RNDr. Okruhlicová Ľudmila, CSc. |
| SAS cosolvers: | Ing. Frimmel Karel, PhD., Mgr. Križák Jakub, MUDr. RNDr. Púzserová Angelika, PhD., D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS |
| Prenatal programming of psychiatric diseases: experimental approaches for evaluation of causes and mechanisms of their origin | |
| Duration: | 1. 1. 2016 - 31. 12. 2019 |
| Evidence number: | 2/0166/16 |
| Program: | VEGA |
| Project leader: | RNDr. Mach Mojmír, PhD. |
| SAS cosolvers: | Mgr. Bögi Eszter, PhD., RNDr. Dubovický Michal, CSc. , RNDr. Gáspárová Zdenka, PhD., MVDr. Koprdová Romana, PhD., Mgr. Sedláčková Natália, PhD., Doc. RNDr. Ujházy Eduard, CSc. |
| Annotation: | There are many evidences on neurodevelopmental origin of mental diseases. Various environmental and maternal factors acting during prenatal period and early childhood can increase sensitivity of the individual to anxiety, depression or other mental disorders in later postnatal life. Insufficient oxygen and nutrition supply of tissues, excessive stress or chemical substances and drugs can adversely affect the development of the brain. The mechanisms and causes of prenatal programming will be studied using animal model of chronic prenatal asphyxia in rats to uncover basis for the increased sensitivity of the organism to the emergence and development of neurobehavioral and cardiovascular disorders in adulthood. Early detection of these mechanisms on the basis of molecular, biochemical and behavioral indicators can contribute to therapeutic interventions in the early stages of development and thus reduce or eliminate the occurrence of these diseases in later life. |
| Prevention of hypoxic-ischemic damage of the neonatal rat brain: testing of novel approaches involving pharmacological and non-pharmacological intervention | |
| Duration: | 1. 1. 2016 - 31. 12. 2019 |
| Evidence number: | 2/0155/16 |
| Program: | VEGA |
| Project leader: | RNDr. Juránek Ivo, PhD., DrSc. |
| SAS cosolvers: | Mgr. Hodúrová Zuzana, PhD., Mgr. Luptáková Dominika, Mgr. Regeš Michal |
| - | |
| Duration: | 1. 1. 2016 - 31. 12. 2019 |
| Evidence number: | VEGA SR 1/0271/16 |
| Program: | VEGA |
| Project leader: | Ing. Ferko Miroslav, PhD. |
| SAS cosolvers: | Mgr. Farkašová Veronika, PhD, Mgr. Muráriková Martina, PhD., MUDr. Ravingerová Táňa, DrSc., FIACS |
| Investigation of regulatory mechanisms of cardiac cell-cell communication for targeted protection from heart failure. | |
| Duration: | 1. 1. 2016 - 31. 12. 2019 |
| Evidence number: | 2/0076/16 |
| Program: | VEGA |
| Project leader: | RNDr. Tribulová Narcisa, DrSc. |
| SAS cosolvers: | RNDr. Egan Beňová Tamara, PhD., RNDr. Knezl Vladimír, PhD., RNDr. Kura Branislav, PhD., D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS, RNDr. Szeiffová Bačová Barbara, PhD., Mgr. Viczenczová Csilla, PhD. |
| Annotation: | Cardiac cell-to-cell communication via gap junction connexin (Cx) channels is essential for synchronised heart function. While disorders in expression, distribution and phosphorylation of Cx in of both human and animal heart diseases promote occurrence of malignant arrhythmias and heart failure. We hypothesize that targetedmodulation of Cx channel function by exogenous and endogenous compounds may be a promising approach to protect proper heart function. Aim of this project is to elucidate mechanisms implicated in regulation ofCx43-mediated cardiac cell-to-cell communication in healthy and diseased heart. Research findings should enhance knowledge of cardiologists in this field and challenge the realization of clinical trials supporting novel approaches in prevention and/or treatment of heart diseases to fight sudden cardiac death. |
| ENDBIOM - Study of critical endogenous biomarkers and signaling pathways in hypertension and cardiovascular diseases | |
| Duration: | 1. 1. 2017 - 31. 12. 2019 |
| Evidence number: | 2/0148/17 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Dovinová Ima, PhD. |
| SAS cosolvers: | RNDr. Čačányiová Soňa, PhD., Mgr. Grešová Linda, Ing. Kvandová Miroslava, Mgr. Majzúnová Miroslava, PhD., RNDr. Regecová Valéria |
| Annotation: | Several endogenous factors and signaling pathways contribute to the development of cardiovascular diseases. Activation of the renin-angiotensin and aldosterone system (RAAS), deteriorated relaxation of vasoactive systems producing NO and H2S, as well as an imbalance of redox pathways producing reactive oxygen and nitrogen species (ROS a RNS). Hypertension is a major risk factors of cardiovascular diseases and leads to functional and structural alterations in blood vessel walls. The landmarks of developed hypertension are increased vasoconstriction regulated by RAAS, oxidative stress manifested in increased ROS and RNS, endothelial dysfunction (increased levels of assymetric dimethyl-arginine - ADMA - and homocystein) as well as cardiovascular remodeling (activation of metaloproteinases). Detection, monitoring, and regulation of the critical pathology markers can lead to a better management of hypertension- and metabolic syndrome-related diseases. |
| Specific methods and innovative procedures for assessing performance in athletes and physical fitness in the general population | |
| Duration: | 1. 1. 2017 - 31. 12. 2019 |
| Evidence number: | VEGA 1/0824/17 |
| Program: | VEGA |
| Project leader: | RNDr. Bzdúšková Diana, PhD. |
| SAS cosolvers: | Mgr. Hirjaková Zuzana, PhD., Ing. Hlavačka František, CSc., RNDr. Kimijanová Jana, PhD., Mgr. Mokošáková Miroslava, PhD. |
| Annotation: | The project will design specific tests and innovative methodological procedures for assessing performance inathletes and physical fitness in the general population. These will be based on analysis of performance inselected sports and age specificities of the general population. Methodology of measurement and data analysiswith the highest accuracy of motor abilities evaluation will be verified. Their ability to differentiate between andwithin groups differences will also be evaluated. Part of the project will be testing guidance scales on groups ofelite athletes of selected sports and large population of varied ages. This will provide a basis for testing protocolsand recommendations for utilization of novel diagnostic methods in practice. Such diagnostics taking into accountspecific conditions of particular sports and age specificities represent significant shift in obtaining relevantinformation on performance in athletes and physical fitness in the general population and their longitudinalchanges. |
| The effect of STAT1 and ISG15 inhibitors on biochemical and morphological parameters in experimental myocardial infarction | |
| Duration: | 1. 1. 2017 - 31. 12. 2019 |
| Evidence number: | 2/0170/17 |
| Program: | VEGA |
| Project leader: | RNDr. Cebová Martina, PhD. |
| SAS cosolvers: | MVDr. Barta Andrej, PhD., RNDr. Klimentová Jana, PhD., Mgr. Košútová Michaela, MUDr. Lakota Ján, CSc., doc. RNDr. Pecháňová Oľga, DrSc. |
| Annotation: | Myocardial infarction (MI) remains a major cause of morbidity and mortality throughout the world. Atherosclerosis,chronic inflammation and metabolic diseases are the main causes of MI. Hypertension is the most serious riskfactors which worsen the prognosis of MI via induction of oxidative and inflammatory mediators. Chronic ischemialeads to irreversible myocardial damage. Reperfusion of myocardium may potentially save myocardial function,paradoxically, this process causes further damage of the myocardium and apoptosis of cardiomyocytes alongwith upregulation of STAT1 and ISG15. Thus, it is important to study different molecules which may block orrevers pathological processes in myocardial reperfusion injury following MI at different levels. Therefore, the aimof our study is to analyze the effects of STAT1 and ISG15 inhibitors on reperfusion injury in the experimentalmodel of MI (ischemia-reperfusion injury after STEMI revascularization) and determination of pathophysiologicalchanges in this process. |
| The role of extracellular vesicles in inter-organ communication related to remote cardioprotection | |
| Duration: | 1. 1. 2016 - 31. 12. 2019 |
| Evidence number: | 2/0061/16 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Barteková Monika, PhD. |
| SAS cosolvers: | RNDr. Barančík Miroslav, DrSc., Mgr. Ferenczyová Kristína, PhD., Mgr. Fogarassyová Mária, Mgr. Jelemenský Marek, doc. MUDr. Radošinská Jana, PhD. |
| Annotation: | Inter-organ communication plays a crucial role in cardioprotection induced by an ischemic (or other) insult on remote organ to the heart, called remote ischemic preconditioning, or remote conditioning in general. Extracellular vesicles (EVs) are membrane-bound structures secreted by a wide range of mammalian cell types that can be secreted and specifically taken up by other cells. Since EVs contain a high concentration of RNAs and proteins, they are of a high interest as potential mediators of remote cardioprotection, and thus for inter-organ signal transfer mechanisms in general. Revealing the role of EVs in communication between different cells and organs as well as identifying substances transported by EVs to be potential mediators of cardioprotection as the main goal of the current project could lead to better understanding of remote cardioprotection and inter-organ communication in general, and rise up new potential targets of therapy of heart ischemia. |
| Vplyv transkraniálnej stimulácie mozgu jednosmerným prúdom na senzorimotorické vrátkovanie u človeka | |
| Duration: | 1. 1. 2017 - 31. 12. 2019 |
| Evidence number: | VEGA 2/0039/17 |
| Program: | VEGA |
| Project leader: | MUDr. Jagla Fedor, CSc. |
| SAS cosolvers: | Ing. Bendžala Štefan, RNDr. Cimrová Barbora, PhD., Mgr. Marko Martin, PhD., Mgr. Murínová Jana, MUDr. Riečanský Igor, PhD., Mgr. Roháriková Veronika, Mgr. Rovný Rastislav |
| Annotation: | The term sensorimotor gating refers to a basic inhibitory process, which prevents processing of and reacting to irrelevant stimuli so that resources can be allocated to salient aspects of the environment. Disrupted gating is considered to play a causal role in the development of psychosis in schizophrenia spectrum disorders. Prefrontal cortex (PFC) is involved in inhibitory control processes and its dysfunction is a hallmark of schizophrenia. Transcranial direct current stimulation stimulation (tDCS) can be used to increase or decrease excitability of neuronal tissue and is increasingly used to modulate human brain activity and cognitive processes. In this project, we will systematically explore in healthy adults the possibility to modulate sensorimotor gating by tDCS of the PFC, which has not been investigated so far. Our findings will bring important new knowledge on the brain mechanisms of sensorimotor gating, pathogenesis of mental disorders and possibilities of their treatment. |
| Interaction of nitrergic, neurotrophic and endocrine signaling in the etiopathogenesis of schizophrenia | |
| Duration: | 1. 7. 2015 - 30. 6. 2019 |
| Evidence number: | APVV-14-0840 |
| Program: | APVV |
| Project leader: | MUDr. Riečanský Igor, PhD. |
| SAS cosolvers: | Ing. Bendžala Štefan, RNDr. Cebová Martina, PhD., RNDr. Graban Ján, PhD., RNDr. Hlaváčová Nataša, PhD., PharmDr. Hrivíková Katarína, PhD., PharmDr. Chomanič Pavol, prof. PharmDr. Ježová Daniela, DrSc., RNDr. Karailiev Peter, PhD., RNDr. Karailievová Lucia, PhD., doc. PaedDr. RNDr. Katina Stanislav, PhD., Mgr. Marko Martin, PhD., Mgr. Mitka Milan, PhD., Peťová Jana, RNDr. Puhová Agneša, PhD., Mgr. Rovný Rastislav, PhD., MSc. Spodniaková Barbora, Mgr. Šťastná Sarah, RNDr. Vranková Stanislava, PhD., RNDr. Wojtyła Chmelová Magdaléna, PhD., Žilavá Ľudmila |
| Annotation: | Schizophrenia is a common and severe mental disorder but its pathogenesis is yet poorly understood. Susceptibility to schizophrenia is largely genetic but the genetic predisposition is determined in a complex network of interactions between multiple risk genes and environmental factors, resulting in disordered brain development and function. There is increasing evidence that chronic stress and dysregulation of several signaling pathways plays role in the neurodevelopmental impairment underlying schizophrenia. In this project, by adopting a multidisciplinary approach, we will address at several levels (genetic, neurobiological and behavioral) a candidate pathophysiological pathway, involving nitrergic, neurotrophic and stress signaling, which might be importantly involved in the disordered brain development in schizophrenia. A focus on schizophrenia endophenotypes will enable us to integrate findings from human subjects at genetic risk of the disorder with those from a rodent neurodevelopmental model of schizophrenia. This project will bring important new knowledge on the etiopathogenesis of this devastating disorder and potential novel strategies of its treatment. |
| Design and implementation of visual biofeedback for the rehabilitation of mobility deficiencies in patients with low back pain | |
| Duration: | 1. 7. 2017 - 30. 6. 2019 |
| Evidence number: | APVV-16-0233 |
| Program: | APVV |
| Project leader: | Ing. Hlavačka František, CSc. |
| SAS cosolvers: | RNDr. Bzdúšková Diana, PhD., Mgr. Hirjaková Zuzana, PhD., RNDr. Kimijanová Jana, PhD. |
| Annotation: | The main goal of this project is to design, optimize and implement a specialized method for the improved rehabilitation of mobility deficiencies in patients suffering from low back pain (LBP). The system will be equipped with accurate inertial measuring units embedded with highly sensitive micro-electro-mechanical (MEMS) accelerometers and gyroscopes, as well as a force platform providing input signals that will be processed and displayed back to the patient (visual biofeedback). LBP is a worldwide health problem affecting people of all ages, with recurring symptoms. Based on positive long-term experiences with visual biofeedback, the project strives to design an effective rehabilitation program for the improvement of impaired trunk mobility during sitting, and also impaired balance control during stance in LBP patients. The project not only includes the accurate acquisition of postural data, but also the development of software which will process, interpret and display this data in an easy to understand way. The software is intended to be easily operated and include training tasks that can be personalized to patient specific requirements. The ultimate goal of the project is to implement complex sensor systems capable of accurate measurements but process the data into an easy to use and easy to interpret rehabilitation tool for improving postural and motor function deficiencies in patients suffering from LBP. |
| NANOSIMKA - Effects of nanoencapsulated simvastatin on cardiovascular system in experimental metabolic syndrome | |
| Duration: | 1. 7. 2015 - 30. 6. 2019 |
| Evidence number: | APVV-14-0932 |
| Program: | APVV |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| - | |
| Duration: | 1. 3. 2015 - 31. 3. 2019 |
| Evidence number: | |
| Program: | Iné projekty |
| Project leader: | RNDr. Horáková Ľubica, PhD. |
| Effect of lyophylisate Cornus mas L. on cardiometabolic and inflammatory parameters in experimental metabolic syndrome | |
| Duration: | 1. 1. 2016 - 31. 12. 2018 |
| Evidence number: | 2/0137/16 |
| Program: | VEGA |
| Project leader: | Doc.MUDr. Lietava Ján, CSc. |
| Inhibition of proliferation and induction of apoptosis in cancer cells by affecting the metabolic profile | |
| Duration: | 1. 1. 2015 - 31. 12. 2018 |
| Evidence number: | 2/0148/15 |
| Program: | VEGA |
| Project leader: | RNDr. Blaškovič Dušan, PhD. |
| Annotation: | The aim of the project is to inhibit the growth and induce apoptosis in cancer cells by affecting the following metabolic pathways: glycolysis, Krebs cycle, the pentose phosphate cycle and fatty acid synthesis. Cancer cells HeLa ( cervix ) , HCT - 116 ( colon ) and MCF - 7 ( breast ) will be incubated with inhibitors of particular metabolic pathways to determine the pathway, which inhibition caused the greatest decrease of the growth, respectively the induction of apoptosis . The project is also aimed on the study of the effect of inhibiting of various metabolic pathways by natural substances, which are non-toxic for the normal cells. Multiple pathways will be simultaneously inhibited in cancer cells using natural substances to reach the most significant suppression of cancer cell growth and/or induction of apoptosis. Research will also focus on determation of the impact of coltsfoot extract on selected metabolic pathways and viability of cancer cells. |
| Mechanisms, early detection and therapy of asphyxial injury in perinatal period - comparison of experimental data with clinical observation of asphyxial newborns | |
| Duration: | 1. 1. 2015 - 31. 12. 2018 |
| Evidence number: | 2/0129/15 |
| Program: | VEGA |
| Project leader: | Doc. RNDr. Ujházy Eduard, CSc. |
| SAS cosolvers: | RNDr. Dubovický Michal, CSc. , RNDr. Gáspárová Zdenka, PhD., MVDr. Koprdová Romana, PhD., RNDr. Mach Mojmír, PhD. |
| Annotation: | The results from our studies concerning uncovering the mechanisms and possibilities of early detection of embryo-fetal damage confirmed that our proposed model of subchronic perinatal asphyxia using rat model is suitable for next studies. We will use this model for further expansion of knowledge about the mechanisms of actions of asphyxia in the process of late organogenesis and perinatal period. It is important to detect suitable biochemical and morphological markers to reduce the risk of complications due to asphyxia during development, as well as the possibility of its early therapy via antioxidant active ingredients of natural and synthetic origin. The ability of these compounds to bind to transport blood components (albumin, hemoglobin) will be monitored and a method for testing the effects on neuronal cell cultures will be developed. Integral part of this project will be correlations of given data from experimental studies with clinical observations in full-term asphyxiated newborns. |
| - | |
| Duration: | 1. 1. 2015 - 31. 12. 2018 |
| Evidence number: | 2/0044/15 |
| Program: | VEGA |
| Project leader: | PharmDr. Bauerová Katarína, PhD., DrSc. |
| SAS cosolvers: | PharmDr. Dráfi František, PhD., MPH, PharmDr. Jančinová Viera, PhD., Mgr. Krnáčová Katarína, PhD., Ing. Mihalová Danica, PharmDr. Poništ Silvester, PhD., Ing. Račková Lucia, PhD., PharmDr. Slovák Lukáš, PhD., Ing. Švík Karol, CSc., Mgr. Vaváková Magdalena, PhD. |
| Other cosolvers: | spoluriešitelia z FaF UK a LF UPJS |
| Protection of the heart from maladaptive extracellular matrix remodeling and searching the mechanisms of its regression. | |
| Duration: | 1. 1. 2015 - 31. 12. 2018 |
| Evidence number: | 2/0167/15 |
| Program: | VEGA |
| Project leader: | RNDr. Szeiffová Bačová Barbara, PhD. |
| Annotation: | Heart diseases are accompanied by exracellular matrix remodeling and fibrosis resulting in development of heartfailure and malignant arrhythmias. Fibrosis is a major medical problem without existing cure. However, there arecardioprotective compounds that exhibit antifibrotic effects but underlying mechanisms are poorly understood.This project is aimed to characterize key factors implicated in profibrotic signaling in rats suffering fromhypertension, diabetes, hypothyroidism and post-infarction injury and to determine targets of examinedpharmacological and nonpharmacological compounds. This approach should reveal signaling pathways andfactors, whose modulation could hamper or reverse fibrosis. It is expected that findings of this preclinical studymay outline design of clinical trials how to protect the heart from its dysfunction by non-invasive way. |
| Protection of hypertensive and failure heart by I(f) channel blocker ivabradin: comparison with ACE inhibition and melatonin | |
| Duration: | 1. 1. 2015 - 31. 12. 2018 |
| Evidence number: | VEGA 1/0071/15 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| Protective effects of natural and synthetic substances against oxidative damage of high-molar-mass hyaluronan, isolated mammal cells and their mitochondria | |
| Duration: | 1. 1. 2015 - 31. 12. 2018 |
| Evidence number: | 2/0065/15 |
| Program: | VEGA |
| Project leader: | RNDr. Valachová Katarína , PhD. |
| SAS cosolvers: | RNDr. Juránek Ivo, PhD., DrSc., Ing. Šoltés Ladislav, DrSc., Ing. Topoľská Dominika, PhD. |
| Annotation: | Hyaluronan (HA) is a polysaccharide of molar mass several megaDaltons present in tissues of vertebrates. In inflammatory diseases the average molar mass of HA decreases by action of oxidants. A significant decrease of synovial fluid (SF) viscoelasticity was detected, thereby its lubricating properties are worsened. High-molar-mass HA solutions are relevantly used for in vitro studies of free radicals and oxidants performance and also for a study of protective effects of antioxidants/drugs in a role of prevention or chain-breaking degradation of HA macromolecules.Substances of synthetic origin such as antiinflammatory drugs, mitochondria targeted antioxidants and natural substances with demonstrated antioxidative effects against HA degradation will be tested as protectors of oxidative degradation of cell lines of fibroblasts NIH-3T3, B-HNF-1, VH10 and cell organels, especially mitochondria. |
| Protective effect of NO and CO donors in experimental myocardial infarction with hypertensive complications | |
| Duration: | 1. 1. 2015 - 31. 12. 2018 |
| Evidence number: | 2/0195/15 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| Redox control of the professional phagocytes in blood and in the central nervous system: Molecular mechanisms and functional significance. | |
| Duration: | 1. 1. 2016 - 31. 12. 2018 |
| Evidence number: | VEGA 2/0029/16 |
| Program: | VEGA |
| Project leader: | PharmDr. Jančinová Viera, PhD. |
| SAS cosolvers: | MVDr. Koprdová Romana, PhD., prof. MUDr. Nosáľ Radomír, DrSc., PharmDr. Piešová Michaela, Ing. Račková Lucia, PhD., Ing. Švecová Blanka |
| Annotation: | The submitted project is a continuation of our previous research in the pharmacological regulation of inflammatory processes. The focus is on neutrophils and microglial cells (resident brain macrophages) which are considered active participants in the initiation and progression of pathological states connected with chronic inflammation such as arthritis or neurodegenerative diseases. The aim of the project is to explain cellular and molecularmechanisms involved in the pharmacological modulation of these cells. Attention will be paid to drugs and derivatives of natural substances which are able to influence the production of reactive oxygen and nitrogen species. The coordinated research of two types of phagocytes creates an opportunity for the sharing of modern instruments and excellent methods as immunofluorescence microscopy or flow cytometry. Cooperation betweenbasic research and clinical practice will allow the use of these methods in the analysis of phagocytes from patients with rheumatoid arthritis. |
| Risk factors of cardiovascular and cerebrovascular diseases and pharmacological possibilities of their influence | |
| Duration: | 1. 1. 2015 - 31. 12. 2018 |
| Evidence number: | 2/0054/15 |
| Program: | VEGA |
| Project leader: | RNDr. Gáspárová Zdenka, PhD. |
| SAS cosolvers: | MVDr. Bezek Štefan, DrSc., Ing. Brnoliaková Zuzana, PhD., RNDr. Gajdošíková Alena, RNDr. Knezl Vladimír, PhD., Mgr. Lipták Boris, Ing. Pádej Ivan, RNDr. Sotníková Ružena, CSc., Mgr. Stará Veronika, Mgr. Tyukos Kaprinay Barbara, PhD. |
| Annotation: | The project is aimed at the study of mechanisms of etiopathogenesis of metabolic syndrome (MS) and metabolic cognitive syndrome (MSC). The goal is to design new effective therapy affecting the origin and development of risk factors of cardiovascular and cerebrovascular diseases. Experiments will be performed on a genetic model of rats with hereditary hypertriglyceridemia, fed with hyperlipidemic diet. The induced metabolic disorders willbecome manifest by hypertension, hypercholesterolemia, hyperglycemia, hypertriglyceridemia, inflammatory reactions and increased markers of oxidative stress. Effect on the risk factors of MS and MCS, lipidic profile, on markers of damage at cellular and molecular level, function, behavioral and histopathological changes will be studied after repeated administration of the new pyridoindole SMe1EC2, flavonoid rutin, and atorvastatin as a standard. Action on several risk factors of cardiovascular and cerebrovascular diseases simultaneously is expected. |
| Study of consequences of maternal depression and antidepressant venlafaxine treatment on functional development of the brain and behavior of rat offspring | |
| Duration: | 1. 1. 2015 - 31. 12. 2018 |
| Evidence number: | 2/0168/15 |
| Program: | VEGA |
| Project leader: | RNDr. Dubovický Michal, CSc. |
| SAS cosolvers: | Mgr. Belovičová Kristína, PhD. , Mgr. Bögi Eszter, PhD., RNDr. Mach Mojmír, PhD., Doc. RNDr. Ujházy Eduard, CSc. |
| - | |
| Duration: | 1. 1. 2017 - 31. 12. 2018 |
| Evidence number: | 2/0048/17 |
| Program: | VEGA |
| Project leader: | RNDr. Kristek František, DrSc. |
| SAS cosolvers: | RNDr. Čačányiová Soňa, PhD., RNDr. Drobná Magdaléna, PhD., Ing. Kožík Jozef |
| The influence of constitutional factors of redox regulation on endophenotypic markers of schizophrenia | |
| Duration: | 1. 1. 2016 - 31. 12. 2018 |
| Evidence number: | 2/0056/16 |
| Program: | VEGA |
| Project leader: | MUDr. Riečanský Igor, PhD. |
| SAS cosolvers: | Ing. Bendžala Štefan, doc. PaedDr. RNDr. Katina Stanislav, PhD., Mgr. Mitka Milan, PhD., Mgr. Murínová Jana, Mgr. Roháriková Veronika, Mgr. Rovný Rastislav |
| Other cosolvers: | Dragašek Jozef, MUDr. PhD.; |
| Age-related changes in sensory control of balance during sit-to-stand and gait | |
| Duration: | 1. 1. 2016 - 31. 12. 2018 |
| Evidence number: | 2/0094/16 |
| Program: | VEGA |
| Project leader: | Ing. Hlavačka František, CSc. |
| SAS cosolvers: | RNDr. Bzdúšková Diana, PhD., Mgr. Hirjaková Zuzana, PhD., RNDr. Kimijanová Jana, PhD., MUDr. Šaling Marián, CSc. |
| Annotation: | The ability to reliably perform functional movements like sit-to-stand, gait or maintaining the erect posture is a basis for the independent living. Difficulties with conducting these motor activities increase with age. Early diagnostics and suitable therapeutic interventions can help to moderate these problems and prevent falls. The goal of our project is to obtain new knowledge about the physiological mechanisms of sit-to-stand movement and gait in young and elderly adults, and also to expand information about the sensory influence on these motor functions. We will focus on analysis of balance control in static and dynamic conditions during sit-to-stand, step initiation and gait using unique 6-camera motion capture system BTS SMART-DX. We assume that results of our project would be worthwhile in designing of perspective rehabilitative methods for elderly people with mobility deficit to improve their balance and functional mobility, and also to enhance diagnostics of early stages of neurological disorders. |
| KANASTA - Cardiovascular Effects of Nanoencapsulated Simvastain and Coenzyme Q10 in Experimental Hyperlipidemia (KANASTA) | |
| Duration: | 27. 11. 2015 - 26. 11. 2018 |
| Evidence number: | |
| Program: | Iné projekty |
| Project leader: | RNDr. Reháková Radoslava |
| SAS cosolvers: | MVDr. Barta Andrej, PhD., RNDr. Cebová Martina, PhD., Mgr. Košútová Michaela, Ing. Kovácsová Mária, PhD., Mgr. Matúšková Zuzana, PhD., doc. RNDr. Pecháňová Oľga, DrSc., doc. MUDr. Török Jozef, CSc. |
| Annotation: | The project is aimed to investigate cardiovascular effects of simvastatin together with CoQ10 in experimental hyperlipidemia and to increase bioavailability of simvastatin in the liver, thus reducing the daily dose and consequently to prevent the reduction of CoQ10 levels. |
| - | |
| Duration: | 1. 9. 2015 - 31. 8. 2018 |
| Evidence number: | Req-00174-0006 |
| Program: | Vedecko-technické projekty |
| Project leader: | RNDr. Dubovický Michal, CSc. |
| - | |
| Duration: | 1. 7. 2014 - 30. 6. 2018 |
| Evidence number: | APVV-14-0334 |
| Program: | APVV |
| Project leader: | RNDr. Barančík Miroslav, DrSc. |
| Aldo-keto reductases in chronic diseases – in silico modeling of significant enzymes and their complexes with indole derivatives | |
| Duration: | 1. 1. 2014 - 31. 12. 2017 |
| Evidence number: | 2/0033/14 |
| Program: | VEGA |
| Project leader: | RNDr. Májeková Magdaléna, PhD. |
| SAS cosolvers: | RNDr. Balleková Jana, Ing. Ďurišová Mária, DrSc., Ing. Šoltésová Prnová Marta, PhD., Ing. Štefek Milan, CSc. |
| Other cosolvers: | Májek Pavol Ing. CSc. |
| Annotation: | The aldo-keto reductases belong into a family of enzymes characterized as monomeric NADPH-dependentoxidoreductases. Till now the number of more than 100 enzymes from this family is known. They are divided according to their substrate specificity to individual subgroups. Apart from their beneficial physiological functions hold by biosynthesis, metabolism and detoxication, they can play also a negative role by various pathologic processes as chronic diabetic complications, inflammation, carcinogenesis, asthma etc. The aim of this work is toelaborate and test the specific models of significant subgroups of aldoketoreductases by means of in silico methods. The individual models are to be used for considering the inhibition properties of indole compounds with measured or perspective biological activity. |
| Bioenergetic aspects of myocardial protection by means of remote ischemic preconditioning. The role of cardiac mitochondria | |
| Duration: | 1. 1. 2015 - 31. 12. 2017 |
| Evidence number: | 2/0133/15 |
| Program: | VEGA |
| Project leader: | Ing. Ferko Miroslav, PhD. |
| Annotation: | Any sufficiently strong challenge induced by physiological or pathological stimuli leads to myocardial changes that can be considered as abnormal. These changes partially reflect endogenous protective processes. Pathological stimuli triggering the endogenous protection are hypoxia, ischemia, diabetes mellitus and hypertension. Cardioprotective approaches involve pharmacological and ischemic preconditioning (IP) as well as clinically applicable form of IP, so called remote ischemic preconditioning (RIP). Numerous mechanisms of RIP induction and effects have been investigated. Still, the character of the signals from the site of RIP leading to target structures in the heart is not elucidated. Little is known also with respect to bioenergetics aspects and role of cardiac mitochondria in RIP induced cardioprotection. The aim of this project is to contribute to elucidation of the molecular mechanisms of RIP and role of mitochondria in the signaling processes of RIP and heart adaptation to hypoxia and ischemia. |
| Indole-1-acetic acid derivatives as aldose reductase inhibitors: design, synthesis and biological activity | |
| Duration: | 1. 1. 2015 - 31. 12. 2017 |
| Evidence number: | 2/0041/15 |
| Program: | VEGA |
| Project leader: | Ing. Štefek Milan, CSc. |
| Matrix-metalloproteinases, microRNAs and deformability of erythrocytes as a novel diagnostic and predictive biomarkers of heart failure | |
| Duration: | 1. 1. 2014 - 31. 12. 2017 |
| Evidence number: | 1/0032/14 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Barteková Monika, PhD. |
| SAS cosolvers: | doc. RNDr. Barteková Monika, PhD., RNDr. Egan Beňová Tamara, PhD., RNDr. Szeiffová Bačová Barbara, PhD. |
| Molecular mechanisms involved in the effects of doxorubicin in rats with developed hypertension and ways of modulation of of these effects of doxorubicin by quercetin. | |
| Duration: | 1. 1. 2015 - 31. 12. 2017 |
| Evidence number: | 2/0108/15 |
| Program: | VEGA |
| Project leader: | RNDr. Barančík Miroslav, DrSc. |
| SAS cosolvers: | doc. RNDr. Barteková Monika, PhD., prof. Ing. Breier Albert, DrSc. |
| - | |
| Duration: | 1. 1. 2015 - 31. 12. 2017 |
| Evidence number: | 2/0021/15 |
| Program: | VEGA |
| Project leader: | D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS |
| Nitric oxide and brain redox status in an experimental neurodevelopmental model of schizophrenia | |
| Duration: | 1. 1. 2015 - 31. 12. 2017 |
| Evidence number: | 2/0165/15 |
| Program: | VEGA |
| Project leader: | RNDr. Vranková Stanislava, PhD. |
| SAS cosolvers: | Ing. Bendžala Štefan, Mgr. Matúšková Zuzana, PhD., Mgr. Murínová Jana, MUDr. Riečanský Igor, PhD., Mgr. Rovný Rastislav |
| Annotation: | Schizophrenia is a severe mental disorder. Research suggests that an important role its pathophysiology may play the oxidative stress, i.e., redox imbalance in neurons of the central nervous system, leading to an impairment of brain development. This redox imbalance might be caused by an overproduction of nitric oxide (NO). Therefore, this project is focused at the role of NO in brain development. We will adopt the postweaning social isolation rearing of rats, which is an established neurodevelopmental model of schizophrenia. We will explore whether social isolation affects NO synthesis in the brain and whether NO production is linked with redox status of the brain tissue and schizophrenia-like behavioral alterations. We will also explore whether the changes in neurobiology and behavior, induced by isolation rearing, can be positively influenced by an antioxidative treatment. Results of this project will contribute to elucidating the pathogenesis of schizophrenia and its treatment possibilities. |
| NO and H2S signal pathways and their interaction in the control of vascular tone during early developmental stage of experimental hypertension | |
| Duration: | 1. 1. 2014 - 31. 12. 2017 |
| Evidence number: | 2/0074/14 |
| Program: | VEGA |
| Project leader: | RNDr. Čačányiová Soňa, PhD. |
| SAS cosolvers: | Mgr. Berényiová Andrea, PhD., doc. RNDr. Dovinová Ima, PhD., RNDr. Kristek František, DrSc. |
| Annotation: | Nitric oxide (NO) and hydrogen sulphide (H2S) belong to important gaseous molecules engaged to vascular smooth muscle regulation during normotensive as well as hypertensive conditions. In adult rats it is well documented the role of NO originated from endothelial isoform of NO-synthase, the specificity and originality of NO released from neuronal isoform of enzyme as well as the existence of specific NO-H2S interaction – not just yet identified nitroso-sulphide signalization. The aim of the project is to characterize and compare the role of NO and H2S, their signal pathways and interaction, in young normotensive rats and in rats with developing experimental hypertension(NO-deficient and essential hypertension. Simultaneous following of both signal pathways on the same vessels isolated from normotensive and hypertensive rats and humans represents the actual way how to associate the results of basic research with clinical praxis. |
| Study of the clinically relevant forms of preconditioning as an alternative method of myocardial protection against acute ischemia in the organism challenged with civilization diseases | |
| Duration: | 1. 1. 2015 - 31. 12. 2017 |
| Evidence number: | 2/0201/15 |
| Program: | VEGA |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| SAS cosolvers: | Mgr. Farkašová Veronika, PhD, Ing. Ferko Miroslav, PhD., Ing. Gablovský Ivan, Mgr. Jašová Magdaléna, PhD., Mgr. Kancírová Ivana, PhD., Mgr. Muráriková Martina, PhD., MUDr. Styk Ján, CSc., MUDr. Zálešák Marek, PhD., Ing. Ziegelhöffer Attila, DrSc. |
| Annotation: | Hypertension, metabolic disorders, sex and aging have a negative impact on the adaptive mechanisms of innate cardioprotection and alter heart survival upon acute ischemia/reperfusion (I/R). These comorbidities suppress the mechanisms of cell signaling involved in protective effects of ischemic preconditioning (PC) and accelerate necrotic and apoptotic processes during I/R, reduce energy production and contribute to enhanced arrhythmogenesis. The project is aimed to investigate the possiblities to restore adaptive potential in the pathologically altered myocardium including aged heart by means of modulation of the intensity and forms of adaptive stimuli. Effects of clinically relevant forms of PC: „remote“ PC of the heart induced by ischemia of the distant organ and its pharmacological simulations by drugs regulating energy metabolisms and involved in the mechanisms of PC, as well as their genomic and non-genomic effects including the impact on mitochondrial function and apoptotic cascade will be investigated |
| The role of perivascular adipose tissue in the regulation of vascular tone in rats with cardiovascular dysfunction | |
| Duration: | 1. 1. 2015 - 31. 12. 2017 |
| Evidence number: | 2/0202/15 |
| Program: | VEGA |
| Project leader: | Mgr. Zemančíková Anna, PhD. |
| SAS cosolvers: | Ing. Kovácsová Mária, PhD., doc. MUDr. Török Jozef, CSc. |
| Annotation: | Perivascular adipose tissue (PVAT) which surrounds most of the systemic arteries is considered to be an important modulator of their functions. Relaxant factors produced by this tissue inhibit vascular contractile responses to many vasoconstrictor substances. The aim of this project is to analyse the mechanisms which are responsible for this modulatory effect. In addition to the direct action of the PVAT-released substances on vascular smooth muscle we intend to study also the possible interaction of PVAT with vascular sympathetic nervous system. These interactions are important for maintaining vascular tone in physiological as well as in pathological conditions associated with vascular dysfunction, e.g. in hypertension. Our goal is to discover whether the changes in paracrine functions of PVAT may participate in the origin of vascular disorders and whether they precede the abnormalities of vascular reactivity at the level of smooth muscle. |
| Cognitive skills form the perspective of functional asymmetry of the brain | |
| Duration: | 1. 1. 2015 - 31. 12. 2017 |
| Evidence number: | 1/0083/15 |
| Program: | VEGA |
| Project leader: | RNDr. Cimrová Barbora, PhD. |
| Annotation: | Recent research using dichotic stimulation and a visual half-field technique indicate that sex differences in cognitive skills could be connected with lateralization of perceptual cognitive functions particularly because men and women differ not only in cognitive skills but also in degree of lateralization of cognitive functions. In general, perceptual asymmetries are greater in men. An assumtion is that a certain degree of the leftward lateralization (but not the maximal lateralization) is optimal for verbal functions, so that high left hemisphere lateralization is not associated with superior performance. Therefore, women outperform men in verbal tasks. In nonverbal task, a greater degree of lateralization towards the right hemisphere is associated with better performance. The proposed project will try to answer a question whether a degree of lateralization could explain the variation in performance within the groups of men and women. The sex differences in lateralization will be explored as well. |
| Chemoenzymatic synthesis and evaluation of biological activities of natural glycophenols and their analogues | |
| Duration: | 1. 10. 2013 - 30. 9. 2017 |
| Evidence number: | APVV-846-12 |
| Program: | APVV |
| Project leader: | RNDr. Barančík Miroslav, DrSc. |
| SAS cosolvers: | doc. RNDr. Barteková Monika, PhD. |
| Study of regulation of radical and cellular signaling during hypertension and influence of novel therapies on this signaling | |
| Duration: | 1. 10. 2013 - 30. 9. 2017 |
| Evidence number: | APVV-0348-12 |
| Program: | APVV |
| Project leader: | RNDr. Barančík Miroslav, DrSc. |
| SAS cosolvers: | doc. RNDr. Dovinová Ima, PhD. |
| HYPERAD - Study of regulation of radical and cellular signaling during hypertension and influence of novel therapies on this signaling. | |
| Duration: | 1. 10. 2013 - 30. 9. 2017 |
| Evidence number: | APVV-0348-12 |
| Program: | APVV |
| Project leader: | doc. RNDr. Dovinová Ima, PhD. |
| SAS cosolvers: | RNDr. Bališ Peter, PhD., RNDr. Barančík Miroslav, CSc., RNDr. Bernátová Iveta, DrSc., Mgr. Grešová Linda, Ing. Kvandová Miroslava, Mgr. Majzúnová Miroslava, PhD., RNDr. Regecová Valéria, RNDr. Szeiffová Bačová Barbara, PhD., Ing. Šimončíková Petra, PhD., RNDr. Tribulová Narcisa, DrSc. |
| Annotation: | New project was started in october 2013. This year we studied mechnisms involved in blood pressure regulation of young SHR after treatment of PPAR gamma agonist- pioglidazone (PIO). Application of PIO significantly influenced development of high blood pressure and improved lipid profile and vessels relaxation. PIO ifluenced also: i) regulation of SOD enzymes, ii) renin-angiotenzin system a iii) intracellular signaling pathways of Akt kinase and beta-catenin. Outputs: 1 publication CC. |
| How synchrony shapes human social bonding: mechanisms and neural pathways | |
| Duration: | 1. 5. 2015 - 20. 9. 2017 |
| Evidence number: | 0101/01/02 |
| Program: | SASPRO |
| Project leader: | MUDr. Riečanský Igor, PhD. |
| SAS cosolvers: | Dr. Majdandžić Jasminka |
| Annotation: | Human societies are characterized by flexibly changing social groups with remarkably strong bonds. A striking, universal characteristic of bonded groups is a widespread tendency their members to synchronize their movements. Such behavioral synchronization supports deindividuation, cooperation, and group solidarity. However, the psychological and neural mechanisms of the link between synchrony and bonding are poorly understood. This project aims to fill this gap by using a multi-level social neuroscience approach based on a series of behavioral, functional neuroimaging and psychopharmacological experiments. Insights from the project will advance our understanding of the complex processes of social behavior. The principal investigator of this project is Dr. Jasminka Majdandzic. |
| Effect of aging on the endothelial function in experimental hypertension | |
| Duration: | 17. 4. 2014 - 17. 4. 2017 |
| Evidence number: | SKS grant |
| Program: | Iné projekty |
| Project leader: | MUDr. RNDr. Púzserová Angelika, PhD. |
| SAS cosolvers: | RNDr. Bališ Peter, PhD., RNDr. Bernátová Iveta, DrSc., doc. MUDr. Török Jozef, CSc., Mgr. Zemančíková Anna, PhD. |
| Other cosolvers: | Jana Radošinská MUDr., PhD. (Fyziologický ústav LF UK) |
| Annotation: | The aim of this project is to investigate the impact of aging on the cardiovascular system, mainly the functional state of the endothelium in the large, medium-sized and resistance arteries during normotension and hypertension. The project studies the role of various endothelium-dependent relaxing and contracting factors in peri-pubertal, adult and senescent rats. In addition, we determine the effect of aging on deformability of red blood cells, nitric oxide bioavailability and reactive oxygen species in the heart and selected arteries. |
| - | |
| Duration: | 2. 2. 2014 - 1. 2. 2017 |
| Evidence number: | |
| Program: | Iné projekty |
| Project leader: | RNDr. Egan Beňová Tamara, PhD. |
| The efect of nitric oxide and hydrogen sulfide on structure and function of cardiovascular system in normotenzive and hypertenzive rats. | |
| Duration: | 1. 1. 2013 - 31. 12. 2016 |
| Evidence number: | 2/0067/13 |
| Program: | VEGA |
| Project leader: | RNDr. Kristek František, DrSc. |
| SAS cosolvers: | RNDr. Cebová Martina, PhD., RNDr. Čačányiová Soňa, PhD., doc. RNDr. Dovinová Ima, PhD., RNDr. Drobná Magdaléna, PhD. |
| Annotation: | In blood pressure regulation are, besides clasical transmitters,engaged gaseous transmiters - mainly nitric oxide (NO) and new very perspective substance hydrogen sulfide (H2S). Completely new signal pathway seems to be neuronal NO synthase (nNOS) and its interactions with other regulatory systems including H2S. nNOS inhibits renin synthesis in macula densa cells and via it influences renin-angiotensin system, which is intimately related to sympathetic nervous system. Enzymes responsible for H2S production are also present in kidney and H2S is, beside others, engaged in renal blood flow and vessel wall tone regulation. The aim of the present project is to study the effect of nNOS and eNOS alone and/or in combination with H2S and other systems engaged in cardiovascular regulation during normotensive and hypertensive conditions. The availability of the results will be reached via complex functional (in vivo and in vitro), morphological, and biochemical approach. |
| Epicatechin in prevention of early development of primary hypertension: mechanisms of action in the cardiovascular and central nervous systems | |
| Duration: | 1. 1. 2014 - 31. 12. 2016 |
| Evidence number: | VEGA 2/0084/14 |
| Program: | VEGA |
| Project leader: | RNDr. Bernátová Iveta, DrSc. |
| SAS cosolvers: | RNDr. Bališ Peter, PhD., Mgr. Kluknavský Michal, PhD., RNDr. Okruhlicová Ľudmila, CSc., MUDr. RNDr. Púzserová Angelika, PhD., RNDr. Regecová Valéria, RNDr. Sotníková Ružena, CSc. |
| Other cosolvers: | LF UK Bratislava |
| Annotation: | This project investigates the effect of epicatechin (Epi) in the cardiovascular and central nervous systems of normotensive, borderline hypertensive (BHR) and spontaneously hypertensive rats as well as in the young humans. Epi has been given to rats in the age of 6-7 weeks which is a critical developmental window regarding development of blood pressure. The effect of Epi on behaviour, blood pressure and selected metabolic, functional and structural parameters of the brain, heart and arteries has been determined. The attention has been paid to the mechanisms of blood pressure regulation and vascular function mediated by nitric oxide, reactive oxygen species and endothelium-derived constricting factors. In young humans Epi has been administered in flavanol-rich chocolate and the reactivity of blood pressure during mental load was determined. The results allow us to evaluate the use of Epi in prevention of hypertension in rats with genetic predisposition to hypertension as well as in humans in conditions of mental load. |
| - | |
| Duration: | 1. 1. 2014 - 31. 12. 2016 |
| Evidence number: | VEGA 2/0084/14 |
| Program: | VEGA |
| Project leader: | RNDr. Sotníková Ružena, CSc. |
| Sensory information filteringin persons with genetic risk of schizophrenia | |
| Duration: | 1. 1. 2014 - 31. 12. 2016 |
| Evidence number: | |
| Program: | VEGA |
| Project leader: | MUDr. Jagla Fedor, CSc. |
| SAS cosolvers: | Ing. Bendžala Štefan, Mgr. Budáč Stanislav, RNDr. Cimrová Barbora, PhD., MUDr. Riečanský Igor, PhD., Mgr. Roháriková Veronika, RNDr. Vranková Stanislava, PhD. |
| Annotation: | Schizophrenia is a devastating mental disorder, but its pathophysiology not clarified yet. An important role in the development of the disorder seems to play an insufficient filtration of irrelevant sensory stimuli. Genetic predisposition is the major risk factor for developing schizophrenia and research indicates involvement of common polymorphisms in multiple functionally coupled genes. There is increasing evidence that redox dysbalance importantly contributes to schizophrenia. In this project, we will use electrophysiological methods to assess how common variability in key enzymes regulating cellular redox status, neuronal nitric oxide synthase and glutamate cysteine ligase, is related to filtering auditory stimuli in humans. This project will provide important novel knowledge on the pathomechanism of schizophrenia. |
| Functional tests in diagnostics of postural stability and strength of core muscles | |
| Duration: | 1. 1. 2014 - 31. 12. 2016 |
| Evidence number: | 1/0373/14 |
| Program: | VEGA |
| Project leader: | Ing. Hlavačka František, CSc. |
| SAS cosolvers: | RNDr. Bzdúšková Diana, PhD., Mgr. Hirjaková Zuzana, PhD., RNDr. Kimijanová Jana, PhD., Mgr. Šuttová Kristína, PhD., Prof. MUDr. Valkovič Peter, PhD. |
| Annotation: | The aim of the project is to design new methods for evaluation of postural stability and trunk muscles strength in static and dynamic conditions. The results will include testing protocols and recommendations for using the devices and medhots in praxis. |
| Development of SQUID Gradiometric and Susceptometric Methods for Iron Homeostasis Related Bio-Applications | |
| Duration: | 1. 1. 2013 - 31. 12. 2016 |
| Evidence number: | VEGA 2/0152/13 |
| Program: | VEGA |
| Project leader: | RNDr. Bernátová Iveta, DrSc. |
| Annotation: | The aim of this project is to design and optimaze the SQUID gradiometric and susceptometric measuring methods and devices for detection and localization of the cancer tissue as well as for investigation of processes related to a disturbed iron metabolism in cardiovascular diseases. We investigate iron homeostasis and biomineralization in ferritin cores in above mentioned diseases. We also investigate the limit sensitivity of this measuring system. We identify the factors which affect the diagnostic interpretation of the results achieved. |
| Participation of HMGB1 in experimental myocardial infarction: cardioprotection vs. cardiac depression | |
| Duration: | 1. 1. 2014 - 31. 12. 2016 |
| Evidence number: | 2/0144/14 |
| Program: | VEGA |
| Project leader: | RNDr. Cebová Martina, PhD. |
| SAS cosolvers: | MVDr. Barta Andrej, PhD., RNDr. Klimentová Jana, PhD., Mgr. Košútová Michaela, Ing. Kovácsová Mária, PhD., Mgr. Matúšková Zuzana, PhD., doc. RNDr. Pecháňová Oľga, DrSc., RNDr. Reháková Radoslava |
| Annotation: | Since many of proteins expressed during myocardial infarction (MI) could have either protective or harmful effectson function and structure of myocardium, it is important to analyze their activity as well as extensity of expression.High-mobility group box 1 (HMGB1) has been recently found as a nuclear protein released during the cerebralischemic event and myocardial ischemia. The goal of this project is to determine the expression of HMGB1 afterexperimental MI and evaluate its effects. To analyze protective or by contrast damaging effects, the protein will beadded or blocked, respectively. In case of protection, the optimal dose of added protein will be analyzed. In caseof harmful effects, the protein will be blocked by both specific antibody or new Affibody molecules. The Affibodymolecules are smaller and penetrate more deeply into the tissue. Thus, better protective effects may beexpected. The results could be used to generate a drug characterized and optimized for subsequeuent clinicaldevelopment. |
| Response of the Na,K-ATPase, representing one of the crucial systems in maintaining the sodium homeostasis, to civilization diseases namely: hypertension, diabetes and hypertriglyceridemia. | |
| Duration: | 1. 1. 2013 - 31. 12. 2016 |
| Evidence number: | 2/0141/13 |
| Program: | VEGA |
| Project leader: | RNDr. Vrbjar Norbert, CSc. |
| SAS cosolvers: | Ing. Frimmel Karel, PhD., MUDr., Ing. Jendruchová (Javorková) Veronika, PhD., Mgr. Kaločayová Barbora, PhD., RNDr. Mézešová Lucia, RNDr. Vlkovičová Jana, PhD. |
| Annotation: | The present project is oriented to obtain new data concerning the maintenance of intracellular homeostasis of sodium, representing one of the unavoidable factors for appropriate regulation of cellular viability. Various widely spread diseases, like hypertension, diabetes mellitus and hypertriglyceridemia are accompanied by disturbances in the maintenance of intracellular sodium homeostasis. Using in vivo models (rat) we will investigate the influence of above listed diseases on the adaptation of Na,K-ATPase which is one of the crucial systems in maintaining intracellular concentration of sodium ions. The data will contribute to elucidation of molecular background of processes involved in maintaining the cell’s viability in the heart, in the kidney and in the brain, from the aspect of the possible protection of the organism against hypertension, diabetes mellitus and hypertriglyceridemia. |
| Effect of PPAR gamma agonists on antioxidant response and on regulation of radical and cell signaling in hypertension | |
| Duration: | 1. 1. 2014 - 31. 12. 2016 |
| Evidence number: | 2/0129/14 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Dovinová Ima, PhD. |
| SAS cosolvers: | RNDr. Bališ Peter, PhD., Mgr. Grešová Linda, Ing. Kvandová Miroslava, Mgr. Majzúnová Miroslava, PhD., MUDr. RNDr. Púzserová Angelika, PhD., Ing. Šimončíková Petra, PhD. |
| Annotation: | An important factor in human and experimental hypertension is the excesive oxidative load. The oxidative stress up-regulates antioxidant response (phase II response) by activation of transcription factor Nrf2. Application of substances modulating the expression of such antioxidant response may be beneficial in reduction of blood pressure and in regression againts blood vessels and other tissues damage. An important role in processes asociated with free radicals and development of hypertension is activation of intracellular signaling, which includes kinase pathways. The PPAR gamma agonists, using dominantly in diabetes melittus therapy, seem to be helpfull also in regulation of hypertension and are important in studying„cross-talk“ among Nrf2 a PPAR gamma. The aim of the project is to search effect of short and long therm therapy of PPAR gamma agonists on antioxidant response, blood vessels and heart damage and on find out the molecular mechanisms. |
| NODAGATE - The influence of variability of NOS1 and DAT1 genes on sensorimotor gating in humans: the implications for the pathophysiology of schizophrenia | |
| Duration: | 1. 1. 2013 - 31. 12. 2016 |
| Evidence number: | 2012/52-SAV-2 |
| Program: | Vedecko-technické projekty |
| Project leader: | MUDr. Riečanský Igor, PhD. |
| SAS cosolvers: | Ing. Bendžala Štefan, doc. PaedDr. RNDr. Katina Stanislav, PhD., Mgr. Murínová Jana, Mgr. Roháriková Veronika, Mgr. Rovný Rastislav |
| Other cosolvers: | Minárik Gabriel, RND |
| Annotation: | Research shows that interactions of functionally related genes play major role in the pathogenesis of schizophrenia. In this project, we investigate the association between combined polymorphisms of NOS1 a DAT1 genes and sensorimotor gating, a endophenotype of schizophrenia. The project will yield novel knowledge on the regulatory mechanisms of dopaminergic signaling, importantly involved in schizophrenia. |
| MVTS An integrated European platform for pancreas cancer research: from basic science to clinical and public health interventions for a rare disease | |
| Duration: | 1. 6. 2013 - 13. 12. 2016 |
| Evidence number: | |
| Program: | Iné projekty |
| Project leader: | RNDr. Májeková Magdaléna, PhD. |
| SAS cosolvers: | RNDr. Balleková Jana, Mgr. Miláčková Ivana, Ing. Šoltésová Prnová Marta, PhD., Ing. Štefek Milan, CSc. |
| Other cosolvers: | Pavol Májek, Ústav analytickej chémie, Fakulta chemickej a potravinárskej technológie STU |
| Annotation: | To present the method based on molecular modeling, which is connected with potential molecular target for pancreas cancer detection, treatment and prevention. The aldo-keto reductases (AKRs) are enzymes with beneficial physiological functions, but they can play also a negative role by various pathologic processes. Our aim is to elaborate models of AKR subtypes specific for pancreatic cancer, drug design and characterization of novel aldo-keto reductase inhibitors of indole type with potential therapeutic effect in relation to pancreatic cancer and to evaluate their use together with biochemical experiments. |
| Project website: | http://www.cost.eu/domains_actions/bmbs/Actions/BM1204 |
| NPPOSC - National Programme for Prevention of Cardiovascular Disease | |
| Duration: | 1. 12. 2011 - 1. 12. 2016 |
| Evidence number: | |
| Program: | Iné projekty |
| Project leader: | RNDr. Regecová Valéria |
| Other cosolvers: | MUDr. Pavol Šimurka, PhD, Univer |
| Annotation: | Cardiovascular program for children and adolescents is a part of the National Programme for prevention of cardiovascular disease (NPPCVD) in SR and is also included in the contract on cooperation between the Ministry of Health and the WHO Regional Office for Europe.Basic objectives and means NPPCVD for children and adolescents: Healthy Heart for Slovakia:• Determine the real incidence of the early stages of cardiovascular disease,in the Slovak Republic in children• Determine the prevalence of risk factors (RF) in children and adolescent of Slovakia • Put in place uniform diagnostic and therapeutic procedures for CVD• Find the control mechanisms for the implementation of preventive and therapeutic procedures• Start with preventive action from early childhood.Final goals NPPCVD:• Reduce the incidence of cardiovascular disease,• Reduce the number of complications from cardiovascular disease,• Reduce mortality and morbidity from cardiovascular disease. |
| - | |
| Duration: | 27. 10. 2015 - 31. 12. 2015 |
| Evidence number: | ITMS: 26230120006 |
| Program: | Štrukturálne fondy EÚ Výskum a vývoj |
| Project leader: | RNDr. Barančík Miroslav, DrSc. |
| SAS cosolvers: | Ing. Sulová Zdena, DrSc. |
| Other cosolvers: | Breier Albert, dos. Ing. DrSc. (STU Bratislava) |
| Pharmacological regulation of phagocyte activity and apoptosis: studies on cellular and molecular levels | |
| Duration: | 1. 1. 2013 - 31. 12. 2015 |
| Evidence number: | VEGA 2/0010/13 |
| Program: | VEGA |
| Project leader: | RNDr. Drábiková Katarína, PhD. |
| Kinematic analysis of posture and gait in healthy subjects and patients with balance impairment. | |
| Duration: | 1. 1. 2013 - 31. 12. 2015 |
| Evidence number: | 2/0138/13 |
| Program: | VEGA |
| Project leader: | Ing. Hlavačka František, CSc. |
| SAS cosolvers: | RNDr. Bzdúšková Diana, PhD., Mgr. Hirjaková Zuzana, PhD., RNDr. Kimijanová Jana, PhD., RNDr. Szathmáry Vavrinec, CSc., MUDr. Šaling Marián, CSc., Mgr. Šuttová Kristína, PhD., Prof. MUDr. Valkovič Peter, PhD. |
| Annotation: | Kinematics of posture and gait including physiological motion analysis plays an important role in relation toneurological and motor disorders.The goal of our project is to bring new knowledge about mechanisms of humanbalance control, gait dynamics and step initiation, and also to expand information about sensory influence onthese functions.The objective of proposal is to analyse mechanisms of sensorimotor control during step initiationand gait using unique 6-cameras motion capture system BTS SMART-DX. Postural sway of body segments willbe measured also by 3D accelerometers placed on the body. Data will be used for description of initial phase ofgait and subsequent gait cycle in healthy subjects.We will focus on age-related differences in motion kinematics.The aim of our project is to compare posture and gait kinematic parameters in healthy individuals and patientsand to find methods for detection of early stages of neurological disorders with sensory impaired balance,sensory deficits and unsafe gait. |
| Yeasts in protection of endothelial intercellular connections against inflammation-induced injury | |
| Duration: | 1. 1. 2013 - 31. 12. 2015 |
| Evidence number: | 2/0065/13 |
| Program: | VEGA |
| Project leader: | RNDr. Sotníková Ružena, CSc. |
| Yeasts in protection of endothelial intercellular connections against inflammation-induced injury. | |
| Duration: | 1. 1. 2013 - 31. 12. 2015 |
| Evidence number: | 2/0065/13 |
| Program: | VEGA |
| Project leader: | RNDr. Okruhlicová Ľudmila, CSc. |
| SAS cosolvers: | Ing. Frimmel Karel, PhD., RNDr. Mitašíková (Fialová) Marcela, Ing. Navarová Jana, PhD., Ing. Pancza Dezider, MUDr. RNDr. Púzserová Angelika, PhD., D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS, RNDr. Sotníková Ružena, CSc., RNDr. Vlkovičová Jana, PhD. |
| Multifunctional activity of calcium/calmodulin dependent protein kinase II (CaMKII) in the heart: a relevance to disturbances in heart rhythm, contractility and cellular death. | |
| Duration: | 1. 1. 2012 - 31. 12. 2015 |
| Evidence number: | VEGA SR 1/0638/12 |
| Program: | VEGA |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| SAS cosolvers: | RNDr. Čarnická Slávka, PhD, Ing. Ferko Miroslav, PhD., RNDr. Nemčeková Martina, Ing. Pancza Dezider |
| Annotation: | Role of Ca2+/calmodulin dependent protein kinase II (CaMKII) is controversial in excitacion-contraction coupling. It is not clear if activation or inhibition of CaMKII improves the heart function. Duration, type of injury and selective influence on the cytoplasmic/nuclear isoform dC,B determine the final action of CaMKII. The effects of CaMKII inhibition on arrhythmias induced by catecholamines, ischemia, ischemia/reperfusion and on cardiac performance will be studied. With respect to ECC in these pathological conditions, the protein content of CaMKIIdB,C, LTCC, NCX, PLB will be investigated. As CaMKII affects Ca2+ levels, which in turn influence apoptosis, we assume that the modulation of CaMKII may also determine the extent of cell death. It will be studied imunohistochemically and by measuring CaMKII activity, protein expression of caspases, Apaf-1, calpaine, Cyt C oxidase. The effects of the concomitant inhibition of CaMKII and beta-receptors, or RAAS, the main activators of CaMII, will be also investigated. |
| Proton radiation-induced cardiovascular toxicity - pathophysiology and prevention. | |
| Duration: | 1. 7. 2012 - 31. 12. 2015 |
| Evidence number: | APVV-0241-11 |
| Program: | APVV |
| Project leader: | D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS |
| Prenatal programming of psychiatric diseases: experimental approaches for evaluation of causes and mechanisms of their origin | |
| Duration: | 1. 1. 2012 - 31. 12. 2015 |
| Evidence number: | VEGA 2/0107/12 |
| Program: | VEGA |
| Project leader: | RNDr. Mach Mojmír, PhD. |
| SAS cosolvers: | Mgr. Bögi Eszter, PhD., RNDr. Dubovický Michal, CSc. , RNDr. Gáspárová Zdenka, PhD., MVDr. Koprdová Romana, PhD., Mgr. Ponechalová Veronika, Mgr. Sedláčková Natália, PhD., Doc. RNDr. Ujházy Eduard, CSc. |
| Annotation: | Incidence of mental diseases in the developed countries has an increasing trend. At least one mental disease occurred per year approximately in 27% of EU inhabitants (more than 82 mil. people). It is estimated that till 2020, depression will be the main cause of morbidity in the developed countries. There are many evidences on neurodevelopmental origin of mental diseases. Various environmental and maternal factors acting during prenatal period and early childhood can increase sensitivity of the individual to anxiety, depression or other mental disorders in later postnatal life. Insufficient oxygen and nutrition supply of tissues, excessive stress or chemical substances and drugs can adversely affect the development of the brain. Objective of the project proposal will be the evaluation of key epigenetic factors which may play an important role in development of mental diseases.Up-to-date molecular biology as well as non-invasive methods of ethological analyses of appropriate animal models will be utilized. |
| - | |
| Duration: | 19. 7. 2013 - 31. 12. 2015 |
| Evidence number: | 2012/51-SAV-1 |
| Program: | Iné projekty |
| Project leader: | RNDr. Kristek František, DrSc. |
| SAS cosolvers: | Mgr. Balážová Lucia, PhD., Mgr. Berényiová Andrea, PhD., RNDr. Čačányiová Soňa, PhD., doc. RNDr. Dovinová Ima, PhD., RNDr. Drobná Magdaléna, PhD., Ing. Kršková Katarína, PhD., Mgr. Majzúnová Miroslava, PhD., Mgr. Mišák Anton, PhD., RNDr. Ondriaš Karol, DrSc., doc. MUDr. Török Jozef, CSc., Mgr. Zemančíková Anna, PhD., Ing. Zorad Štefan, CSc. |
| - | |
| Duration: | 1. 1. 2012 - 31. 12. 2015 |
| Evidence number: | 2/0046/12 |
| Program: | VEGA |
| Project leader: | RNDr. Tribulová Narcisa, DrSc. |
| SAS cosolvers: | RNDr. Egan Beňová Tamara, PhD., RNDr. Mitašíková (Fialová) Marcela, doc. MUDr. Radošinská Jana, PhD., RNDr. Szeiffová Bačová Barbara, PhD. |
| - | |
| Duration: | 1. 1. 2012 - 31. 12. 2015 |
| Evidence number: | VEGA 2/0031/12 |
| Program: | VEGA |
| Project leader: | Ing. Račková Lucia, PhD. |
| Ochrana srdca pr - Investigation of the cardioprotection using n-3 PUFA against injury and malignant arrhythmias induced by altered thyroid status. | |
| Duration: | 1. 1. 2014 - 31. 12. 2015 |
| Evidence number: | SK-CZ-2013-0256 |
| Program: | APVV |
| Project leader: | RNDr. Tribulová Narcisa, DrSc. |
| SAS cosolvers: | RNDr. Egan Beňová Tamara, PhD., RNDr. Szeiffová Bačová Barbara, PhD., Mgr. Viczenczová Csilla, PhD. |
| Annotation: | The purpose of the proposed project is the bilateral collaboration enabling effective use ofmethodological and instrumental facilities of each laboratory with the following scientific aims.The main goal is to evaluate whether supplementation of anti-arrhythmogenic n-3polyunsaturated fatty acids (n-3 PUFA) with known protective effects in patients will havebeneficial effect in our experimental model of rats with altered thyroid hormone levels, and tocontribute to our knowledge of factors helping in protection against heart damage and malignantarrhythmias with the following detailed aims:i) to follow frequency of arrhythmias after supplementation of protective fatty acids by the methodof perfused heart under control and modified conditions;ii) to analyze changes at the protein and mRNA levels of connexin channels and PKC-εsignalization in connection with heart sensitivity to malignant arrhythmias, and to verify ourhypothesis suggesting that modulation of PKC-ε signalization caused by thyroid hormones in theheart plays an important role in occurrence of malignant arrhythmias;iii) to analyze changes in MyHC composition and to verify our hypothesis suggesting thatdifferences in MyHC isoform expression can influence occurrence and frequency of malignant arrhythmias. |
| H2S - Study of molecular mechanisms of H2S biological effects. | |
| Duration: | 1. 7. 2012 - 31. 12. 2015 |
| Evidence number: | APVV-0074-11 |
| Program: | APVV |
| Project leader: | RNDr. Čačányiová Soňa, PhD. |
| SAS cosolvers: | RNDr. Bertová Anna, PhD., RNDr. Jurkovičová Dana, PhD., prof. Ing. Križanová Oľga, DrSc., Mgr. Mišák Anton, PhD., RNDr. Ondáčová Katarína, PhD., Mgr. Ševčíková Tomášková Zuzana, PhD. |
| Annotation: | Recently, endogenously produced hydrogen sulphide (H2S) is recognized as the third signál molecule-gasotransmitter. Thus H2S influences numerous biological processes, e.g. neuromodulation, proliferation, apoptosis, regulation of heart, cardioprotection, ischemia-reperfusion, hypertension, vasorelaxation, septic and hemorrhagic shock, inflammation processes, penile erection, hibernation or atherosclerosis, yet its molecular mechanism is not fully understood. The aim of the project is to understand the numerous biological effects of H2S. We will study how H2S releases NO from endogenous NO-donors and how cysteine, glutathione and other biologically active drugs influence the NO release. WhetherH2S canbind to proteins and release NO from endogenous NO-donors. H2S together with NO-donors will be studied on activities of K+, Cl- and Ca2+ membrane channels and on the contraction/relaxation of aorta in vitro, rat heart beat and blood pressure. Because H2S acts as a neuromodulátor, it is involved in neuroprotection but also in neurodegenerative processes. On neuronal cells, we will study three H2S-producing enzymes and their changes at the level of mRNA géne expression and at the level of proteins under normál and pathophysiological conditions. The results of these studies may explain the H2S numerous biological effects and extend the knowledge on mechanism of the H2S actions to šuch level that the results could be used as support for application studies of H2S in medicíne. |
| The influence of genetic control of nitric oxide production and dopamine re-uptake on sensorimotor gating in humans | |
| Duration: | 1. 1. 2013 - 31. 12. 2015 |
| Evidence number: | 2/0080/13 |
| Program: | VEGA |
| Project leader: | MUDr. Riečanský Igor, PhD. |
| SAS cosolvers: | Ing. Bendžala Štefan, MUDr. Jagla Fedor, CSc., doc. PaedDr. RNDr. Katina Stanislav, PhD., Mgr. Murínová Jana, Mgr. Roháriková Veronika, PhDr. Špajdel Marián, PhD. |
| Other cosolvers: | Minárik Gabriel, RND |
| Annotation: | Schizophrenia is a severe mental disorder, but its pathophysiology is poorly understood. A major role in its etiopathogenesis seem to play interactions of functionally coupled genes. One of core neurobiological abnormalities is increased synaptic dopamine in the striatum. This is also linked with disrupted filtering of behaviorally irrelevant stimuli, so called sensorimotor gating, which is an important schizophrenia intermediate phenotype. Nitric oxide (NO), a gaseous neurotransmitter, inhibits re-uptake of dopamine by blocking dopamine transporter (DAT1). Variability of both DAT1 and neuronal nitric oxide synthase (NOS1), the enzyme mediating NO production, is associated with schizophrenia risk. In this project we will explore how combination of common functional polymorphisms of NOS1 and DAT1 determines gating in healthy human subjects. This project will yield novel knowledge on the mechanisms regulating dopaminergic signaling, which may be of great importance in the pathophysiology of schizophrenia. |
| The effect of chronic stress on cell proliferation in the heart | |
| Duration: | 1. 1. 2012 - 31. 12. 2015 |
| Evidence number: | 2/0140/12 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Barteková Monika, PhD. |
| SAS cosolvers: | RNDr. Barančík Miroslav, DrSc. |
| RIFADMY - The effect of the lifestyle-related risk factors on the adaptive processes in the ischemic myocardium | |
| Duration: | 1. 7. 2012 - 31. 12. 2015 |
| Evidence number: | APVV-0102-11 |
| Program: | APVV |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| SAS cosolvers: | RNDr. Čarnická Slávka, PhD, Mgr. Farkašová Veronika, PhD, Ing. Ferko Miroslav, PhD., RNDr. Klimentová Jana, PhD., Ing. Kovácsová Mária, PhD., Mgr. Muráriková Martina, PhD., RNDr. Nemčeková Martina, doc. RNDr. Pecháňová Oľga, DrSc., D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS, MUDr. Styk Ján, CSc., MUDr. Zálešák Marek, PhD., Ing. Ziegelhöffer Attila, DrSc. |
| Other cosolvers: | Adameová Adriana PharmDr PhD, Rajtík Tomáš Mgr,Jankyová Stanislava PharmDr PhD - Farmaceutická fakulta UK |
| Annotation: | Lifestyle-related risk factors (RF) including, besides elevated blood pressure, hyperglycemia and dyslipidemia have a negative impact on the heart exposed to ischemia: they promote its lethal injury (infarction) and the occurrence of sudden death due to malignant ventricular arrhythmias. On the other hand, some stressful factors including free radicals and increased glucose levels may play a dual role in the mechanisms of ischemia-reperfusion injury (IRI) and induce, except deleterious effects, adaptive processes stimulating cardiac endogenous mechanisms of resistance against IRI. Increased ischemic tolerance that can be evoked by the pleiotropic actions of some hypolipidemics and antidiabetic drugs is also characteristic for female myocardium, however, it declines with age in both genders. The efficiency of adaptation may be reduced by comorbidities related to lifestyle, although the effect of RF has not been definitively proven. It has been shown that even pathologically altered myocardium need not completely loose its ability to be adapted. We aim to verify the hypothesis that lifestyle RF alter myocardial response to acute ischemia not only via interference with the pathophysiological mechanisms of IRI but also via suppression of the intrinsic adaptive mechanisms in the myocardium and its ability to tolerate ischemic challenge. The project is focused on the study of the mentioned RF on the cellular protective mechanisms in relationship with gender differences and age, as well as on the exploration of the possibilities to inhibit unwanted effects of RF and to restore the lost adaptive potential of the myocardium. |
| RIFADMY - The effect of lifestyle-related factors on the adaptive processes in ischemic myokardium | |
| Duration: | 1. 7. 2012 - 31. 12. 2015 |
| Evidence number: | APVV-0102-11 |
| Program: | APVV |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| Cerebral energy metabolism failure as one of patho-biochemical mechanisms involved in hypoxic-ischemic insult of the neonatal brain | |
| Duration: | 1. 1. 2012 - 31. 12. 2015 |
| Evidence number: | 2/0149/12 |
| Program: | VEGA |
| Project leader: | RNDr. Juránek Ivo, PhD., DrSc. |
| Annotation: | The main purpose of the project is to contribute for elucidation of mechanisms of hypoxic-ischemic damage (HID) of the neonatal brain, which is cause of ~50% of newborn deaths. Survived infants often suffer from chronic neuro-psychiatric disorders (e.g. cerebral palsy, epilepsy, cognitive and behavioral disorders). Secondary energy failure (SEF) is likely to play a key role in the evolving HID. In our previous studies, we found that primary energy failure (PEF) in the brain of newborn rats is proportional to the maturity of brain energy metabolism. Since SEF determines the severity of brain HID, our goals for the present project are: 1) to monitor HID of the neonatal rat brain; 2) to determine the time interval between PEF and SEF, as we propose its usage for an effective therapy; 3) to affect pharmacologically SEF. We expect that the inhibition of SEF should alleviate the process of brain HIP. We shall utilize biochemical, molecular-biological and, in particular, non-invasive MR approaches. |
| CM1103 Structure-based drug design for diagnosis and treatment of neurological diseases | |
| Duration: | 1. 1. 2014 - 27. 11. 2015 |
| Evidence number: | |
| Program: | Iné projekty |
| Project leader: | RNDr. Májeková Magdaléna, PhD. |
| SAS cosolvers: | RNDr. Balleková Jana, Ing. Šoltésová Prnová Marta, PhD., Ing. Štefek Milan, CSc. |
| Other cosolvers: | Májek Pavol |
| Annotation: | Based on our knowledge in design and modeling of indole compounds with neuroprotective effect and inhibition effect towards aldo-keto reductases we plan to use a multi-target potential of these compounds for the problems studied in the project COST CM1103. Our aims are:1) To elaborate molecule models for individual types of aldo-keto reductases (AKRs) important for neurological diseases.2) To suggest AKR inhibitors with indolic structure with optimal efficiency and bioavailability.3) To test new compounds as the inhibitors of enzymes important for monoamines metabolism.4) Structure-activity study.5) To test other effects of our compounds on an in vitro level in the framework of COST CM1103 collaboration. |
| NOREG - Centre of excellence for examination of regulatory role of nitric oxide in civilization diseases | |
| Duration: | 1. 8. 2011 - 30. 6. 2015 |
| Evidence number: | |
| Program: | Centrá excelentnosti SAV |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| NOREG - Centre of excellence of SAS for research of regulatory role of nitric oxide in civilization diseases | |
| Duration: | 1. 8. 2011 - 30. 6. 2015 |
| Evidence number: | |
| Program: | Centrá excelentnosti SAV |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| SAS cosolvers: | RNDr. Čarnická Slávka, PhD, Mgr. Farkašová Veronika, PhD, Ing. Ferko Miroslav, PhD., RNDr. Nemčeková Martina, D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS |
| Other cosolvers: | LFUK, PriFUK |
| Characterization of cardiovascular and metabolic changes in fructose-induced metabolic syndrome in the rat | |
| Duration: | 1. 1. 2012 - 31. 12. 2014 |
| Evidence number: | 2/0188/12 |
| Program: | VEGA |
| Project leader: | doc. MUDr. Török Jozef, CSc. |
| SAS cosolvers: | MVDr. Barta Andrej, PhD., Ing. Tabačeková Marcela, Mgr. Zemančíková Anna, PhD. |
| Annotation: | The aim of this project is to evaluate the extent of cardiovascular impairments in metabolic syndrome induced by excessive intake of fructose which is considered to be an important obesitogenic factor in industrially developed countries. In fructose-induced rat model of metabolic syndrome, our effort will be oriented to reveal negative effects of long-term excessive intake of fructose on cardiovascular system with emphasis to participation of increased activity of peripheral sympathetic system, lipotoxicity and oxidative stress. We will analyse the intensity of fructose-induced changes in genetically related rat strains with different predisposition to individual components of metabolic syndrome. At the same time, we will examine the effect of long-term administration of antihypertensive and hypolipidemic drugs on hemodynamic and metabolic effects in rats fed with fructose. The results obtained in rats with long-term excessive intake of fructose could be used in evaluation of cardiovascular risk in obese individuals. |
| Mechanisms involved in the effects of doxorubicin on animal cells and searching for possibilities of modulation of doxorubicin-induced effects. | |
| Duration: | 1. 1. 2012 - 31. 12. 2014 |
| Evidence number: | 2/0169/12 |
| Program: | VEGA |
| Project leader: | RNDr. Barančík Miroslav, DrSc. |
| SAS cosolvers: | doc. RNDr. Barteková Monika, PhD., prof. Ing. Breier Albert, DrSc., Ing. Ivanová Monika, PhD., MUDr. Styk Ján, CSc., Ing. Šimončíková Petra, PhD. |
| Annotation: | Doxorubicin (DOX) is one of the most frequently drugs used in chemotherapy. However, systems influenced by DOX account for realization of both anticancer and toxic effects. The latter effects of DOX ivolve injury of several organs and are complications in its use. Project will be focused on the study of changes connected with action of DOX in different kinds of animal cells (normal tissue, leukemic cells). The differences and common characteristics in molecular mechanisms involved in DOX effects in these cells will be clarified. The changes in mitochondrial function, regulation of apoptosis and role of intra- and inter-cellular signaling (Akt kinase, JAK/STAT, MMP, connexins) will be determined. The tolerance of hearts against ischemia/reperfusion injury after DOX application will be determined. By the study of possibilities to modulate DOX effects, omega-3-fatty acids and flavonoids will be used. Studies will be performed at both in vivo and in vitro models, at the organ, cellular and subcellular levels. |
| - | |
| Duration: | 1. 1. 2011 - 31. 12. 2014 |
| Evidence number: | 2/0038/11 |
| Program: | VEGA |
| Project leader: | RNDr. Horáková Ľubica, PhD. |
| Annotation: | Attention will be given to the impairment of calcium homeostasis under the conditions of oxidative stress and conditions of elevated glucose concentration in relation to diabetes mellitus in several experimental models (SR, RBc, beta –cells).Calcium pumps, SERCA and PMCA plays important role in the regulation of calcium homeostasis and thus the mechanism of their modulation would be an important contribution to explain mechanisms of initiation of several physiological and pathological cell events including apoptosis directed to pancreatic beta -cell death.Studies on SR would be focused on posttranslational and conformational alterations of SERCA in relation to changes of SERCA activity due oxidative stress and high level of glucose. Studies on red blood cells will be directed mainly to apoptosis in relation to PMCA activity alteration due to oxidative stress and high level of glucose. |
| Molecular modeling, synthesis and biological activity of substituted pyridoindoles as bifunctional agents in prevention of diabetic complications | |
| Duration: | 1. 1. 2011 - 31. 12. 2014 |
| Evidence number: | 2/0067/11 |
| Program: | VEGA |
| Project leader: | Ing. Štefek Milan, CSc. |
| New model of experimental hypertension, left ventricular remodeling and heart failure induced by nuclear factor kappaB inhibition: pprotection by melatonin and captopril | |
| Duration: | 1. 1. 2012 - 31. 12. 2014 |
| Evidence number: | 1/0227/12 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| SAS cosolvers: | doc. RNDr. Pecháňová Oľga, DrSc. |
| Annotation: | Inhibition of nuclear factor kappaB induced left ventricular remodeling. The aim of the project is to study mechanisms leading to the remodeling and high blood pressure. Possible protective role of melatonin and ACE inhibitor - captopril will be studied as well. |
| Effects of melatonin, omega-3 fatty acids and aliskiren on myocardial connexin-43 and heart function in rats with CVD. | |
| Duration: | 12. 10. 2012 - 31. 12. 2014 |
| Evidence number: | |
| Program: | Iné projekty |
| Project leader: | RNDr. Tribulová Narcisa, DrSc. |
| Study of combination of immunosuppressive treatment and substances affecting redox balance of organism on animal models of rheumatoid arthritis | |
| Duration: | 1. 1. 2011 - 31. 12. 2014 |
| Evidence number: | 2/0045/11 |
| Program: | VEGA |
| Project leader: | PharmDr. Bauerová Katarína, PhD., DrSc. |
| Annotation: | The focus of the project will be the study of the therapeutic potential of the substances with anti-oxidative properties within RA therapy, and in particular of MTX combined therapy. The adjuvant arthritis (AA) model will be used in Lewis rats. AA progress and its pharmacological influencing will be characterized by parameters expressing immunological, oxidative, and inflammatory processes. The chronic AA model will be supplemented by the model of inflammation induced by carrageenan, as well as by the study of substances evaluated in macrophage cell culture.For potential utilization in combined RA therapy, the following substances will be evaluated: carnosine and its acetyled derivative, natural polysaccharides, low-molecular antioxidants with thiol groups, herbal antioxidants, and anti-inflammatory antihistaminics. Evaluation in vivo of the aforementioned substances will take place after the in vitro analysis of the anti-oxidative efficiency in two independent models |
| Study of Actions of the Reactive Oxygen/Nitrogen Species on High-Molar-Mass Hyaluronan, Synoviocytes, and Chondrocytes | |
| Duration: | 1. 1. 2011 - 31. 12. 2014 |
| Evidence number: | 2/0011/11 |
| Program: | VEGA |
| Project leader: | Ing. Šoltés Ladislav, DrSc. |
| SAS cosolvers: | Ing. Topoľská Dominika, PhD., RNDr. Valachová Katarína , PhD. |
| Annotation: | Hyaluronan (HA) is a polysaccharidic constituent of numerous tissues in the vertebrate organisms. One ml of synovial fluid (SF) – an essential joint component – contains 2-3 mg HA, which molar mass reaches in healthy adults the magnitude of about several megaDaltons. However, at the inflammatory joint disorders, the mean molar mass of HA is significantly decreased. This decrease is accompanied by a pronounced decline of the HA solution viscoelasticity and loss of the lubricating properties of SF.Low resistance of HA against the action of oxidative species – free radicals, anions – stimulated our efforts to use this biopolymer as a relevant (endogenic) substance for in vitro investigations of the “damaging” action of oxidants and/or for evaluation of the efficacy of various compounds/drugs to act as scavenging antioxidants.The substances, which will have significant antioxidant effect against HA degradation will be tested in relation to their protective effect against damage of joint elements. |
| REINOC - Effect of (pro)renin antagonist (RER-24) loaded naoparticles in experimental hypertension | |
| Duration: | 1. 1. 2012 - 31. 12. 2014 |
| Evidence number: | 2/0183/12 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| Annotation: | Binding of prorenin to (pro)renin receptor leads to its activation via a non-proteolytic mechanism and to local generation of angiotensin I. RER-24 is a highly specific (pro)renin receptor antagonist with good affinity to(pro)renin receptors of all tissues. The simultaneous blockade of regulative as well as pathologic effects of(pro)renin receptors may however represent a limitation of RER-24 use. The aim of this project is to target inhibition of angiotensin I production directly to the organs mostly suffered from increased blood pressure – to the heart and kidney which could protect also the structure of tissues. To achieve this aim nanoencapsulation of RER-24 and magnetic nanoencapsulation will be performed followed by application and biological analysis of encapsulated RER-24 forms. While encapsulation assures increase of bioavailability, magnetization amplifies direct delivery of RER-24 to the target tissues. By this way cardio- and renoprotective effect beside blood pressure reduction will be reached. |
| Effect of pyridoindole derivatives under conditions of the experimental model of neurodegeneration | |
| Duration: | 1. 1. 2011 - 31. 12. 2014 |
| Evidence number: | 2/0048/11 |
| Program: | VEGA |
| Project leader: | RNDr. Gáspárová Zdenka, PhD. |
| Annotation: | Stroke and brain ischemia occur more frequently in the aging population. In our last project we studied consequences of acute ischemic brain injury and the effect of pyridoindoles related to age. The aim of this project is to study the effect of pyridoindoles in the model of neurodegeneration induced by trimethyltin. Neurodegeneration is associated with oxidative injury and inflammation of CNS. Functional and morphologicalchanges, loss of neurons, activated microglia, increased level of pro-inflammatory compounds and markers of oxidative stress are associated with many diseases, as Alzheimer´s and Parkinson´s disease, multiple sclerosis, etc. Neurodegeneration is connected with memory trace injury and it aggravates the action to other stressors, e.g.ischemic brain injury. The aim of the new project is to study the effect of pyridoindole antioxidants with the prospect of using them in slowing down the progress of pathological events accompanied with neurodegenerative changes in CNS. |
| The role of mitochondria in adaptation of cardiac energetics to various pathological stimuli and noxae: ischemia, diabetes, hypertension | |
| Duration: | 1. 1. 2012 - 31. 12. 2014 |
| Evidence number: | 2/0101/12 |
| Program: | VEGA |
| Project leader: | Ing. Ferko Miroslav, PhD. |
| Other cosolvers: | Waczul |
| Annotation: | It is accepted that both, physiologically tolerable challenge and numerous pathological signals trigger endogenous defensive response in the heart leading to increased resistance or adaptation to a respective impuls. However, molecular mechanisms of adaptive changes are not yet sufficiently clarified. Basically they may appear as abnormalities difficult to distinquish from pathological alterations and may be sometimes improperly considered as therapeutic targets. With this respect, major attention deserve stimuli such as ischemia, diabetes, hypertension and delayed response to „remote preconditioning“ that has some clinical applications. In these conditions, adaptive response to altered tissue energy demand is less studied. Thus, our goal is to elucidate adaptive regulation of oxidative phosphorylation in relationship to changes in the properties of cardiac mitochondrial membrane, fluidity, oxidation of lipid bilayer, activity of mitochondrial ATP-ase and cytochromoxidase, under aforementioned states. |
| - | |
| Duration: | 1. 11. 2010 - 1. 11. 2014 |
| Evidence number: | |
| Program: | Iné projekty |
| Project leader: | RNDr. Horáková Ľubica, PhD. |
| Molecular principles of regulation of phagocyte activity and apoptosis. Contribution to new pharmacological strategy for modulation of inflammatory processes | |
| Duration: | 1. 5. 2011 - 31. 10. 2014 |
| Evidence number: | APVV-0052-10 |
| Program: | APVV |
| Project leader: | prof. MUDr. Nosáľ Radomír, DrSc. |
| Annotation: | The submitted project is a continuation of our previous successful programmes (APVV-51-0296/02, APVV-0315-07, VEGA 2/7019/27), which resulted in significant, published and cited results in the area of pharmacological modulation of mechanisms involved in inflammatory processes. We intend to analyse drugs, potential drugs and synthetic derivatives of natural substances with respect to their effects on selected parameters of phagocyte activity (formation of reactive oxygen and nitrogen species, phagocytosis, expression of surface glycoproteins) and apoptosis (externalisation of phosphatidylserine, propidium iodide intercalation, caspase-3 activity). Moreover, we will concentrate on several regulatory mechanisms (activation of protein kinase C, alterations in intracellular calcium concentration) and the in vivo effectiveness of the compounds tested will be studied under conditions of experimental arthritis. The scientific goal of the project is to obtain new information about effects of the compounds tested at different levels – from the molecular and cellular up to the whole organism. Original data expected to be acquired concern pharmacological regulation of phagocyte activity and apoptosis. These results may contribute to the formation of new strategies in the therapy of chronic inflammatory diseases with focus on the support of natural antiinflammatory mechanisms and the resolution of inflammation. |
| Hyperstres - Sex differences in etiopathogenesis of social stress-related cardiovascular and behavioral disorders in individuals with predisposition to hypertension. | |
| Duration: | 1. 5. 2011 - 31. 10. 2014 |
| Evidence number: | APVV-0523-10 |
| Program: | APVV |
| Project leader: | RNDr. Okruhlicová Ľudmila, CSc. |
| SAS cosolvers: | RNDr. Čarnická Slávka, PhD, Mgr. Farkašová Veronika, PhD, MUDr., Ing. Jendruchová (Javorková) Veronika, PhD., RNDr. Mézešová Lucia, RNDr. Nemčeková Martina, MUDr. Ravingerová Táňa, DrSc., FIACS, RNDr. Vlkovičová Jana, PhD., RNDr. Vrbjar Norbert, CSc. |
| - | |
| Duration: | 1. 5. 2011 - 31. 10. 2014 |
| Evidence number: | APVV-0523-10 |
| Program: | APVV |
| Project leader: | RNDr. Sotníková Ružena, CSc. |
| The study of mechanisms and possible early detection of embryofetal damage caused by intrauterine perinatal hypoxia | |
| Duration: | 1. 1. 2011 - 31. 10. 2014 |
| Evidence number: | 2/0081/11 |
| Program: | VEGA |
| Project leader: | Doc. RNDr. Ujházy Eduard, CSc. |
| SAS cosolvers: | MVDr. Bezek Štefan, DrSc., RNDr. Dubovický Michal, CSc. , RNDr. Gajdošíková Alena, RNDr. Gáspárová Zdenka, PhD., RNDr. Mach Mojmír, PhD., Ing. Navarová Jana, PhD., Mgr. Sedláčková Natália, PhD. |
| Annotation: | Unfavorable conditions for intrauterine development represent foundation for health disturbances and morbidity after birth and in later life. For the proper diagnosis and reduction of hypoxia/ischemia (H/I) consequences it is essential to identify basic mechanisms and markers of H/I. Experimental approaches are important for the basic research. Chronic intrauterine hypoxia and acute perinatal hypoxia in rats belong to animal models appropriate for study H/I during sensitive stages of development. The aim of the project will be the sceening and evaluation of the indicators of H/I damage in mothers and fetuses during perinatal period. We will focus on observation of the structural and functional changes after H/I insult and finding suitable biomarkers of H/I in blood and urine samples. Integral part of this project will be correlations of given data from experimental studies with clinical observations in full-term asphyxiated newborns. |
| NANOALIS - The effect of aliskerin loaded nanoparticles in experimental hypertension | |
| Duration: | 1. 5. 2011 - 31. 10. 2014 |
| Evidence number: | APVV-0742-10 |
| Program: | APVV |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| SAS cosolvers: | RNDr. Čarnická Slávka, PhD, Mgr. Farkašová Veronika, PhD |
| NANOALIS - The effect of aliskiren loaded nanoparticles in experimental hypertension | |
| Duration: | 1. 5. 2011 - 31. 10. 2014 |
| Evidence number: | APVV-0742-10 |
| Program: | APVV |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| NeuroCa - Calcium channels in neuronal excitability | |
| Duration: | 1. 5. 2011 - 31. 10. 2014 |
| Evidence number: | APVV-0212-10 |
| Program: | APVV |
| Project leader: | RNDr. Vrbjar Norbert, CSc. |
| SAS cosolvers: | MUDr., Ing. Jendruchová (Javorková) Veronika, PhD., Mgr. Kaločayová Barbora, PhD., RNDr. Vlkovičová Jana, PhD., RNDr. Vrbjar Norbert, CSc. |
| - | |
| Duration: | 1. 5. 2011 - 31. 10. 2014 |
| Evidence number: | APVV-0351-10 |
| Program: | APVV |
| Project leader: | Ing. Šoltés Ladislav, DrSc. |
| - | |
| Duration: | 1. 1. 2011 - 31. 10. 2014 |
| Evidence number: | 2/0084/11 |
| Program: | VEGA |
| Project leader: | RNDr. Dubovický Michal, CSc. |
| LEUPGLY - Alteration in cell metabolism associated with drug transporter P-glycoprotein everexpression in leukemia cells. | |
| Duration: | 1. 5. 2011 - 31. 10. 2014 |
| Evidence number: | APVV-0290-10 |
| Program: | APVV |
| Project leader: | RNDr. Barančík Miroslav, DrSc. |
| HYPERSTRES - Gender differences in etiopathogenesis of social stress-related cardiovascular and behavioral disorders in individuals with predisposition to hypertension | |
| Duration: | 1. 5. 2011 - 30. 10. 2014 |
| Evidence number: | APVV-0523-10 |
| Program: | APVV |
| Project leader: | RNDr. Bernátová Iveta, DrSc. |
| SAS cosolvers: | RNDr. Bališ Peter, PhD., RNDr. Čarnická Slávka, PhD, doc. RNDr. Dovinová Ima, PhD., MUDr., Ing. Jendruchová (Javorková) Veronika, PhD., MUDr. Kellerová Eva, DrSc., RNDr. Mézešová Lucia, Ing. Navarová Jana, PhD., RNDr. Nemčeková Martina, RNDr. Okruhlicová Ľudmila, CSc., MUDr. RNDr. Púzserová Angelika, PhD., MUDr. Ravingerová Táňa, DrSc., FIACS, RNDr. Regecová Valéria, Mgr. Slezák Peter, RNDr. Sotníková Ružena, CSc., Mgr. Šestáková Natália, RNDr. Vlkovičová Jana, PhD., RNDr. Vrbjar Norbert, CSc. |
| Other cosolvers: | Jana Muchová, Ingrid Žitňanová, Zdenka Ďuračková, Zuzana Kralovičová, Martin Kopál,Lucia Laubertová, Ivan Sekaj, Adriana Adameová |
| CARDINFO - Measuring, communication and information systems for monitoring of cardiovascular risk in hypertension patients. | |
| Duration: | 1. 5. 2011 - 30. 6. 2014 |
| Evidence number: | APVV-0513-10 |
| Program: | APVV |
| Project leader: | RNDr. Szathmáry Vavrinec, CSc. |
| SAS cosolvers: | Ing. Hlavačka František, CSc. |
| Annotation: | Arterial hypertension is a cardiovascular disorder affecting 20-50% of adult population in developed countries and increases significantly with the age after 50. It is also a risk factor for developing coronary artery disease, heart failure, arrhythmias and sudden cardiac death. The aim of the project is research of methods and development of electronic measuring, communication and information systems for monitoring of hypertensive patients and evaluation of their heart functional state to find characteristics enabling to distinguish hypertensive myocardium without coronary involvement from that with an atherosclerotic plate.Using a computer model, relations between hypertension, heart electrophysiology and measurable biosignals will be investigated. Results will be compared with examinations using high resolution ECG mapping and MR imaging of the heart and its perfusion. On this basis, suitable parameters will be selected for patient monitoring and classification of this cardiovascular risk.Following the objectives of the eHealth Program in Slovakia in the field of telemedicine services, the monitoring will be based on Wireless Body Sensor Networks (WBSN) and information systems for decision support of the healthcare personal (CDSS). Connection between these concepts enables diagnostics and therapy of cardiac patients. System integration of telemedicine services with Electronic Health Record (EHR) forms the basis for automated creation of records for risk patients. |
| Modulatory effect of lifestyle-related risk factors on the mechanisms of subcellular adaptation to myocardial ischemia | |
| Duration: | 1. 1. 2011 - 31. 12. 2013 |
| Evidence number: | VEGA SR 2/0054/11 |
| Program: | VEGA |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| SAS cosolvers: | doc. RNDr. Barteková Monika, PhD., RNDr. Čarnická Slávka, PhD, Ing. Ferko Miroslav, PhD., Ing. Ivanová Monika, PhD., RNDr. Klimentová Jana, PhD., Mgr. Muráriková Martina, PhD., RNDr. Nemčeková Martina, Ing. Pancza Dezider, MUDr. Styk Ján, CSc., MUDr. Štrbák Vladimír, DrSc., MUDr. Zálešák Marek, PhD., Ing. Ziegelhöffer Attila, DrSc. |
| Other cosolvers: | Adameová Adr |
| Annotation: | Lifestyle-related fisk factors (RF) including high blood pressure, hyperglycemia and dyslipidemia have a negative impact on the heart exposed to ischemia: they exacerbate irreversible injury (infarction) and incidence of sudden death due to lethal arrhythmias. On the other hand, some stressful factors such as free radicals and enhanced glucose might play a dual role in the mechanism of ischemia-reperfusion injury (IRI) and besides deleterious effects, induce adaptive processes that stimulate mechanisms of heart’s own resistance to IRI. Enhanced ischemic tolerance that can be evoked via pleiotropic effects of some hypolipidemics is characteristic for female myocardium and is declining with age in both genders. The project is focused on the study of the effects of aforementioned RF on the cellular self-defence mechanisms in relationship with gender differences and age, and on the possibilities to suppress undesired effects of RF by activation of adaptive processes in the heart increasing its tolerance to IRI |
| CAN POLYPHENOLIC SUBSTANCES FROM RED WINE AFFECT THE HIGHER BRAIN FUNCTIONS? | |
| Duration: | 1. 1. 2011 - 31. 12. 2013 |
| Evidence number: | 2/0173/11 |
| Program: | VEGA |
| Project leader: | MUDr. Jagla Fedor, CSc. |
| SAS cosolvers: | Ing. Bendžala Štefan, RNDr. Cimrová Barbora, PhD., MUDr. Riečanský Igor, PhD. |
| Annotation: | The project is aimed to add knowledge about the effects of polyphenolic compounds isolated from red wines upon several basic physiological mechanism and their benefits related to those higher brain functions which mediate the interactions between individuals and his/her environment. It is directed to the priority „Health – Quality of life“ implemented in the long-term intentions of the state science politics up to 2015. The aim is to analyze the effects of the above mentioned substances upon the attention and accuracy in processing the visual stimuli localized in the different segments of the surrounding environment. Following analyzes will be done: the timing and accuracy of saccadic eye movements and time-locked bioelectrical brain activity (the EEG spectra, power and coherence). The selected psychological tests will be used as well. Defining the effect of polyphenolic concentrates upon the space memory and attention is expected. It is supposed to help in the study of selected |
| Performance tests of postural stability in functional diagnosis of sportmen and individuals with motor disorders | |
| Duration: | 1. 1. 2011 - 31. 12. 2013 |
| Evidence number: | 1/0070/11 |
| Program: | VEGA |
| Project leader: | Ing. Hlavačka František, CSc. |
| SAS cosolvers: | Mgr. Hirjaková Zuzana, PhD., Ing. Hlavačka František, CSc., RNDr. Kimijanová Jana, PhD., Mgr. Šuttová Kristína, PhD. |
| Annotation: | The aim of the project is to develop system for monitoring COM motion during the visual biofeedback control. |
| The participation of neuronal NO synthase in the regulation of function and structure in cardiovascular system of normotensive and spontaneouly hypertensive rats. | |
| Duration: | 1. 1. 2010 - 31. 12. 2013 |
| Evidence number: | 2/0111/10 |
| Program: | VEGA |
| Project leader: | RNDr. Čačányiová Soňa, PhD. |
| SAS cosolvers: | Mgr. Berényiová Andrea, PhD., RNDr. Cebová Martina, PhD., doc. RNDr. Dovinová Ima, PhD., RNDr. Kristek František, DrSc., MUDr. Smieško Vladimír, CSc. |
| Annotation: | More than half of Slovak republic inhabitans suffer by diseases of cardiovascular system. Among the most risk factors resulting in still increasing morbidity and mortality belong hypertension. Understanding of courses leading to hypertension enable to reveal new preventive and therapeutic decisions. For understanding of individual pathological processes is necessary as a first step to reveal basic mechanisms and inter-relationship between structure and function of the heart-vessel system. A new regulatory system involved in vessel tree regulation seems to be neuronal NO-synthase (nNOS) and its interactions with other regulatory systems. In the present project (using functional, morphological, and biochemical methods) we would like to follow effect of nNOS inhibition itself and/or nNOS inhibition in combination with other vasoactive substances on vessel tree of normotensive and hypertensive animals. We suggest that the obtained results should help to better understandformation of cardiovascular diseases. |
| Gender differences in etiopathogenesis of social stress-related cardiovascular and behavioral disorders in individuals with predisposition to hypertension | |
| Duration: | 1. 1. 2010 - 31. 12. 2013 |
| Evidence number: | VEGA 2/0084/10 |
| Program: | VEGA |
| Project leader: | RNDr. Sotníková Ružena, CSc. |
| Social stress as a risk factor of early development of hypertension in predisposed individuals | |
| Duration: | 1. 1. 2010 - 31. 12. 2013 |
| Evidence number: | 2/0084/10 |
| Program: | VEGA |
| Project leader: | RNDr. Bernátová Iveta, DrSc. |
| SAS cosolvers: | RNDr. Bališ Peter, PhD., MUDr. Kellerová Eva, DrSc., RNDr. Kopincová Jana, RNDr. Okruhlicová Ľudmila, CSc., MUDr. RNDr. Púzserová Angelika, PhD., RNDr. Regecová Valéria, Mgr. Slezák Peter, RNDr. Sotníková Ružena, CSc., Mgr. Šestáková Natália |
| Other cosolvers: | Žitňanová Ingrid,Kráľová Eva,Stankovičová Tatiana, Ondrejovičová Iveta |
| Substituted pyridoindoles as potential multi-target-directed ligands in prevention and treatment of chronic diseases - theoretical screening | |
| Duration: | 1. 1. 2011 - 31. 12. 2013 |
| Evidence number: | 2/0030/11 |
| Program: | VEGA |
| Project leader: | RNDr. Májeková Magdaléna, PhD. |
| Other cosolvers: | Májek Pavol, Ing. PhD. |
| Annotation: | Substituted pyridoindoles proved to be agents efficient in many processes involved in development and progressof various chronic diseases as diabetes mellitus, neurodegenerative diseases and other disorders. In agreementwith recent conception a compound capable of multi-target action in the framework of one or similar diseasesturns to be better drug candidate as single-target ligand. One of the latest compounds of this type, dimebolin, isknown with its antihistamine effects and recently it is getting to a clinical praxis as a drug slowing impacts ofAlzheimer and Huntington diseases. We plan to choose a representative sample of number 6-8 derivatives fromthe amount of almost one hundred pyridoindoles derivatives designed and synthesized in our Institute. Thederivatives chosen will be compared with reference compounds as to the calculated parameters factoring anantioxidant activity, a conformational flexibility and inhibition activities towards enzymes chosen from the ProteinData Bank. |
| The role of nuclear factor kappa B in experimental hypertension | |
| Duration: | 1. 1. 2011 - 31. 12. 2013 |
| Evidence number: | 2/0190/11 |
| Program: | VEGA |
| Project leader: | RNDr. Vranková Stanislava, PhD. |
| SAS cosolvers: | MVDr. Barta Andrej, PhD., RNDr. Čarnická Slávka, PhD, RNDr. Klimentová Jana, PhD., Ing. Kovácsová Mária, PhD., doc. RNDr. Pecháňová Oľga, DrSc. |
| Influence of ionizing radiation on cardiovascular system and possibilities to minimize its adverse effect | |
| Duration: | 1. 1. 2011 - 31. 12. 2013 |
| Evidence number: | VEGA SR 2/0207/11 |
| Program: | VEGA |
| Project leader: | D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS |
| SAS cosolvers: | Ing. Ivanová Monika, PhD., RNDr. Okruhlicová Ľudmila, CSc., MUDr. Styk Ján, CSc., RNDr. Tribulová Narcisa, DrSc., Ing. Ziegelhöffer Attila, DrSc. |
| CEG - Centre of excellence for glycomics | |
| Duration: | 1. 10. 2010 - 31. 10. 2013 |
| Evidence number: | ITMS 26240120031 |
| Program: | Štrukturálne fondy EÚ Bratislavský kraj |
| Project leader: | Ing. Brnoliaková Zuzana, PhD. |
| SAS cosolvers: | RNDr. Barák Imrich, DrSc., RNDr. Barančík Miroslav, DrSc., Ing. Koóš Miroslav, DrSc., RNDr. Kozánek Milan, CSc., prof. Ing. Križanová Oľga, DrSc. |
| Annotation: | The research of abnormnal glycosylation of proteins related to human diseases symptomatics is highly attractive nowadays. Within Slovakia, this research field oriented on biosythesis and biological functions of biomacromolecules is strictly limited: escpecially in case of separational and structural methodical issues as well as in case of computational technologies availability. The goal of this project is to create Centre of Excellence for Glycomics (CEG) to provide inevitable technical and methodical equipment to study biological functions of glycoproteins in living organisms. The information gained might be applied in clinical medicine and pharmacology. The potential of new glyco-markers and the development of new generation of glyco-therapeutics might contribute to the treatment of various hereditary and/or civilization diseases. |
| The effect of variability in NOS-1 gene on sensorimotor gating: implications for pathophysiology of schizophrenia | |
| Duration: | 16. 10. 2012 - 15. 9. 2013 |
| Evidence number: | |
| Program: | Vedecko-technické projekty |
| Project leader: | MUDr. Riečanský Igor, PhD. |
| SAS cosolvers: | doc. PaedDr. RNDr. Katina Stanislav, PhD., Mgr. Roháriková Veronika |
| Other cosolvers: | RNDr. Gabriel Minárik, PhD. (LF UK), RNDr. |
| Annotation: | Research grant of the Slovak Psychiatric Association. |
| ENDOMECH - Activation of cell signaling mechanisms as a potential target of cardiac protection against ischemic injury | |
| Duration: | 1. 9. 2009 - 1. 9. 2013 |
| Evidence number: | APVV-LPP-0393-09 |
| Program: | APVV |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| SAS cosolvers: | RNDr. Nemčeková Martina |
| Annotation: | A new project approved in 2009 aimed to support a supervisor and the education of PhD student.The project is focused on the investigation of endogenous defensive mechanisms in the myocardium and possiblity to enhance its resistance to the main manifestations of acute ischemia (infarction, myocardial dysfunction and lethal arrhythamia) by means of cardiac adaptation to stress. The research will be aimed to characterize the mechanisms of cell signalling with particular regards to the role of phosphatidylinositol 3-kinase (PI3K)/Akt as a key enzyme system involved in antiapoptotic processes and metabolic regulations, as well as on the study of PI3K/Akt interaction with transcription factors (nuclear receptors PPAR). The role of activation of PI3K/Akt and PPAR in the mechanisms of cardiac ischemic tolerance will be investigated during short-term adaptive response (preconditioning) in the hearts of the healthy rats and diabetic animals exposed to acute myocardial ischemia or hypoxia. Using physiological, pharmacological and biochemical methods on the models in vitro the relationship of the above processes with generation of free radicals and function of mitochondrial K(ATP) channels will be also studied. The obtained results may contribute to the elucidation of the pathophysiological mechanisms of ischemic injury in the healthy and diseased myocardium as well as to the development of new methods of its protection against ischemia that may be potentially utilized in the treatment of ischemic heart disease |
| Centre of Excellence for Glycomics | |
| Duration: | 1. 9. 2010 - 31. 8. 2013 |
| Evidence number: | ITMS: 26240120031 |
| Program: | Štrukturálne fondy EÚ Výskum a vývoj |
| Project leader: | RNDr. Barančík Miroslav, DrSc. |
| CEKOMAT II - Centre of Excellence for Research and Development of Constructive Composite Materials II | |
| Duration: | 1. 9. 2009 - 30. 6. 2013 |
| Evidence number: | ITMS NFP26240120006 |
| Program: | Štrukturálne fondy EÚ Výskum a vývoj |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| SAS cosolvers: | RNDr. Bágeľ Ľubomír, Ing. Balog Martin, PhD., RNDr. Ing. Bartl Ján, CSc., RNDr. Bernátová Iveta, DrSc., RNDr. Bzdúšková Diana, PhD., Dr. Ing. Florek Roman, RNDr. Hain Miroslav, PhD., Ing. Ivan Jozef, CSc., Ing. Iždinský Karol, CSc., Dr. Ing. Jerz Jaroslav, RNDr. Krajčí Marián, DrSc., Ing. Kriváček Jozef, CSc., Ing. Matiašovský Peter, CSc., Ing. Mihálka Peter, PhD.,, MUDr. RNDr. Púzserová Angelika, PhD., Ing. Simančík František, PhD., Prof. Ing. Sládek Ján, DrSc., Prof. RNDr. Sládek Vladimír, DrSc., Ing. Švec Peter, DrSc. |
| Other cosolvers: | Slovenská technická univerzita |
| - | |
| Duration: | 1. 6. 2010 - 31. 5. 2013 |
| Evidence number: | ITMS kód 26240220040 |
| Program: | Štrukturálne fondy EÚ Bratislavský kraj |
| Project leader: | RNDr. Horáková Ľubica, PhD. |
| Neurocognitive mechanisms of selective and sustained attention | |
| Duration: | 1. 1. 2010 - 31. 12. 2012 |
| Evidence number: | 2/0023/10 |
| Program: | VEGA |
| Project leader: | MUDr. Riečanský Igor, PhD. |
| SAS cosolvers: | Ing. Bendžala Štefan, Mgr. Budáč Stanislav, MUDr. Jagla Fedor, CSc. |
| Other cosolvers: | Špajdel Marián Mgr., Žitný Peter Mgr. |
| Annotation: | The project is aimed at exploration of attention, a fundamental cognitive function enabling adaptive behaviour. We focus at important unsolved problems of brain mechanisms of selective and sustained attention in human. In a series of behavioural and electrophysiological experiments we will search for specific connections between electrical brain activity and attentional processes. The project will yield new knowledge about processes underlying higher brain functions. |
| Molecular and functional aspects of the pharmacological modulation of protein kinase C activity | |
| Duration: | 1. 1. 2010 - 31. 12. 2012 |
| Evidence number: | 2/0003/10 |
| Program: | VEGA |
| Project leader: | prof. MUDr. Nosáľ Radomír, DrSc. |
| Annotation: | The project is focused on the analysis of cellular and molecular mechanisms participating in the pharmacological regulation of neutrophil activity. We shall concentrate our studies on the modulation of protein kinase C activity in relation to altered oxidative burst and apoptosis of neutrophils. Natural polyphenols - newly synthetised derivatives of stilbene, flavonoids and coumarins will be studied as potential regulators of neutrophil activity and as inhibitors of protein kinase C activity in enzyme and cell models. Biological effects of polyphenols will be compared with their structure parameters. We expect to acquire relevant information about regulation of neutrophil activity by natural compounds, which might be useful in the therapy of diseases connected with chronic inflammation. |
| neuronálna NO-sy - Etiopatogenesis of compromise blood pressure control: manifestation on structure and function of cardiovascular system. | |
| Duration: | 1. 1. 2009 - 31. 12. 2012 |
| Evidence number: | 2/0019/09 |
| Program: | VEGA |
| Project leader: | RNDr. Kristek František, DrSc. |
| SAS cosolvers: | RNDr. Cebová Martina, PhD., RNDr. Čačányiová Soňa, PhD., doc. RNDr. Dovinová Ima, PhD., MUDr. Gerová Mária, DrSc., Kosnáčová Ľubica, RNDr. Kristek František, DrSc., MUDr. Smieško Vladimír, CSc. |
| Annotation: | The health protection of the European community has never been higher then now. However, serious health problems have remained. Among the most serious causes belong cardiovascular diseases based on hypertension. Thus, new preventive and therapeutic strategies against the most frequently civilization diseases are needed. Further new regulatory systems in blood pressure regulation are revealed. Their misunderstanding is a severe hamper in development of new diagnostic and therapeutic programs. The aim of this project is to study, in a more complexity, a new supposed regulatory system - the effect of neuronal NO-synthase inhibition (nNOS) on vasculature. We will apply a complex approach using morphological, functional, immunological, and biochemical methods. In the effort to clarify mechanisms of nNOS action specific inhibitor of nNOS 7-nitroindazole will be used individually and/or in the combination with other vasoactive substances. The results should help to understand etiology of the cardiovascular diseases. |
| ROSK-QSAR - IN SILICO, IN VITRO AND EX VIVO RESEARCH CONCERNING ANTI-INFECTIVE COMPOUNDS | |
| Duration: | 1. 1. 2011 - 31. 12. 2012 |
| Evidence number: | SK-RO-0008-10 |
| Program: | APVV |
| Project leader: | RNDr. Májeková Magdaléna, PhD. |
| SAS cosolvers: | Mgr. Miláčková Ivana, Ing. Štefek Milan, CSc. |
| Other cosolvers: | Májek Pavol |
| Annotation: | As a result of the researches performed as part of the Romanian Project PNII- Partnerships in priority domains, contract no.41-055/2007 “Multidisciplinary research concerning synthesis, physico-chemical characterization and antimicrobial evaluation for new sulfones with dibenzothiepine structure” an original series of new dibenzothiepine sulfones was obtained, which exhibited antimicrobial and antifungal properties. Present Romanian- Slovak partnership intends to contribute to the effort to obtain new compounds as anti-infective active agents, which could respond to the current global requirements. We propose the rational synthesis of new dibenzothiepine anti-infective agents identified by theoretical calculus and by correlation with experimental determinations as having optimum activity, and a better pharmacokinetics.The project relies on the experience of the Romanian researchers (University of Medicine and Pharmacy, Faculty of Pharmacy, Bucharest) in drug synthesis, biopharmaceutical and pharmacokinetic studies and also relies on the experience of the Slovak researchers (Institute of Experimental Pharmacology & Toxicology, Bratislava) in the field of quantum- chemistry, molecular modelling, Quantitative Structure –Activity Releationships (QSAR). |
| - | |
| Duration: | 1. 1. 2010 - 31. 12. 2012 |
| Evidence number: | APVV SK-CZ-0034-09 |
| Program: | APVV |
| Project leader: | prof. MUDr. Nosáľ Radomír, DrSc. |
| Antiinflammatory protection of intercellular communication of cardiovascular system. | |
| Duration: | 1. 1. 2010 - 31. 12. 2012 |
| Evidence number: | 2/0108/10 |
| Program: | VEGA |
| Project leader: | RNDr. Okruhlicová Ľudmila, CSc. |
| SAS cosolvers: | Ing. Frimmel Karel, PhD., RNDr. Mitašíková (Fialová) Marcela, Ing. Pancza Dezider, MUDr. RNDr. Púzserová Angelika, PhD., D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS, RNDr. Tribulová Narcisa, DrSc., RNDr. Vlkovičová Jana, PhD. |
| Regulation of homeostasis of sodium and potassium ions in normal and pathphysiological conditions. | |
| Duration: | 1. 1. 2010 - 31. 12. 2012 |
| Evidence number: | VEGA 2/0115/10 |
| Program: | VEGA |
| Project leader: | RNDr. Vrbjar Norbert, CSc. |
| SAS cosolvers: | Ing. Frimmel Karel, PhD., MUDr., Ing. Jendruchová (Javorková) Veronika, PhD., RNDr. Mézešová Lucia, RNDr. Vlkovičová Jana, PhD. |
| Improvement of balance in stance and gait by feedback from body sway. | |
| Duration: | 1. 1. 2010 - 31. 12. 2012 |
| Evidence number: | 2/0186/10 |
| Program: | VEGA |
| Project leader: | Ing. Hlavačka František, CSc. |
| SAS cosolvers: | RNDr. Bzdúšková Diana, PhD., MUDr. Dzurková Oľga, Mgr. Hirjaková Zuzana, PhD., RNDr. Kimijanová Jana, PhD., RNDr. Szathmáry Vavrinec, CSc., Mgr. Šuttová Kristína, PhD., Prof. MUDr. Valkovič Peter, PhD. |
| Annotation: | Loss of balance leading to falls is a primary cause of injury and accidents in elderly. The goal of our project is tobring a new knowledge about biofeedback information on balance control and gait dynamics in human. Theobjective of proposal is to analyse mechanisms of postural activity in static stance and during gait in contition ofvibrotactile feedback loop from body tilts. The new vibrotactile belt will be used, which we developed in project EUFP6 Sensactional-AAL.We will develop an optimal way how feedback information from body tilts can improve balance control and gait.The tilt of body segments will be measured by 3D accelerometers placed on body with output transferred wirelessBluetooth to the PC. The data will be used not only for feedback loop but also for balance evaluation. A betterunderstanding the ways of balance and gait improvement via body sway feedback is perspective to preventpostural instability and falls in seniors and to innovate rehabilitation method of balance disorders. |
| TransTox - - | |
| Duration: | 1. 1. 2010 - 30. 6. 2012 |
| Evidence number: | Kód ITMS: 26240220005 |
| Program: | Štrukturálne fondy EÚ Bratislavský kraj |
| Project leader: | prof. MUDr. Nosáľ Radomír, DrSc. |
| Cerebral energy metabolism studied by magnetic resonance spectroscopy as a basis for studying mechanisms of hypoxia-ischemic damage of the neonatal brain | |
| Duration: | 1. 1. 2009 - 31. 12. 2011 |
| Evidence number: | 2/0083/09 |
| Program: | VEGA |
| Project leader: | RNDr. Juránek Ivo, PhD., DrSc. |
| SAS cosolvers: | RNDr. Gáspárová Zdenka, PhD., RNDr. Horáková Ľubica, PhD., RNDr. Knezl Vladimír, PhD., Mgr. Šnirc Vladimír, PhD. , Mgr. Štrosová Miriam, PhD. |
| Other cosolvers: | Sumbalová Zuzana RNDr. PhD.; Belan Víťazoslav h.doc. MUDr. CSc.; Brücknerová Ingrid MUDr. PhD.; Kaliňák Michal Mgr.; Kašparová Svatava RNDr. PhD.; Liptaj Tibor doc. Ing. CSc., Bačiak Ladislav Mgr. |
| Annotation: | Authors of the project together with their foreign partners aim to contribute to explanation of hypoxia-ischemic damage (HID) mechanisms of the neonatal brain. Surviving individuals (mortality up to 50%) often suffer from permanent defects (palsy, epilepsy, behavioural abnormalities, and mental diseases) as a consequence of HID. Based on our hypothesis that the high energy demand of neonatal brain is crucial (cell differentiation, myelinisation, synaptogenesis), some fundamental questions were raised: 1) whether susceptibility of the neonatal brain to HID is related to the maturity of cerebral energy metabolism; 2) what is the role of creatine (depoes energy in the form of creatine phosphate) and oxidative stress in HID of the neonatal brain. The study will be realised using animal models and applying in vivo and in vitro magnetic resonance spectroscopy, biochemical, molecular-biological and other approaches. The new fundamental knowledge may help to propose effective therapeutic approaches to HID that represents a serious health care problem with the eminent socio-economical consequences. |
| Investigation of molecular mechanisms involved in doxorubicin-induced cardiomyopathy and possibilities to modulate the cardiotoxicity of doxorubicin. | |
| Duration: | 1. 1. 2009 - 31. 12. 2011 |
| Evidence number: | 2/0205/09 |
| Program: | VEGA |
| Project leader: | RNDr. Barančík Miroslav, DrSc. |
| SAS cosolvers: | doc. RNDr. Barteková Monika, PhD., RNDr. Bertová Anna, PhD., RNDr. Boháčová Viera, CSc., prof. Ing. Breier Albert, DrSc., Ing. Ivanová Monika, PhD., Ing. Šimončíková Petra, PhD. |
| Early screening of anxiolytic and antidepressive properties of pyridoindole derivatives | |
| Duration: | 1. 1. 2009 - 31. 12. 2011 |
| Evidence number: | 2/0066/09 |
| Program: | VEGA |
| Project leader: | RNDr. Mach Mojmír, PhD. |
| SAS cosolvers: | RNDr. Dubovický Michal, CSc. , Mgr. Ponechalová Veronika, Ing. Šoltés Ladislav, DrSc., Doc. RNDr. Ujházy Eduard, CSc. |
| Other cosolvers: | RNDr. |
| Annotation: | Generalized anxiety disorder (GAD) is the most common of the anxiety disorders. More than 27% of adult Europeans are estimated to experience at least one form of mental illness during any one year.Introduced over 40 years ago, benzodiazepines (BZs) quickly became the most widely used psychotropic drugs. However, in recent years, attitudes toward these compounds have greatly changed, and growing awareness and concern about dependence liability, withdrawal phenomena, and short and long-term side effects have broughtthe long-term use of these compounds into question.In our project we would like to focus on pyridoindol derivatives, synthesized in our institute and study their potential anxiolytic or antidepressive effects in rats using behavioral and molecular approaches. Preliminary dataindicated their anxiolytic potential. These derivatives are chemically unrelated to benzodiazepines with remarkable antioxidant properties and they might be useful in therapy of anxiety disorders and depression. |
| Could the diabetic cataract prevention be achieved by substituted pyridoindoles with their antioxidant and aldose reductase inhibitory potential? Study on in vitro cultivated eye lenses from rats | |
| Duration: | 1. 1. 2009 - 31. 12. 2011 |
| Evidence number: | 02/0056/09 |
| Program: | VEGA |
| Project leader: | Ing. Brnoliaková Zuzana, PhD. |
| SAS cosolvers: | RNDr. Bekešová Slávka, PhD., MUDr. Dřímal Ján, DrSc., RNDr. Gajdošíková Alena, Ing. Štefek Milan, CSc., Ing. Tomášková Iveta , Ing. Turjan Jozef |
| Annotation: | Substituted pyridoindoles, originally synthesized at IEP, with its antioxidant activity and ability to inhibit aldose reductase will be studied as potential anticataract agents on in vitro cultured eye lens model. To mimic the hyperglycaemia of a diabetic state and different glycation archetype as well, several carbohydrates (glucose, galactose, xylose) will be used in the cultivation media. The severity of opacification and cataract progression will be recorded and subjected to digital image analysis. The pathophysiological changes will be correlated with biochemical parameters of the lens. The advance in describing the differences of the lens particular crystallines is to be achieved by applying the proteomic approach. Changes in post-translational modifications will be evaluated. The effect of the compounds tested will be thoroughly evaluated. The novel compounds are expected to have a therapeutic potential in multitarget treatment not only of diabetic cataract but other diabetic complications as well. |
| Metabogenic factors of hypertension development: antioxidant therapy in the prevention and treatment | |
| Duration: | 1. 1. 2009 - 31. 12. 2011 |
| Evidence number: | 2/0178/09 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| Effect of natural compounds on the action of endogenous and exogenous oxidants | |
| Duration: | 1. 1. 2009 - 31. 12. 2011 |
| Evidence number: | 2/0050/09 |
| Program: | VEGA |
| Project leader: | Prof. MUDr. Bauer Viktor, DrSc. |
| SAS cosolvers: | RNDr. Bernátová Iveta, DrSc., RNDr. Drábiková Katarína, PhD., MUDr. Dřímal Ján, DrSc., RNDr. Knezl Vladimír, PhD., Ing. Navarová Jana, PhD., MUDr. Nosáľová Viera, PhD., RNDr. Sotníková Ružena, CSc. |
| Other cosolvers: | Košťálová Daniel |
| Annotation: | The aim of the project is to contribute to the understanding of the pathophysiological role of endogenous or exogenous reactive oxygen and nitrogen species (RONS) involved in civilisation diseases (inflammation, post-ischaemic injury, diabetes) and to their treatment. Research will be realised on models of cardiovascularand gastrointestinal tissue injury by analysis of its mechanisms (functional status, protection of the endothelium and epithelium, antioxidative status, expression of proinflammatory cytokines, etc.) Since all these effects ofRONS are not thouroughly known as yet, and thus neither is their interaction with other biomolecules and protective tissue mechanisms, the pathophysiological part of the project might help to answer these givenquestions. In the pharmacological part of the project, the effects of natural compounds (from Arctostaphilos uva-ursi and Mentha piperita) will be tested against vascular, myocardial and intestinal injury and compared with synthetic compounds, e.g. pyridoindoles. |
| Study of essential oils and their components from the point of view of the protective action in the initiation step of carcinogenesis; experimental systems in vitro and ex vivo | |
| Duration: | 1. 1. 2009 - 31. 12. 2011 |
| Evidence number: | 2/0072/09 |
| Program: | VEGA |
| Project leader: | Ing. Navarová Jana, PhD. |
| SAS cosolvers: | Dytrichová Viera, Ing. Navarová Jana, PhD., RNDr. Slameňová Darina, DrSc., RNDr. Šramková Monika, PhD., Vokalíková Alžbeta |
| Annotation: | DNA damage connected with different changes on the genetic level is at present considered to be the most significant stimulus of initiation of the process of carcinogenesis. Study of antimutagenic and anticarcinogenic effects of natural compounds, which are frequently used in different areas of human life, is therefore of great importance. In the framework of the proposed project we intend 1 to ascertain the antioxidant potential of selected essential oils and their components by biochemical methods; 2 to assess their antimutagenic activity by applying in vitro systems using mammalian cells, bacteria, yeast and algae; 3 on using an ex vivo approach todetermine whether the cells freshly isolated from experimental rats which obtained the compounds studied in drinking water would manifest DNA-protective effects; 4 in cell extracts obtained from cells of animals kept at anormal or modified drinking regimen to investigate repair enzymatic activity and activities of some of the most important cellular enzymes. |
| The role of connexins in protection of the heart against letal arrhythmias and failure | |
| Duration: | 1. 1. 2009 - 31. 12. 2011 |
| Evidence number: | 2/0049/09 |
| Program: | VEGA |
| Project leader: | RNDr. Tribulová Narcisa, DrSc. |
| Effect of antioxidants on blood pressure and manifestation of sympathetic activity in conduit arteries in rats with experimental hypertension | |
| Duration: | 1. 1. 2009 - 31. 12. 2011 |
| Evidence number: | 2/0193/09 |
| Program: | VEGA |
| Project leader: | doc. MUDr. Török Jozef, CSc. |
| SAS cosolvers: | MVDr. Barta Andrej, PhD., MUDr. Smieško Vladimír, CSc., Ing. Tabačeková Marcela, Mgr. Zemančíková Anna, PhD. |
| Annotation: | Production of reactive oxygen species is enhanced in certain cardiovascular diseases including hypertension. The aim of this project is to obtain new data on the effect of selected antioxidants on vascular manifestation of sympathetic nerve activity in rats with experimental hypertension. We will examine the possible involvement of oxidative stress in the changes observed in the modulation of sympathetic neurotransmission in spontaneously hypertensive rats. Also, we will examine long-term administration of quercetin on blood pressure and mechanical activity of vascular muscle in conduit and small arteries in rats with spontaneous and nitric oxide-deficient hypertension. The understanding the mechanism of antioxidants action in cardiovascular system would lead to a better prevention and/or treatment of hypertension and other cardiovascular diseases which are accompanied with high level of reactive oxygen species production. |
| Influence of hypercholesterolemia on endogenous adaptive mechanisms in early stage of diabetes: interference with hypolipidemic agents. | |
| Duration: | 1. 1. 2010 - 31. 12. 2011 |
| Evidence number: | 1/0620/10 |
| Program: | VEGA |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| SAS cosolvers: | RNDr. Čarnická Slávka, PhD, Ing. Ferko Miroslav, PhD., RNDr. Matejíková Jana, PhD., RNDr. Mujkošová Jana, Ing. Pancza Dezider, Ing. Ziegelhöffer Attila, DrSc. |
| Other cosolvers: | PharmDr. Adriana Adameová, PhD., Farmaceutická fakulta UK |
| Annotation: | In diabetic (DIA) heart, increased Ca signals and free radicals participate in the induction of endogenous protective mechanisms (EPM) and adaptation resulting in a higher resistance to ischemia-reperfusion (I/R) injury.Mitochondria (MIT) play a key role in this action. Hypercholesterolaemia (HCH) interferes with EPM via unknown mechamisms. It appears that HCH affects chemical composition and function of membranes. The project will be focused on biophysical, biochemical and functional parameters of MIT (membrane fluidity, lipoperoxidation, O2 utility, bioenergetics) with respect to Ca-signalling (L-channel, NCX, RyR2 etc.) and effects of I/R on myocardial injury (contractile disorders, arrhythmias, infarct size). Statins therapy seems to be an effective agent in the prevention of deleterious effect of HCH on EPM. Thus, in regard to pharmacokinetic properties (lipophility) of statins, we plan to study the interaction of simvastatin and rosuvastatin with some parameters of adaptive signalling pathway. |
| Sensory biofeedback for human balance improvement | |
| Duration: | 1. 1. 2011 - 31. 12. 2011 |
| Evidence number: | 2010-03-15-0004 |
| Program: | Podpora MVTS z prostriedkov SAV |
| Project leader: | Ing. Hlavačka František, CSc. |
| SAS cosolvers: | Mgr. Hirjaková Zuzana, PhD., RNDr. Kimijanová Jana, PhD., Prof. MUDr. Valkovič Peter, PhD. |
| Annotation: | The project is a first step of bilateral Austrian-Slovak collaboration in the field of human posture and gait control. Loss of balance leading to falls is a primary cause of injury and accidents in elderly. A better understanding the ways of balance and gait improvement using body sway feedback is perspective to prevent postural instability and falls in seniors and to innovate rehabilitation method of balance disorders. The overall aim of the project is to inform each other about methods of all collaborating laboratories, to perform a preliminary experiment and to prepare common research project with main participation of young scientists. |
| ENOG - Gasotransmitters: from basic science to therapeutic applications | |
| Duration: | 1. 5. 2011 - 1. 12. 2011 |
| Evidence number: | COST BM1005 |
| Program: | Iné projekty |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| Determination of normal blood pressure and heart rate values for children and adolescents in Slovakia with respect to selected somatic parameters - investigation of the influence of cardiovascular and environmental risk factors | |
| Duration: | 26. 10. 2007 - 26. 10. 2011 |
| Evidence number: | |
| Program: | Iné projekty |
| Project leader: | RNDr. Regecová Valéria |
| SAS cosolvers: | MUDr. Kellerová Eva, DrSc. |
| Other cosolvers: | Doc. MUDr. E. Čižmárová CSc., Detská kardiologi |
| Farmakológia neu - Cellular and molecular aspects of pharmacological regulation of neutrophil pro-inflammatory activity | |
| Duration: | 9. 9. 2008 - 30. 6. 2011 |
| Evidence number: | APVV-0315-07 |
| Program: | APVV |
| Project leader: | prof. MUDr. Nosáľ Radomír, DrSc. |
| SAS cosolvers: | PharmDr. Bauerová Katarína, PhD., DrSc., RNDr. Drábiková Katarína, PhD., PharmDr. Jančinová Viera, PhD., Komendová Denisa, RNDr. Mačičková Tatiana, CSc., Ing. Mihalová Danica, Mgr. Pajtinka Martin, RNDr. Pečivová Jana, PhD., Mgr. Perečko Tomáš , PhD., PharmDr. Poništ Silvester, PhD., Ing. Račková Lucia, PhD., Straková Zuzana |
| Other cosolvers: | Ing. Juraj Har |
| Annotation: | Unique research is focussed on the role of neutrophil leukocytes in proinflammatory processes of the organism with respect to mechanisms of their activation at cellular and molecular level. At present the target is the role of neutrophils in important pathophysiological units like ischaemia-reperfusion damage of the heart and brain, as well as nonspecific inflammatory processes (rheumatoid polyarthritis), diabetes, carcinoma, atherosclerosis, etc. We shall concentrate our studies on the mechanisms of oxidative burst in isolated neutrophils, their responses in whole blood and tissues as well as on processes in connection with their activation and apoptosis, at the level of reactive oxygen species, enzyme activation and expression od proinflammatory active substances. Original results will enrich the knowledge on the role of neutrophils in the process of adjuvant arthritis and its pharmaco-therapeutic intervention. Our attention is focussed first of all on substances of natural origin, which are expected to provide significant supportive effect in suppression of proinflammatory reactions of the organism. Our method for differentiation between extra- and intracellular chemiluminescence will be applied for detection of neutrophil oxidative burst. |
| CEKOMAT I - Centre of Excellence for Research and Development of Constructive Composite Materials I | |
| Duration: | 1. 6. 2009 - 28. 2. 2011 |
| Evidence number: | ITMS NFP26240120006 |
| Program: | Štrukturálne fondy EÚ Výskum a vývoj |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| In-vivo antioxidant gene therapy in the therapy of hypertension | |
| Duration: | 1. 1. 2008 - 31. 12. 2010 |
| Evidence number: | 2/0066/08 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Dovinová Ima, PhD. |
| SAS cosolvers: | RNDr. Bernátová Iveta, DrSc., RNDr. Jendeková Lýdia, PhD., RNDr. Kristek František, DrSc., RNDr. Vranková Stanislava, PhD. |
| Other cosolvers: | Pau |
| Annotation: | Increased oxidation stress of the organism is an important factor in human and experimental hypertension. In developed hypertension, increased activity of the superoxide-generating NADPH-oxidase combins with changed expression and activity of main antioxidant enzymes. To-date, experimental studies indicate that application of substances stimulating expression of antioxidant enzymes brings measurable benefit in terms of reduction of blood pressure and regression of organic and blood vessel damage. Application of gene therapy increasing antioxidant reserves of the organism complete and extend traditional views of hypertension therapy.The present project aims at determining optimum regimes of antioxidant therapy based on bacterial and plasmid vectors carrying genes for antioxidant enzymes, and at studying the principal mechanisms that determine efficiency of the therapy. |
| Project website: | http://www.unpf.sav.sk/slovak/index.php?id=2 |
| CEKVY - Centre of Excellence for Cardiovascular Research | |
| Duration: | 1. 1. 2007 - 31. 12. 2010 |
| Evidence number: | |
| Program: | Centrá excelentnosti SAV |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| Hyaluronan degradation by reactive oxygen species: The reaction kinetics and molecular characteristics of generated polymer fragments | |
| Duration: | 1. 1. 2008 - 31. 12. 2010 |
| Evidence number: | 2/0003/08 |
| Program: | VEGA |
| Project leader: | Ing. Šoltés Ladislav, DrSc. |
| SAS cosolvers: | RNDr. Valachová Katarína , PhD. |
| Annotation: | Hyaluronan (HA) is a polysaccharidic constituent of numerous tissues in the vertebrate organisms. 1 ml of synovial fluid (SF) – an essential joint component – contains 2-3 mg HA, which molar mass reaches in healthy adults magnitude about several MDa. However, at the inflammatory joint disorders, this value is significantly decreased. This decrease is accompanied by a pronounced decline of the HA solution viscoelasticity and loss of the lubricating properties of SF.Low resistance of HA against the action of oxidative species – free radicals, anions – stimulated our efforts to use this biopolymer as a relevant substance/probe for in vitro investigations of the “damaging” action of oxidants and/or for evaluation of the efficacy of various substances to act as antioxidants.The goals to attain are1. To establish experimental study protocols enabling proper evaluation of the changes in viscoelasticity of the HA solution caused by oxidant(s): the experimental study protocol put-in-work should provide exact evaluation/classification of (novel) low-molar-mass substances/drugs to function as inhibitors/scavengers of the HA degradation caused by oxidants – mainly, •OH radicals.To clarify chemical, biochemical, and molecular-biological aspects of the protective effects of (novel) drugs in terms of their antioxidative/radical scavenging properties in order to elaborate a suggestion of relevant strategy of the combined therapy (a so-called multi-bullet concept) of the oxidative stress associated diseases: The major disease of concern will be inflammation of the joints – its initial acute phase. |
| HYPERSYNDROM - Hypertension and diabetes as the parts of metabolic syndrome: the effects of antioxidant therapy | |
| Duration: | 1. 6. 2008 - 31. 12. 2010 |
| Evidence number: | APVV-0538-07 |
| Program: | APVV |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| SAS cosolvers: | Ing. Bendžala Štefan, RNDr. Bernátová Iveta, DrSc., RNDr. Cimrová Barbora, PhD., doc. RNDr. Dovinová Ima, PhD., MUDr. Jagla Fedor, CSc., RNDr. Jendeková Lýdia, PhD., RNDr. Kopincová Jana, RNDr. Matejíková Jana, PhD., RNDr. Ondrejčáková Mária, PhD., MUDr. RNDr. Púzserová Angelika, PhD., MUDr. Ravingerová Táňa, DrSc., FIACS, MUDr. Riečanský Igor, PhD., doc. MUDr. Török Jozef, CSc., RNDr. Vranková Stanislava, PhD. |
| Annotation: | he aim of the submitted project is to investigate the development of hypertension and diabetes as parts of metabolic syndrome from the molecular, biochemical, immunohistochemical, physiological, and morphological point of view. Such a study was not done yet. Relatively new model of metabolic syndrome [rats SHR/NDmcr-cp (cp/cp)] allow us to obtain a complex analysis of development and treatment of this serious disease.The second important aim of this project is to analyze the impact of antioxidant therapy on the experimental hypertension and diabetes within the metabolic syndrome. Having in the mind that increased production of reactive oxygen species was demonstrated in all risk factors of metabolic syndrome, it is more that feasible that such therapy will be beneficial. Polyphenolic compound isolated from slovak red wine which besides antioxidant properties has the activate effect on nitric oxide synthase and apocynine, NADPH oxidase inhibitor with antioxidant properties only will be used for antioxidant therapy. Effects of both antioxidants will be compared to the effects of perindopril, the ACE inhibitor which is suggested to have antioxidant properties in addition to ACE inhibition. It is expected that antioxidant therapy will affect all factors of metabolic syndrome. To find the extent of beneficial effect of antioxidant therapy on individual factors of metabolic syndrome is the next aim of the project. The evaluation of preventive and medical effect of antioxidant therapy on the metabolic syndrome and on hypertension particularly is the last aim of the submitted project. Realization of this aim especially may have important impact for clinic. |
| Hypertension and diabetes as the parts of metabolic syndrome: the effects of antioxidant therapy | |
| Duration: | 1. 6. 2008 - 31. 12. 2010 |
| Evidence number: | APVV-0538-07 |
| Program: | APVV |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| SAS cosolvers: | RNDr. Čarnická Slávka, PhD, RNDr. Matejíková Jana, PhD., Ing. Pancza Dezider |
| - | |
| Duration: | 1. 1. 2008 - 31. 12. 2010 |
| Evidence number: | 1/0438/08 |
| Program: | VEGA |
| Project leader: | PharmDr. Bauerová Katarína, PhD., DrSc. |
| Inhibitors of HMG-CoA reductase and their alternative effects: the role of mitochondrials and coenzyme Q | |
| Duration: | 1. 1. 2010 - 31. 12. 2010 |
| Evidence number: | 1/0328/10 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| SAS cosolvers: | RNDr. Kristek František, DrSc. |
| Modification of hypertrophy and heart failure in the model of continual light-induced hypertension in rats by melatonin and captopril | |
| Duration: | 1. 1. 2009 - 31. 12. 2010 |
| Evidence number: | 1/0187/09 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| SAS cosolvers: | MVDr. Barta Andrej, PhD., doc. RNDr. Pecháňová Oľga, DrSc., RNDr. Vranková Stanislava, PhD. |
| Effect of pyridoindoles and other antioxidants on consequences of acute ischemia of brain related to age | |
| Duration: | 1. 1. 2008 - 31. 12. 2010 |
| Evidence number: | 2/0093/08 |
| Program: | VEGA |
| Project leader: | RNDr. Gáspárová Zdenka, PhD. |
| Annotation: | The aim of the project is to study consequences of brain ischemia and effects of pyridoindoles and other antioxidants in dependence of the age of animals. |
| New pharmacological approaches affecting rheumatoid arthritis studied on adjuvant arthritis | |
| Duration: | 1. 1. 2008 - 31. 12. 2010 |
| Evidence number: | 2/0090/08 |
| Program: | VEGA |
| Project leader: | PharmDr. Bauerová Katarína, PhD., DrSc. |
| Annotation: | Rheumatoid arthritis is a chronic, systemic inflammatory disease. Administration of nonsteroidalanti-inflammatory drugs and disease modifying drugs to patients is associated with adverse effects. Safer therapies are therefore required. The sources for new drugs for mono- or combined therapy of arthritis could be not only synthetic but also of natural origin. Coenzyme Q10, new pyridoindoles ad natural polysaccharides,which intended to be studied in the model of adjuvant arthritis, are expected to provide an important contribution.Further the activity of plant extracts and their active compounds will be studied. Arthritis will be induced to Lewisrats by Mycobacterium butyricum in adjuvans . The animals will receive the substances tested repeatedly. Theparameters evaluating the effects of the substances tested on immune, endocrine, and oxidative processes will be analyzed to describe and characterize the development of adjuvant arthritis as well as the effect ofpharmacological treatments. |
| - | |
| Duration: | 1. 3. 2010 - 31. 12. 2010 |
| Evidence number: | |
| Program: | Iné projekty |
| Project leader: | RNDr. Regecová Valéria |
| Project website: | http://www.petrzalka.sk/index.php?id_menu=43594 |
| CEKVY SAV - - | |
| Duration: | 1. 1. 2007 - 31. 12. 2010 |
| Evidence number: | |
| Program: | Centrá excelentnosti SAV |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| SAS cosolvers: | RNDr. Barančík Miroslav, DrSc. |
| Substituted pyridoindoles as antioxidants and aldose reductase inhibitors in multitarget treatment of diabetic complications: a preclinical study | |
| Duration: | 1. 1. 2008 - 31. 12. 2010 |
| Evidence number: | 2/0001/08 |
| Program: | VEGA |
| Project leader: | Ing. Štefek Milan, CSc. |
| SAS cosolvers: | Ing. Brnoliaková Zuzana, PhD., MVDr. Gajdošík Andrej, RNDr. Gajdošíková Alena, RNDr. Horáková Ľubica, PhD., Mgr. Jusková Mária , Mgr. Šnirc Vladimír, PhD. , Mgr. Štrosová Miriam, PhD., Ing. Tomášková Iveta |
| Annotation: | Novel substituted pyridoindoles with combined antioxidant activity and ability to inhibit aldose reductase will be studied as potential antidiabetic agents. Critical property for their efficacy in vivo is how well they penetrate into target tissues. This issue will be initiallyaddressed by measuring their antioxidant activity and ability to block aldose reductase embedded in the intact erythrocytes under in vitroconditions. Structure-activity relationship will be evaluated. The most promising compounds will be subjected to in vivo tests: in diabetic ratsthe metabolic products of the polyol pathway and lipid/protein oxidation markers will be determined in erythrocytes, pathophysiological changes of the eye lens will be recorded, and the effect of the compounds tested will be evaluated. The biochemical parameters of erythrocytes will be correlated with severity of eye lens opacification. The novel compounds are expected to have a therapeutic potential inmultitarget treatment of diabetic complications. |
| Influence of sensory interaction and cognitive load on postural instability in patients with Parkinson´s disease | |
| Duration: | 1. 1. 2008 - 31. 12. 2010 |
| Evidence number: | 1/0286/08 |
| Program: | VEGA |
| Project leader: | Ing. Hlavačka František, CSc. |
| Other cosolvers: | B |
| Annotation: | The aim of the project is to obtain the new knowledge that could clarify the mechanism of postural instability inpatients with Parkinson’s disease (PD). We will focus on interaction of the somatosensory and visual informationand to influence of mental load on the modification of postural responses to combined sensory stimulation. Thesensory interactions are used by central nervous system in everyday life for postural reactions. These rapidrescue reactions help to control body position during stance and their dysfunction lead to falling. Patients in earlyand advanced-stage PD and the age-matched elderly controls will be tested. As the proprioceptive stimulationwill be used a calf muscles vibration and as the visual stimulation will be used the visual scene rotation. Mentalload will be created by tasks with various demands on cognitive brain resaurces. Postural reactions will beregistered by the stabilometry and the postural synergies between three body segments by means of2-dimensional accelerometers. |
| Experimental models of perinatal asphyxia in evaluation of behavioral disorders and possibility of pharmacological intervention | |
| Duration: | 1. 1. 2008 - 31. 12. 2010 |
| Evidence number: | 2/0083/08 |
| Program: | VEGA |
| Project leader: | Doc. RNDr. Ujházy Eduard, CSc. |
| SAS cosolvers: | MVDr. Bezek Štefan, DrSc., RNDr. Dubovický Michal, CSc. , RNDr. Gajdošíková Alena, RNDr. Gáspárová Zdenka, PhD., RNDr. Mach Mojmír, PhD., Ing. Navarová Jana, PhD., Mgr. Ponechalová Veronika, Doc. RNDr. Ujházy Eduard, CSc. |
| Other cosolvers: | Prof. Ing. Milan Nagy, CSc., Doc. PharmDr. Pavel Mučaji, PhD., Mgr. Elena Prieselová, Mgr. Anna Zahradníková, Mgr. Robert Urblík, Doc. MUDr. Ingrid Brucknerová, PhD., RND |
| Annotation: | Mental diseases are becoming the dread of the third millennium. Their incidence constantly increases and thus they become a serious medical and socio-economic issue. Depression and anxiety disorder are more frequent and affect people of all ages. The marked increase of the attention deficit-hyperactivity disorder is also alarming.Causes of these diseases have a multifactor character. Besides genetic predisposition, various negative factors acting during sensitive brain development play an important role. In our project we will focus on study of hypoxic/ischemic brain damage caused by perinatal asphyxia (PA) and its late neurobehavioural consequences using relevant animal models. Emphasis will be on evaluation of cognitive and motor functions and emotional/anxious responses in adulthood and senescence. Moreover, selected drugs with antioxidant and antiradical properties will be investigated for their potential preventive effects against consequenses of PAincluding in vitro safety screening. |
| Developmental Origin of Metabolic Syndrome:Hypertension, Diabetes and Dyslipidemia | |
| Duration: | 1. 1. 2008 - 31. 12. 2010 |
| Evidence number: | 2/0086/08 |
| Program: | VEGA |
| Project leader: | MVDr. Bezek Štefan, DrSc. |
| SAS cosolvers: | Prof. MUDr. Bauer Viktor, DrSc., MVDr. Bezek Štefan, DrSc., Ing. Brnoliaková Zuzana, PhD., MUDr. Dřímal Ján, DrSc., RNDr. Dubovický Michal, CSc. , MVDr. Gajdošík Andrej, RNDr. Mach Mojmír, PhD., MUDr. Nosáľová Viera, PhD., Ing. Račková Lucia, PhD., RNDr. Sotníková Ružena, CSc., Doc. RNDr. Ujházy Eduard, CSc. |
| Annotation: | Project is dealing with the ehiopathogenesis of the metabolic syndrome. It is expected that repeated administration of novel pyridoindole derivative in rats will simultaneously influence multiple risk factors of experimental metabolic syndrome and reduce hypertension, hyperglycemia, hypercholesterolemia. The effect ofpyridoindole derivatives will be examined on apoptotic dysfunction of pancreatic ß-cells. The most efficient compound from the group will be identified with the prospect of its effective interference with the remission period in the early stages of juvenile diabetes. Investigation of mechanisms regulating fetal growth and development onthe model of hypoxia-reoxygenation and under diabetic condition of postimplantation whole embryo culture and influence of novel pyridoindole derivatives may be beneficial for designing new therapeutic strategies to prevent and treat intrauterine growth retardation. |
| Sensory biofeedback for human balance improvement | |
| Duration: | 1. 1. 2010 - 31. 12. 2010 |
| Evidence number: | |
| Program: | Podpora MVTS z prostriedkov SAV |
| Project leader: | Ing. Hlavačka František, CSc. |
| SAS cosolvers: | Mgr. Hirjaková Zuzana, PhD., RNDr. Kimijanová Jana, PhD., Prof. MUDr. Valkovič Peter, PhD. |
| Annotation: | The project is a first step of bilateral Austrian-Slovak collaboration in the field of human posture and gait control. Loss of balance leading to falls is a primary cause of injury and accidents in elderly. A better understanding the ways of balance and gait improvement using body sway feedback is perspective to prevent postural instability and falls in seniors and to innovate rehabilitation method of balance disorders. The overall aim of the project is to inform each other about methods of all collaborating laboratories, to perform a preliminary experiment and to prepare common research project with main participation of young scientists. |
| Cell signaling pathways and transcription factor activation in adaptive processes in the myocardium as an alternative approach to antiischemic protection | |
| Duration: | 1. 1. 2008 - 1. 12. 2010 |
| Evidence number: | 2/0173/08 |
| Program: | VEGA |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| SAS cosolvers: | RNDr. Čarnická Slávka, PhD, Ing. Ferko Miroslav, PhD., RNDr. Franeková Veronika, RNDr. Matejíková Jana, PhD., RNDr. Mujkošová Jana, RNDr. Nemčeková Martina, Ing. Pancza Dezider, Ing. Ziegelhöffer Attila, DrSc. |
| OCULOMOTOR CONTROL: BEHAVIOURAL AND ELECTROPHYSIOLOGICAL MARKERS OF NORMAL AND PATHOLOGICAL FUNCTION | |
| Duration: | 1. 1. 2008 - 1. 12. 2010 |
| Evidence number: | 2/0160/08 |
| Program: | VEGA |
| Project leader: | MUDr. Jagla Fedor, CSc. |
| SAS cosolvers: | Ing. Bendžala Štefan, MUDr. Jergelová Mariana, CSc., Mgr. Mezeiová Kristína, PhD., MUDr. Riečanský Igor, PhD., PhDr. Špajdel Marián, PhD., Mgr. Teplan Michal, PhD., MUDr. Tóbiková Ľudmila, PhD. |
| Annotation: | It has been suggested that changes of visuo-oculomotor regulations are specifically related to etiopathogenesis of several disorders of the central nervous system. Here we submit an interdisciplinary project that is aimed at investigating visuo-oculomotor integrations and their changes in selected neuropsychiatric diseases by means of novel methods for analysis of eye movements and concurrent electrical brain activity such as independent component analysis, nonlinear dynamics, discriminant analysis, and spectral analysis of short signals. A promising utility of these methods has been indicated also by our previous results. The knowledge gathered from this project will help to identify neuronal mechanisms of visuo-oculomotor regulations in normal and pathological conditions and can lead to novel diagnostic methods and tools for assessment of therapeutic effect. |
| Project website: | www.unpf.sav.sk |
| Long-term administration of low dose of L-NAME: Possibility to improve function of vessel wall in border hypertension? | |
| Duration: | 1. 1. 2007 - 31. 12. 2009 |
| Evidence number: | 2/7064/7 |
| Program: | VEGA |
| Project leader: | RNDr. Sotníková Ružena, CSc. |
| SAS cosolvers: | doc. RNDr. Dovinová Ima, PhD., RNDr. Dubovický Michal, CSc. , RNDr. Jendeková Lýdia, PhD., RNDr. Okruhlicová Ľudmila, CSc., MUDr. RNDr. Púzserová Angelika, PhD., RNDr. Sotníková Ružena, CSc., doc. MUDr. Török Jozef, CSc. |
| Other cosolvers: | Prof. MUDr. P.Babál, CSc., Mudr. S.Štvrtina, MUDr. M.Palkovič, Mgr. M.Jusko, MUDr. T. Stankovičová, CSc., Mgr. E.Kráľová |
| Long-term low dose L-NAME treatment:Possibility to improve the vascular function in borderline hypertension? | |
| Duration: | 1. 1. 2007 - 31. 12. 2009 |
| Evidence number: | 2/7064 |
| Program: | VEGA |
| Project leader: | RNDr. Bernátová Iveta, DrSc. |
| SAS cosolvers: | MVDr. Barta Andrej, PhD., doc. RNDr. Dovinová Ima, PhD., RNDr. Dubovický Michal, CSc. , RNDr. Jendeková Lýdia, PhD., RNDr. Kopincová Jana, RNDr. Okruhlicová Ľudmila, CSc., MUDr. RNDr. Púzserová Angelika, PhD., RNDr. Sotníková Ružena, CSc. |
| Other cosolvers: | Babál Pavel,Stankovicova Tatiana, Kráľová Eva, Jusko Marcel, Štvrtina Svetoslav, Palkovič Michal |
| Epigenetic risk factors of cereberal stroke | |
| Duration: | 1. 1. 2007 - 31. 12. 2009 |
| Evidence number: | APVV-51-058606 |
| Program: | APVV |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| SAS cosolvers: | RNDr. Jendeková Lýdia, PhD., RNDr. Vranková Stanislava, PhD. |
| Annotation: | Cerebrovascular disorders remain a leading cause of death and disability not only in industrialized countries but all over the world. The aim of the project is to study cerebrovascular disorders from the point of view of metabolic syndrome, hyperhomocysteinemia, heart failure and other factors that may influence the disorders in experimental and clinical setings. |
| Pharmacology of inflammatory reactions: Medicaments and natural compounds with antiphagocyte and antiplatelet effects | |
| Duration: | 1. 1. 2007 - 31. 12. 2009 |
| Evidence number: | VEGA 2/7019/27 |
| Program: | VEGA |
| Project leader: | prof. MUDr. Nosáľ Radomír, DrSc. |
| SAS cosolvers: | RNDr. Drábiková Katarína, PhD., PharmDr. Jančinová Viera, PhD., RNDr. Mačičková Tatiana, CSc., RNDr. Pečivová Jana, PhD., PharmDr. Petríková Margita |
| Annotation: | In relation to our recently published results we shall continue our research on studying the mechanisms of antiphagocyte-antioxidative and antiplatelet effect of therapeutically used drugs and natural compounds from groups of stilbenoids and phenylpropanoids. We also wish to extend experimental approaches from the cellular to subcellular and molecular levels with respect to the regulatory pathways of phospholipase D, proteinkinase C and NADPH-oxidase in human blood platelets and neutrophils. |
| ESPZP - Move Europe | |
| Duration: | 1. 1. 2009 - 31. 12. 2009 |
| Evidence number: | |
| Program: | Podpora MVTS z prostriedkov SAV |
| Project leader: | MUDr. Jagla Fedor, CSc. |
| SAS cosolvers: | doc. RNDr. Pecháňová Oľga, DrSc. |
| Other cosolvers: | Regionálne úrad |
| Annotation: | Analysis of workplace health promotion of employers in Slovak Republic |
| Project website: | www.enwhp.org |
| SENSing and ACTION to support mobility in Ambient Assisted Living | |
| Duration: | 1. 1. 2009 - 31. 12. 2009 |
| Evidence number: | |
| Program: | Podpora MVTS z prostriedkov SAV |
| Project leader: | Ing. Hlavačka František, CSc. |
| SAS cosolvers: | Ing. Bendžala Jakub, RNDr. Bzdúšková Diana, PhD., Ing. Hlavačka František, CSc., Ing. Mihálik Viliam |
| The role of matrix metalloproteinases in cardiac remodelation in rats with dietary-induced insulin resistance. | |
| Duration: | 1. 1. 2007 - 31. 12. 2009 |
| Evidence number: | 2/2/7169/27 |
| Program: | VEGA |
| Project leader: | Ing. Ivanová Monika, PhD. |
| SAS cosolvers: | RNDr. Barančík Miroslav, DrSc., doc. RNDr. Barteková Monika, PhD., RNDr. Bertová Anna, PhD., MUDr. Styk Ján, CSc., Ing. Šimončíková Petra, PhD. |
| Annotation: | The aim of the project will be to find new information about the role of matrix metalloproteinases (MMP) in structural and functional changes of myocardium after development of insulin resistance, during ischemia and myocardial adaptation. Mechanisms of intracellular signaling involved in the insulin resistance and modulation of MMP as well as their relationship to responses of myocardium to ischemia will be investigated. The role of cell signaling mediated by mitogen-activated protein kinases (MAPK) and PI3K/Akt kinase pathways in modulation these responses will be studied. Further goal will be the investigation of connection of these processes with structural modulation of myocardium (changes in extracellular matrix, fibrotic changes). The study will be performed on both, in vivo (insulin resistance induced by high fat diet) and in vitro (isolated hearts, model of ischemia) models, as well as at cellular and subcellular levels. Physiological, biochemical, pharmacological and immunochemical methods will be used. |
| Age related changes in human balance and mechanisms of improvent by sensory biofeedback. | |
| Duration: | 1. 1. 2007 - 31. 12. 2009 |
| Evidence number: | 2/7036/27 |
| Program: | VEGA |
| Project leader: | Ing. Hlavačka František, CSc. |
| SAS cosolvers: | RNDr. Bzdúšková Diana, PhD., RNDr. Čapičíková Naďa, PhD., MUDr. Dzurková Oľga, Mgr. Polónyová Alžbeta, Prof. MUDr. Valkovič Peter, PhD. |
| - | |
| Duration: | 1. 1. 2007 - 1. 12. 2009 |
| Evidence number: | 1/4296/07 |
| Program: | VEGA |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| SAS cosolvers: | doc. RNDr. Barteková Monika, PhD., RNDr. Matejíková Jana, PhD., Mgr. Ondrejčáková Mária, Ing. Pancza Dezider |
| Other cosolvers: | Adameová Adriana, PhD |
| Gender specific adaptation of cardiac and renal Na,K-ATPase to hypertension and diabetes | |
| Duration: | 1. 1. 2007 - 1. 12. 2009 |
| Evidence number: | 2/7127/27 |
| Program: | VEGA |
| Project leader: | RNDr. Vrbjar Norbert, CSc. |
| SAS cosolvers: | MUDr., Ing. Jendruchová (Javorková) Veronika, PhD., RNDr. Mézešová Lucia, RNDr. Vlkovičová Jana, PhD. |
| Annotation: | Hypertension and diabetes are accompanied with disturbances in sodium homeostasis. There are cumulative data indicating that sodium (Na+) homeostasis, Na+ transport across the cell membranes, and intracellular concentration of Na+ depend on gender. The presented project is oriented to obtain new data concerning gender specific molecular adaptation of Na,K-ATPase which is one of the crucial systems in maintaining intracellular homeostasis. Using in vivo models (rat) we shall investigate the influence of spontaneous hypertension, and streptozotocin-induced diabetes on Na,K-ATPase. The data will contribute to elucidation of molecular background of processes during the transfer of signals to myocardial and/or renal cell from the aspect of the possible protection of the organism against hypertension and diabetes. |
| - | |
| Duration: | 1. 1. 2007 - 1. 12. 2009 |
| Evidence number: | VEGA 2/7094/27 |
| Program: | VEGA |
| Project leader: | Prof. MUDr. Slezák Ján, D.Sc. D.h.c., FIACS |
| SAS cosolvers: | Ing. Ziegelhöffer Attila, DrSc. |
| Evaluation of activity parameters of potential inhibitors of aldose reductase – a contribution to therapy of chronic diabetic complications | |
| Duration: | 1. 1. 2007 - 1. 12. 2009 |
| Evidence number: | 2/7074/27 |
| Program: | VEGA |
| Project leader: | RNDr. Májeková Magdaléna, PhD. |
| SAS cosolvers: | Ing. Račková Lucia, PhD., Mgr. Šnirc Vladimír, PhD. , Ing. Štefek Milan, CSc. |
| Other cosolvers: | Ing. Pavol Májek, PhD. |
| Annotation: | Inhibitors of the aldose reductase enzyme (ALR2) are drugs capable to prevent a tissue injure caused by diabetes, prevalently by type II, which is insulin-resistant and it is being spread epidemiologically. 3D structure of the ALR2 enzyme was already estimated from various biological sources and in complexes with different adducts. In this project we wish utilize connectivity with existing international and Slovak projects solved at our Institute of Experimental Pharmacology, which are targeted to the projection of new ALR2 inhibitors missing in clinical praxis. We will use the experimental results on the inhibition activity for the pyridoindole-like substances which have been already synthesized and tested at our Institute. First off, we will determine the best theoretical way of estimation of activity by means of the methods of computational chemistry. Then we will create a database of potential pyridoindole-like ALR2 inhibitors which shall fulfill the foregoing theoretical criteria as well as other conditions made for pharmacologically active substances. The most attractive derivatives will be proposed for synthesis and use in the connecting projects. |
| Effect of selected types of antihypertensive therapy on the functional properties of mitochondria and on selected calcium-modulated signalling pathways in heart and kidneys of rats with genetically determined hypertension | |
| Duration: | 1. 1. 2007 - 1. 12. 2009 |
| Evidence number: | 2/7126/27 |
| Program: | VEGA |
| Project leader: | Ing. Ziegelhöffer Attila, DrSc. |
| SAS cosolvers: | Ing. Ferko Miroslav, PhD., RNDr. Mujkošová Jana, Ing. Ziegelhöffer Attila, DrSc. |
| Annotation: | Heart mitochondria (MIT) from hypertensive (HYP) rats exhibited slightly stimulated parameters of ATP production in response to increased energy demands. Captopril (CAP) removed the majority of these adaptation changes. The influence of CAP+Nifedipin (NIF) on MIT function, decrease in blood pressure as well as in heart rate was only non-significantly more effective than that of the CAP. Liver MIT from HYP animals exhibited partially uncoupled oxidation from phosphotylation which was however, partly compensated by slight increase in MIT ATPase (ATPase) activity as well as significant elevation of the phosphorylation rate and MIT membrane fluidity (MF). CAP removed this compensation and intensified the derangement in ATP production. In contrary, CAP+NIF removed the majority of HYP-induced changes with an exception of decrease in ADP¬:O. Kidney MIT from HYP animals showed significant disorder in ATP production accompanied with further increase in MIT MF. CAP application intensified the HYP-induced perturbations in MIT function even more. However, the greatest strenghtening of HYP-induced perturbations in MIT functions was observed after CAP+NIF treatment. |
| POLOS - Molecular mechanisms of new drugs influencing oxidative stress - important ethiopathogenetic factor of numerous diseases | |
| Duration: | 1. 9. 2006 - 31. 10. 2009 |
| Evidence number: | APVV-51-017905 |
| Program: | APVV |
| Project leader: | Prof. MUDr. Bauer Viktor, DrSc. |
| SAS cosolvers: | PharmDr. Bauerová Katarína, PhD., DrSc., RNDr. Drábiková Katarína, PhD., MUDr. Dřímal Ján, DrSc., RNDr. Dubovický Michal, CSc. , MVDr. Gajdošík Andrej, RNDr. Gajdošíková Alena, RNDr. Gáspárová Zdenka, PhD., RNDr. Horáková Ľubica, PhD., PharmDr. Jančinová Viera, PhD., Ing. Jariabka Pavol, doc. Ing. Jurčovičová Jana, CSc., Mgr. Jusková Mária , RNDr. Knezl Vladimír, PhD., Ing. Kogan Grigorij, DrSc., Ing. Kováčik Vladimír, DrSc., Mgr. Kozmon Stanislav, PhD., RNDr. Mach Mojmír, PhD., RNDr. Májeková Magdaléna, PhD., Ing. Mihalová Danica, Ing. Navarová Jana, PhD., prof. MUDr. Nosáľ Radomír, DrSc., MUDr. Nosáľová Viera, PhD., RNDr. Ondrejičková Oľga, PhD., Ing. Pätoprstý Vladimír, PhD., Mgr. Perečko Tomáš , PhD., PharmDr. Poništ Silvester, PhD., Ing. Račková Lucia, PhD., Mgr. Scsuková Soňa, CSc., RNDr. Sotníková Ružena, CSc., Mgr. Šnirc Vladimír, PhD. , Ing. Šoltés Ladislav, DrSc., Ing. Štefek Milan, CSc., MUDr. Štolc Svorad, DrSc., Mgr. Štrosová Miriam, PhD., RNDr. Tribulová Narcisa, DrSc., RNDr. Valachová Katarína , PhD. |
| Other cosolvers: | Liptaj Tibor, Ing., CSc.; Rapta Peter, Doc., Ing., CSc.; Hojerová Jarmila, doc., Ing, CSc; Kašparová Svatava, RNDr. |
| Annotation: | The project is aimed at understanding the mechanism of action of compounds with antioxidative and antiradical properties in tissue inflammation, ischemia/reperfusion, trauma, and chronic hyperglycemia, studied at preclinical level. It is supposed that the drugs may be used in inhibition of tissue oxidative impairment in stroke, neurotrauma, late consequences of diabetes, rheumatoid arthritis, myocardial infarction, etc. The outcome of the targeted analysis will be the suggestion of strategies in therapy, only rarely used in contemporary medicine. New knowledge on pharmacology of compounds interfering with oxidative stress (OS) will contribute to their use in combined prevention and therapy („the multibulletted concept“) of diseases in which OS is participating. The project will contribute to broadening the array of suitable medicines by new drugs with satisfactorily understood mechanism of action and will provide the rationale of pharmacologic intervention based on reduction of OS in tissues. |
| Protection of the heart against malignant arrhythmias and heart failure. | |
| Duration: | 2. 5. 2006 - 30. 4. 2009 |
| Evidence number: | APVV-51-059505 |
| Program: | APVV |
| Project leader: | RNDr. Okruhlicová Ľudmila, CSc. |
| SAS cosolvers: | RNDr. Bernátová Iveta, DrSc., RNDr. Dlugošová Katarína, MUDr., Ing. Jendruchová (Javorková) Veronika, PhD., RNDr. Knezl Vladimír, PhD., RNDr. Mitašíková (Fialová) Marcela, D.h.c., Prof., MUDr. Slezák Ján, DrSc., FIACS, RNDr. Sotníková Ružena, CSc., MUDr. Styk Ján, CSc., RNDr. Tribulová Narcisa, DrSc., RNDr. Vlkovičová Jana, PhD., RNDr. Vrbjar Norbert, CSc. |
| Other cosolvers: | Weismann Peter, RND |
| Effect of immunostimulators and their combination with methotrexate on adjuvant arthrithis in rats | |
| Duration: | 1. 5. 2006 - 30. 4. 2009 |
| Evidence number: | APVV-21-055205 |
| Program: | APVV |
| Project leader: | PharmDr. Bauerová Katarína, PhD., DrSc. |
| Annotation: | Rheumatoid arthritis in humans has been accompanied by chronic activation of the immune system, development of oxidative stress and immunoendocrine dysballance. The mechanisms of these processes will be followed on adjuvant arthritis in rats (AA). The aim of the submitted project is to study: 1) Prophylactic effects of methotrexate, or substances such as immunomodulators on the course of AA, 2) Combinations of these substances with the aim to find the most favorable combination at lowest doses with potential synergic effect. The most effective combination will be used also in therapeutic regiment. We will follow inflammatory and arthritic parameters, parameters of oxidative stress, cytokine and hormone levels. The results will show new possibilities for combined therapy which can be potentially used in the treatment of human rheumatoid arthritis with reduced adverse side effect often seen in monotherapies. |
| Molecular mechanisms of action of new drugs interfering with oxidative stress – the important factor in etiopathogenesis of numerous diseases. | |
| Duration: | 1. 3. 2006 - 1. 2. 2009 |
| Evidence number: | APVV-51-017905 |
| Program: | APVV |
| Project leader: | RNDr. Tribulová Narcisa, DrSc. |
| SAS cosolvers: | Prof. MUDr. Bauer Viktor, DrSc. |
| Model and clinico-physiological analysis of cardiac repolarization at rest and during sympathergic reactions | |
| Duration: | 1. 1. 2006 - 31. 12. 2008 |
| Evidence number: | 2/6187/28 |
| Program: | VEGA |
| Project leader: | RNDr. Szathmáry Vavrinec, CSc. |
| SAS cosolvers: | doc. PaedDr. RNDr. Katina Stanislav, PhD., MUDr. Kellerová Eva, DrSc., RNDr. Regecová Valéria |
| Other cosolvers: | Filipová Slavomíra, Doc., MUDr., CSc. - odborný konzultant |
| Annotation: | The aim of the project is to extend the knowledge on the electrocardiographic T wave genesis, and on the electrocardiologic representation of ventricular repolarization pattern in humans during sympathergic reactions. It is expected that obtained results may improve the diagnostic interpretation of ventricular repolarization. |
| Morphological and molecular changes of tissues as result of cellular damage in decompression sickness | |
| Duration: | 1. 1. 2007 - 31. 12. 2008 |
| Evidence number: | 1/4279/08 |
| Program: | VEGA |
| Project leader: | RNDr. Vranková Stanislava, PhD. |
| SAS cosolvers: | MUDr. RNDr. Púzserová Angelika, PhD. |
| Other cosolvers: | P. Babál, P. Celec, Ľ. Danihel, P. Janega, S. Líšková, F. Novomeský, M.Uličná, |
| Protection of the heart against malignant arhythmis and heart failure | |
| Duration: | 1. 1. 2006 - 31. 12. 2008 |
| Evidence number: | APVV 51-059505 |
| Program: | APVV |
| Project leader: | RNDr. Knezl Vladimír, PhD. |
| SAS cosolvers: | RNDr. Okruhlicová Ľudmila, CSc. |
| Procection of the heart against malignant arrhythmias and heart failure | |
| Duration: | 1. 2. 2006 - 31. 12. 2008 |
| Evidence number: | APVV-51-509505 |
| Program: | APVV |
| Project leader: | RNDr. Bernátová Iveta, DrSc. |
| The study of the biological activity of salivary gland and intestine extracts from saprophagous flies and | |
| Duration: | 1. 1. 2006 - 31. 12. 2008 |
| Evidence number: | 2/6053/26 |
| Program: | VEGA |
| Project leader: | RNDr. Pečivová Jana, PhD. |
| SAS cosolvers: | RNDr. Kozánek Milan, CSc. |
| Mechanism of indapamide effect on the prevention and treatment of experimental hypertension and organ damage | |
| Duration: | 1. 1. 2006 - 1. 12. 2008 |
| Evidence number: | 2/6148/27 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| SAS cosolvers: | MVDr. Barta Andrej, PhD., RNDr. Jendeková Lýdia, PhD., doc. MUDr. Török Jozef, CSc., RNDr. Vranková Stanislava, PhD. |
| Annotation: | Essential hypertension belongs among the diseases with heterogeneous ethiology and complex clinical design. For considering of right position of diuretics with minimal diuretical effect in the therapy of hypertensive disease, it is necessary to know the exact mechanisms by which these new drugs, represented by indapamide, lead to the reduction of blood pressure and prevention of concomitant pathophysiological alterations. Studying the effects of indapamide, it seems to be substantially important to interfere with the L-arginine - NO pathway, renin-angiotensine-aldosteron system, sympathetic nervous system and oxidative status. The interference with such systems may reduce left ventricular hypertrophy, myocardial fibrosis and renal damage. For complex analysis of indapamide effect it is therefore important to complete the clinical studies with basic experimental investigations which may lead to new clinical impact. |
| Melatonine-induced modification of hypertrophy and heart failure in NO deficient hypertension | |
| Duration: | 1. 1. 2006 - 1. 12. 2008 |
| Evidence number: | 1/3429/27 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| SAS cosolvers: | RNDr. Jendeková Lýdia, PhD., RNDr. Vranková Stanislava, PhD. |
| Cardiac gap junctions a potential therapeutic target | |
| Duration: | 1. 1. 2006 - 1. 12. 2008 |
| Evidence number: | |
| Program: | VEGA |
| Project leader: | RNDr. Tribulová Narcisa, DrSc. |
| SAS cosolvers: | RNDr. Dlugošová Katarína, RNDr. Mitašíková (Fialová) Marcela, RNDr. Okruhlicová Ľudmila, CSc., MUDr. Styk Ján, CSc. |
| Investigation of preventive effect of vasoactive substances on development of structure and function of cardiovascular system in SHR as an experimental model of humen essential hypertension | |
| Duration: | 1. 1. 2006 - 1. 12. 2008 |
| Evidence number: | 2/6139 |
| Program: | VEGA |
| Project leader: | RNDr. Kristek František, DrSc. |
| SAS cosolvers: | RNDr. Cebová Martina, PhD., RNDr. Čačányiová Soňa, PhD., doc. RNDr. Dovinová Ima, PhD., RNDr. Koprdová Ria, PhD., doc. MUDr. Török Jozef, CSc. |
| Annotation: | The aim of the project is to study causes and consequences of high blood pressure on structure and function of cardiovascular system in animal model of human essential hypertension. The attention will be focused to investigation of basic functional alterations (in vivo and in vitro)and to structural changes in conduit arteries of spontaneously hypertensive rats (SHR) from early (prehypertensive) period of ontogenic development to late adulthood (1 year). Concomitantly will be studied preventive effect of some vasoactive substances against structural and functional alterations evoked by blood pressure elevation. The drugs will be adminestered from prehypertensive period (4 weeks) to adulthood (9 weeks). Our new results from both morphological and functional studies used in these experimental models could hepl to understand precesses leading to human hypertension and they could contribute to treatment and to prevention of cardiovasculara deseases. |
| The study of damaged bioenergetic and antioxidant systems in different diseases: pharmacologic and non-pharmacologic approaches in the therapy | |
| Duration: | 1. 1. 2006 - 1. 12. 2008 |
| Evidence number: | 1/3442/26 |
| Program: | VEGA |
| Project leader: | doc. RNDr. Pecháňová Oľga, DrSc. |
| SAS cosolvers: | RNDr. Kristek František, DrSc. |
| The role of cell signaling medatend by protein kinase cascades and modulation of cardiac mitochondrial function during myocardial injury and adaptation | |
| Duration: | 1. 1. 2006 - 1. 12. 2008 |
| Evidence number: | |
| Program: | VEGA |
| Project leader: | RNDr. Barančík Miroslav, DrSc. |
| SAS cosolvers: | RNDr. Bertová Anna, PhD., RNDr. Bertová Anna, PhD., RNDr. Boháčová Viera, CSc., prof. Ing. Breier Albert, DrSc., Ing. Drobná Zuzana, CSc., MUDr. Styk Ján, CSc., Ing. Šimončíková Petra, PhD. |
| Pharmacological treatment of hypertension in early stage of its development | |
| Duration: | 1. 1. 2006 - 1. 12. 2008 |
| Evidence number: | |
| Program: | VEGA |
| Project leader: | doc. MUDr. Török Jozef, CSc. |
| SAS cosolvers: | RNDr. Bernátová Iveta, DrSc., RNDr. Koprdová Ria, PhD., MUDr. Smieško Vladimír, CSc., RNDr. Vranková Stanislava, PhD., Mgr. Zemančíková Anna, PhD. |
| Role of bioflavonoids in prevention of social stress-induced hypertension | |
| Duration: | 1. 1. 2005 - 31. 12. 2007 |
| Evidence number: | APVT-51-018004 |
| Program: | APVV |
| Project leader: | RNDr. Bernátová Iveta, DrSc. |
| SAS cosolvers: | RNDr. Barančík Miroslav, CSc., doc. RNDr. Barteková Monika, PhD., Ing. Ivanová Monika, PhD., RNDr. Jendeková Lýdia, PhD., RNDr. Kopincová Jana, RNDr. Matejíková Jana, PhD., RNDr. Okruhlicová Ľudmila, CSc., doc. RNDr. Pecháňová Oľga, DrSc., MUDr. RNDr. Púzserová Angelika, PhD., MUDr. Ravingerová Táňa, DrSc., FIACS, RNDr. Sotníková Ružena, CSc., doc. MUDr. Török Jozef, CSc., RNDr. Vranková Stanislava, PhD. |
| Other cosolvers: | Csizmadiová Z., Babál P., Janega P., |
| Annotation: | The aim of this project is to investigate the mechanisms of development and prevention of social stress-induced hypertension in rats with genetic predisposition to hypertension (borderline hypertensive rats - BHR). The social stress model used will be the model of high-density population (crowding stress) that simulates social tension and stress in the big civic agglomerations. We will investigate the effect of chronic social stress on NO levels in the cardiovascular system including vascular reactivity, myocardial ischemic tolerance, signal transducion pathways that may modulate ischemic tolerance, structural and ultrastructural alterations and apoptosis in the heart and blood vessels.In the next period, the prevention of the social stress-induced hypertension using long-term Provinol (red wine polyphenolic compounds) treatment will be investigated. This project allows to investigate the interactions of the environmental and genetic factors in etiology of social stress-induced hypertension. |
| Hyaluronan-a relevant probe in testing the anti-oxidative properties of antiinflammatory and antirheumaticc drugs as well as of natural and synthetic antioxidants | |
| Duration: | 1. 1. 2005 - 1. 12. 2007 |
| Evidence number: | |
| Program: | VEGA |
| Project leader: | Ing. Šoltés Ladislav, DrSc. |
| SAS cosolvers: | Ing. Kogan Grigorij, DrSc. |
| Interactions of cell signaling mechanisms in the processes of myocardial ischemic injury and endogenous cardioprotection | |
| Duration: | 1. 1. 2005 - 1. 12. 2007 |
| Evidence number: | |
| Program: | VEGA |
| Project leader: | MUDr. Ravingerová Táňa, DrSc., FIACS |
| SAS cosolvers: | doc. RNDr. Barteková Monika, PhD., Ing. Ferko Miroslav, PhD., RNDr. Matejíková Jana, PhD., Mgr. Ondrejčáková Mária, Ing. Pancza Dezider, MUDr. Styk Ján, CSc., Ing. Šimončíková Petra, PhD., MUDr. Uhrík Branislav, CSc., Ing. Ziegelhöffer Attila, DrSc. |
| Endothelial integrity in the injured myocardium | |
| Duration: | 1. 1. 2005 - 1. 12. 2007 |
| Evidence number: | 2/5021/25 |
| Program: | VEGA |
| Project leader: | RNDr. Okruhlicová Ľudmila, CSc. |
| SAS cosolvers: | RNDr. Dlugošová Katarína, RNDr. Mitašíková (Fialová) Marcela, Ing. Pancza Dezider, RNDr. Tribulová Narcisa, DrSc. |
| Ischaemia and reperfusion in experimental diabetes type 2 and possibilities of pharmacological management | |
| Duration: | 1. 1. 2005 - 1. 12. 2007 |
| Evidence number: | |
| Program: | VEGA |
| Project leader: | RNDr. Sotníková Ružena, CSc. |
| SAS cosolvers: | RNDr. Bernátová Iveta, DrSc., MVDr. Bezek Štefan, DrSc., Ing. Brnoliaková Zuzana, PhD., Ing. Navarová Jana, PhD., MUDr. Nosáľová Viera, PhD., MUDr. Szöcs Katalin, PhD. |
| Carboxymethylated pyridoindoles as inhibitors of aldose reductase with antioxidant activity: preclinical implicators for pharmacological prevention of diabetic complications | |
| Duration: | 1. 1. 2005 - 1. 12. 2007 |
| Evidence number: | |
| Program: | VEGA |
| Project leader: | Ing. Štefek Milan, CSc. |
| SAS cosolvers: | Ing. Brnoliaková Zuzana, PhD., MVDr. Gajdošík Andrej, RNDr. Gajdošíková Alena, Ing. Jusková Mária, RNDr. Májeková Magdaléna, PhD., Ing. Račková Lucia, PhD., Mgr. Šnirc Vladimír, PhD. |
| Oxidative injury of skeletal muscle sarcoplasmic reticulum Ca2+-ATPase (SERCA) in vitro in cell cultures and in vivo. Preventive effects of pyridoindole and polyphenolic antioxidants | |
| Duration: | 1. 1. 2005 - 1. 12. 2007 |
| Evidence number: | |
| Program: | VEGA |
| Project leader: | RNDr. Horáková Ľubica, PhD. |
| SAS cosolvers: | Mgr. Štrosová Miriam, PhD. |
| Contribution to prevention and treatment of behavioural disorders evoked by hypotic-ischaemic damage of the brain in perinatal period: experimental model of asphyxia and administration of substances with antiradical and antioxidative effects | |
| Duration: | 1. 1. 2005 - 1. 12. 2007 |
| Evidence number: | |
| Program: | VEGA |
| Project leader: | Doc. RNDr. Ujházy Eduard, CSc. |
| SAS cosolvers: | MVDr. Bezek Štefan, DrSc., RNDr. Dubovický Michal, CSc. , MVDr. Gajdošík Andrej, RNDr. Gajdošíková Alena, RNDr. Juránek Ivo, PhD., DrSc., MUDr. Kosoň Peter, PhD., RNDr. Mach Mojmír, PhD., Ing. Navarová Jana, PhD. |
| Specific antagonists myocardial production and secretion of p roinflammatory cytokines(IC), expression of mitogenic vasopressor peptides (MP), polyferation and pathological remodelation after myocardial infarction (MI) and in chroni heart failure (CHF) | |
| Duration: | 1. 1. 2005 - 1. 12. 2007 |
| Evidence number: | |
| Program: | VEGA |
| Project leader: | MUDr. Dřímal Ján, DrSc. |
| SAS cosolvers: | PharmDr. Bauerová Katarína, PhD., DrSc., RNDr. Knezl Vladimír, PhD., Ing. Kováčik Vladimír, DrSc., Ing. Pätoprstý Vladimír, PhD., Ing. Račková Lucia, PhD. |
| Study of neuroprotective action of new pyridoindole antioxidants | |
| Duration: | 1. 1. 2005 - 1. 12. 2007 |
| Evidence number: | |
| Program: | VEGA |
| Project leader: | MUDr. Štolc Svorad, DrSc. |
| SAS cosolvers: | RNDr. Dubovický Michal, CSc. , RNDr. Gajdošíková Alena, RNDr. Gáspárová Zdenka, PhD., RNDr. Ondrejičková Oľga, PhD., Mgr. Šnirc Vladimír, PhD. |
| Effects of antioxidants and substances afecting the imunita systém studied in vivo using a model of adjuvant arthritis | |
| Duration: | 1. 1. 2005 - 1. 12. 2007 |
| Evidence number: | |
| Program: | VEGA |
| Project leader: | PharmDr. Bauerová Katarína, PhD., DrSc. |
| SAS cosolvers: | MUDr. Dřímal Ján, DrSc., MVDr. Gajdošík Andrej, doc. Ing. Jurčovičová Jana, CSc., Ing. Kogan Grigorij, DrSc., Ing. Mihalová Danica, MUDr. Nosáľová Viera, PhD., RNDr. Ondrejičková Oľga, PhD., PharmDr. Poništ Silvester, PhD., MUDr. Štolc Svorad, DrSc., Doc. RNDr. Ujházy Eduard, CSc. |
| The interaction of stress and genetic factors in the etiology of high blood pressure and behavioral failure: the role of nitric oxide | |
| Duration: | 1. 1. 2004 - 31. 12. 2006 |
| Evidence number: | 2/4156 |
| Program: | VEGA |
| Project leader: | RNDr. Bernátová Iveta, DrSc. |
| SAS cosolvers: | RNDr. Dubovický Michal, CSc. , RNDr. Jendeková Lýdia, PhD., RNDr. Okruhlicová Ľudmila, CSc., MUDr. RNDr. Púzserová Angelika, PhD., RNDr. Sotníková Ružena, CSc., doc. MUDr. Török Jozef, CSc. |
| Other cosolvers: | Babál P., Janega P., Štvrtina S., Stankovičová T., Jusko M., Zenebe W., Csizmadiová Z., |
| Annotation: | Stressor, defined as any physical or emotional influence that causes bodily or mental tension, results in cascade of metabolic, endocrine, cardiovascular, immune and behavioral alterations, so called stress. The goal of the project is to investigate the mechanisms of stress-induced hypertension in rats without history of hypertension (Wistar), spontaneously hypertensive (SHR) and borderline hypertensive rats (BHR, with one hypertensive parent). The social stress model used will be the model of high-density population – crowding stress. The effect of croeding stress on nitric oxide (NO) level in cardiovascular system and its role in stress-induced hypertension will be investigated. Since alterations in NO synthesis may affect the glucocorticoids synthesis and thus the whole stress response, the effect of NO on behavior of rats with different history of hypertension will also be investigated. This experimental design will allow to study the interaction of environmental and genetic factors in modulation of NO-dependent processes as well as the role of NO in etiology of stress-induced hypertension and behavioral failure. |
| Neurocognitive mechanisms of semantic representation and contro | |
| Duration: | 0. 0. 0000 - 0. 0. 0000 |
| Evidence number: | 2/0052/23 |
| Program: | VEGA |
| Project leader: | Mgr. Marko Martin, PhD. |
| SAS cosolvers: | Ing. Bendžala Štefan, RNDr. Cimrová Barbora, PhD., Mgr. Michalko Drahomír, PhD., MUDr. Riečanský Igor, PhD., Mgr. Rovný Rastislav |
| Annotation: | Semantic cognition underpins the processing, organization, and fluid retrieval of knowledge (facts, concepts, andtheir relations) stored in memory. It regulates mental processes and adaptive behavior, whereas deterioration ofthis system is present among several neuropsychiatric disorders and diseases. The aim of this project is to identify cognitive and neurobiological mechanisms that support the ability to search and retrieve conceptualrepresentations within semantic memory. For this purpose, we will carry out a set of original experiments that combine systematic manipulation of cognitive interference, the measurement of cognitive load (effort) using pupillometry, and non-invasive (transcranial) electrical brain stimulation. Via such interdisciplinary approach, we intent to characterize key neurocognitive determinants of automatic and control (executive) functions of the human semantic system, which may inspire effective interventions for their enhancement. |
| HYDMIM - Effects of mesenchymal stem cells and HMGB1 inhibitor on cardiovascular system after experimentally induced myocardial infarction in hypertension and diabetes mellitus | |
| Duration: | 0. 0. 0000 - 0. 0. 0000 |
| Evidence number: | APVV-22-0271 |
| Program: | APVV |
| Project leader: | RNDr. Cebová Martina, PhD. |
| SAS cosolvers: | MVDr. Barta Andrej, PhD., Mgr. Bujnová Katarína, Bc. Hikl Jakub, RNDr. Klimentová Jana, PhD., RNDr. Vranková Stanislava, PhD. |
| Other cosolvers: | doc. Ing. Mária Vojtková, PhD. |